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ABSTRACT 
Nanotechnology is in the limelight concerning the development of new therapeutic 
and diagnostic concepts in all areas of medicine. In this context, iron oxide nanoparticles 
(IONs) have shown to present a wide scope of applications in biomedicine, namely in 
magnetic resonance imaging, tissue repair, drug delivery, hyperthermia, transfection, 
tissue soldering, and as antimicrobial agents. However, their use has generated many 
concerns among public, scientific and regulatory authorities regarding their long-term 
impact on human health, as many lines of evidence show that some IONs may have 
adverse effects on living organisms.  
Regarding immune system, the studies assessing the effect of IONs on the cells of 
this system, namely neutrophils, lymphocytes, monocytes, are scarce and some of them 
contradictory. Moreover, the toxicity of IONs with some coatings that are described as 
promising for some biomedical applications, namely polyacrylic acid (PAA), remains to be 
studied.  Therefore, we felt the need to deepen the knowledge existing so far in this area 
of the immune system. 
Our first approach was to evaluate the effects of PAA-coated and non-coated 
magnetite IONs on human neutrophils, namely their capacity to activate the oxidative 
burst and to modify their lifespan through necrosis and/or apoptosis. It was demonstrated 
that PAA-coated and non-coated IONs trigger neutrophils’ oxidative burst in a 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase dependent manner, and 
that PAA-coated IONs increase, while non-coated IONs prevent, apoptotic signaling and 
apoptosis. 
The second objective of this dissertation was to assess the effect of PAA-coated 
and non-coated IONs on their capacity to induce cytokine production [interleukin (IL)-1β, 
tumor necrosis factor alpha (TNF-α), IL-6, IL-8, interferon gamma (IFN-γ) and IL-10] by 
ex-vivo human blood cells and the pathways involved in this induction. Our results showed 
that PAA-coated and non-coated IONs are able to induce all the tested cytokines and that 
activation of transforming growth factor beta-activated kinase (TAK1), p38 mitogen-
activated protein kinase (MAPK) and c-Jun-N-terminal kinase (JNK) are involved in this 
effect. 
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Subsequently, we studied the ability of PAA-coated and non-coated IONs to 
induce genotoxicity in human T lymphocytes through influence on cell cycle progression 
and on the induction of chromosome aberrations, as well as to exert cumulative effect with 
the iron-dependent genotoxic agent bleomycin (BLM). In this study, we demonstrated that 
the tested IONs are not genotoxic, do not trigger the cell cycle arrest and do not potentiate 
the clastogenic effects of BLM in human T lymphocytes. 
The in vitro studies previously mentioned and performed led us to our last work, a 
in vivo study using male CD-1 mice from Charles River. In this study, we studied the 
biodistribution as well as the effect of acute intravenous PAA-coated IONs administration 
in male CD-1 mice, namely their ability to induce pro-inflammatory processes and induce 
toxicity. The obtained results show that these IONs accumulate mainly in phagocytic cells 
in the periportal zone of the liver and in splenic red pulp of the spleen and, to a lesser 
extent, in lung. Moreover, our data put in evidence that, even though PAA-coated IONs do 
not cause severe organ damage, a light inflammatory process seems to be triggered, as 
evidenced by an increased neutrophils’ and large lymphocytes’ frequency in blood and by 
an accumulation in phagocytes in liver and spleen. The studied IONs also showed to 
trigger lipid peroxidation in liver tissue; however, they did not produce any alteration in the 
parameters total glutathione (GSHt), reduced glutathione (GSH) and oxidized glutathione 
(GSSG) in liver and kidney. 
Keywords: Iron oxide nanoparticles; biological effects; inflammation; blood cells; in vivo 
studies. 
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RESUMO 
A nanotecnologia desempenha atualmente um papel preponderante no 
desenvolvimento de novos métodos terapêuticos e de diagnóstico em todas as áreas da 
medicina. Neste contexto, as nanopartículas de óxido de ferro (IONs) têm demonstrado 
apresentar uma grande variedade de aplicações em biomedicina, nomeadamente em 
ressonância magnética nuclear, reparação tecidular, direcionamento de fármacos, 
hipertermia, transfeção, fusão tecidular e agentes antimicrobianos. Contudo, a sua 
utilização tem sido alvo de preocupação por parte das autoridades públicas, científicas e 
reguladoras relativamente aos possíveis efeitos a longo prazo na saúde humana, pois 
diversas evidências mostram que algumas IONs podem ter efeitos adversos nos 
organismos vivos.  
No que diz respeito ao sistema imune, os estudos existentes que avaliam o efeito 
das IONs nas células deste sistema, nomeadamente neutrófilos, linfócitos, monócitos, 
são escassos e alguns deles até mesmo contraditórios. Adicionalmente, a toxicidade das 
IONs com alguns revestimentos que são descritos como sendo promissores em algumas 
aplicações biomédicas, nomeadamente ácido poliacrílico (PAA), não tem sido estudada. 
Por este motivo, sentimos a necessidade de aprofundar o conhecimento existente até ao 
momento nesta área do sistema imune. 
A nossa primeira abordagem foi avaliar os efeitos das IONs revestidas com PAA e 
não revestidas, na forma magnetite, em neutrófilos humanos, nomeadamente na sua 
capacidade de ativar o “burst” oxidativo e de modificar o seu tempo de vida através de 
fenómenos apoptóticos e necróticos. Foi demonstrado que as IONs revestidas com PAA 
e não revestidas desencadeiam o “burst” oxidativo dos neutrófilos via ativação da enzima 
nicotinamida adenina dinucleótido fosfato (NADPH) oxidase, assim como que as IONs 
revestidas com PAA induzem, enquanto as IONs não revestidas inibem, o processo 
apoptótico e consequente sinalização. 
O segundo objetivo desta dissertação foi avaliar o efeito das IONs revestidas com 
PAA e não revestidas na sua capacidade de induzir produção de citoquinas [interleuquina 
(IL)-1β, fator de necrose tumoral alfa (TNF-α), IL-6, IL-8, interferão gama (IFN-γ) e IL-10] 
pelas células sanguíneas humanas ex-vivo e as vias inflamatórias envolvidas nesta 
indução. Os resultados obtidos revelaram que as IONs revestidas com PAA e não 
revestidas são capazes de induzir todas as citoquinas testadas e que a activação da 
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cinase ativada pelo fator de transformação do crescimento beta (TAK1), proteína cinase 
ativada pelo mitógeno (MAPK) p38 e cinase c-Jun-N-terminal (JNK) estão envolvidas 
nesta indução. 
Seguidamente estudámos a capacidade das IONs revestidas com PAA e não 
revestidas de induzir genotoxicidade em linfócitos T humanos através da influência na 
progressão no ciclo celular e na indução de aberrações cromossómicas, assim como da 
execução de um efeito cumulativo com a bleomicina (BLM), um conhecido agente 
genotóxico dependente do ferro. Neste estudo, demonstrámos que as IONs testadas não 
são genotóxicas, não desencadeiam paragem do ciclo celular e não potenciam os efeitos 
clastogénicos da BLM em linfócitos T humanos. 
Os estudos in vitro previamente mencionados e executados conduziram-nos ao 
nosso último trabalho, um estudo in vivo no qual recorremos a murganhos machos da 
estirpe CD-1 da Charles River. Neste estudo, estudámos a distribuição, assim como o 
efeito da administração aguda e intravenosa de IONs revestidas com PAA em ratinhos 
CD-1, nomeadamente a sua capacidade de induzir processos pro-inflamatórios e
toxicidade. Os resultados obtidos mostram que estas IONs se acumulam principalmente
em fagócitos na zona periportal do fígado e na polpa vermelha do baço e, numa menor
extensão, no pulmão. Adicionalmente, os nossos dados colocam em evidência o facto de,
apesar das IONs revestidas com PAA não aparentarem causar danos orgânicos severos,
um processo inflamatório ligeiro parece ser desencadeado, como é evidenciado pelo
aumento na frequência de neutrófilos e linfócitos grandes no sangue, assim como pela
acumulação em fagócitos no fígado e baço. Estas IONs mostraram também provocar
peroxidação lipídica no fígado. Contudo, elas não produziram qualquer alteração em
parâmetros como glutationa total (GSHt), glutationa reduzida (GSH) e glutationa oxidada
(GSSG) no fígado e no rim.
Palavras-chave Nanopartículas de óxido de ferro; efeitos biológicos; inflamação; células 
sanguíneas; estudos in vivo. 
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substances and/or polymers that can be used to coat the iron oxide core, as well as their 
applications and biological properties, namely their biodistribution in the human organism 
and their cellular internalization pathways. The second subsection (I.1.2.) is an overview 
of the toxicological and pro-inflammatory mechanisms of iron oxide nanoparticles. 
I.2. General and specific objectives of the dissertation
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 Abstract 
 
Iron oxide nanoparticles (IONs) are among the most common types of nanoparticles 
(NPs) used in biomedical applications. IONs can be presented in different forms [e.g. 
magnetite (Fe3O4), hematite (α-Fe2O3) and maghemite (γ- Fe2O3)], and are usually coated 
with substances and/or polymers according to the purpose for which they are intended to 
be used. In recent years, IONs use has been increasing exponentially in many fields of 
biomedicine, namely in magnetic resonance imaging, cell sorting, tissue repair, induction 
of hyperthermia and drug delivery, among others. This review aims to provide an update 
on the different IONs and the substances and/or polymers that can be used to coat the 
IONs core as well as their applications and biological properties, namely their 
biodistribution in the human body and their cellular internalization pathways. 
 
Keywords: Biodistribution; biomedical applications; coatings; internalization routes; iron 
oxide nanoparticles; toxicity. 
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1. Introduction
Nanotechnology encompasses structures of 100 nm or smaller that may present 
several dimensions: nanoscale in one dimension (very thin surface coating), in two 
dimensions (nanotubes and nanowires) or in three dimensions, known as nanoparticles 
(NPs), which comprise nanomaterials. Nanomaterials are present in toothpastes, 
sunscreens, food products and even sanitaryware coatings. Currently, the use of 
nanomaterials is being extended to multiple areas such as cell labeling, gene delivery, 
drug targeting, biosensors, chemistry, material science, physics, medicine, 
microelectronics and hyperthermia therapy [1, 2, 3, 4] 
NPs can present different characteristics and be engineered from almost all 
chemical substances. They have physical and chemical properties that differ from the 
atom or bulk counterparts and have been recognized to have great potential in several 
fields due to the unique properties conferred by their surface-area-to-volume ratios [5, 6, 
7], namely:  
- the ease with which they are captured by the cells;
- avoidance of clearance by the immune system compared to traditional macroscale
materials;
- porous structure;
- lower melting points;
- increased light absorption.
Iron oxide nanoparticles (IONs) are among the most common types of NPs used in 
medical applications. IONs can exist in different forms and are usually coated with 
substances and/or polymers that are able to confer the expected properties according to 
the purpose for which they are intended. Their small dimensions make IONs more 
chemically reactive with particle size being inversely proportional to bioactivity and toxicity 
[8, 9, 10]. From a health and environmental perspective, this can be harmful if the NPs are 
toxic or in some way disturb biological functions and lead to undesirable health effects. In 
particular, people with pre-existing medical conditions are at greater risk [11, 12]. This 
review aims to provide an update on the different types of IONs and the substances 
and/or polymers that can be used to coat the IONs core as well as their applications and 
biological properties, namely their biodistribution in the human body and their 
internalization pathways into cells. 
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2. Types of IONs
IONs are particles with dimensions ranging from 1 to 100 nm, composed of iron 
oxide. IONs consist of a magnetic iron oxide core with a coating of non-magnetic surface 
chemistry and exist in many forms in nature, namely magnetite (Fe3O4), hematite (α-
Fe2O3) and maghemite (γ-Fe2O3) [7, 9]. 
Magnetite is a mixture of FeO and Fe2O3 containing both Fe3+ and Fe2+ ions, with a 
cubic inverse spinel structure. It is thermodynamically unstable due to the oxidation of 
magnetite (from Fe2+ into Fe3+) to form maghemite in the presence of moisture, air and 
light [13, 14, 15, 16, 17]: 
Fe3O4+2H+  γ-Fe2O3+Fe2++H2O     (Equation 1)  
Maghemite NPs (γ-Fe2O3) are composed of fully oxidized cubic crystals and are 
therefore extremely stable under aerobic conditions even when bacteria are present [14, 
18]. 
Hematite (α-Fe2O3) is a mineral form of Fe3+ oxide presenting a rhombohedral 
corundum crystal structure. It is considered the most abundant iron oxide polymorph and 
its iron content is approximately 70%. Due to its application as a pigment, it is one of the 
most common industrially used forms of iron oxide, apart from magnetite [18, 19, 20, 21]. 
3. Sizes of IONs
IONs can be classified according to their size which greatly influences their 
magnetic and biological properties. Ultra-small superparamagnetic iron oxide 
nanoparticles (USPIONs) are less than 50 nm in diameter and comprise 2-3 nm single 
crystal iron oxide cores enclosed in a coating that makes them biocompatible. Particles 
with dimensions larger than 50 nm are denominated superparamagnetic iron oxide 
nanoparticles (SPIONs) [16, 22, 23, 24]. 
4. Coatings
Biomedical applications demand that the IONs present uniform chemical and 
physical properties and for that reason, have high magnetization values with a size lower 
than 100 nm being essential. The nature of the coating determines the total size of the 
colloid as well as the biodistribution and biokinetics of SPIONs in vivo [25]. 
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Since introduction of the first contrast agents in magnetic resonance imaging (MRI) 
in the decade of 1980 [26], most of the SPIONs and USPIONs agents have been 
fabricated with different types of coating material including citrate, dextran, albumin, 
starch, polyethylene glycol (PEG) and silicones to achieve their dispersion status and 
uptake selectivity by macrophage or endothelial cells [27, 28]. The carboxylate group is 
the most common fixation site on an iron oxide core. Other anchoring agents have been 
researched, such as phosphate, sulfonate and phosphonates, despite their strong affinity 
towards the core of iron oxide [29, 30]. The utilization of bifunctional phosphonic acid-
based coupling agents with polar end groups (-OH,-COOH,-NH2) not only makes the NPs 
hydrophilic and stable regarding aggregation, but also conveys functionality on the surface 
to provide easy access to bioconjugates [31]. These coatings ideally should be 
nonantigenic and nonimmunogenic, have a high affinity for the iron oxide core and impede 
opsonization by plasma proteins [32]. 
The coating of SPIONs is indispensable because it: 
- decreases the aggregation tendency of the non-coated NPs (which occurs due to their
hydrophobic surfaces with large surface area to volume ratio and their van-der walls
and magnetic dipole–dipole attractive forces [7, 33, 34]), thus improving their colloidal
stability and dispersibility [35];
- prevents the oxidation of their surface [35], given that non-coated IONs tend to be
transformed from magnetite (Fe3O4) to maghemite (γ-Fe2O3) [13];
- provides a surface for conjugation of targeting ligands and drug molecules such as
proteins, antibodies, therapeutic genes, targeting ligands, etc. [13, 35, 36];
- augments blood circulation time by evading clearance from the reticuloendothelial
system (RES) [35];
- renders the NPs biocompatible and decreases nonspecific interactions, consequently
reducing toxicity [35, 37];
- increases their efficiency of internalization by target cells [35, 37].
4.1. Types of coatings 
Diverse groups of coating materials are used to modify magnetic NPs surface 
chemistry, namely: 
- synthetic polymers, such as poly(ethylene-co-vinyl acetate), poly(vinylpyrrolidone)
(PVP), poly(lactic-co-glycolic acid) (PLGA), PEG and polyvinyl alcohol (PVA);
- natural polymers, such as dextran, pullulan, gelatin and chitosan;
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- organic surfactants, such as dodecylamine, sodium carboxymethylcellulose and sodium
oleate;
- inorganic metals, such as gold;
- inorganic oxides, such as carbon and silica;
- bioactive molecules and structures, such as liposomes, lipids, ligands/receptors and
peptides [9, 13, 28, 38].
In this review, we refer only to the most relevant coatings described in the literature 
(figure 1). 
Figure 1. Most widely coatings used in IONs. 
4.1.1. Polyvinyl alcohol (PVA) 
PVA is a water soluble synthetic polymer that has exceptional emulsifying, film-
forming and adhesive properties. Besides the fact that PVA enhances polymer-surface 
interactions, PVA also forms hydrogen bonds between the polymer chains which results in 
a hydrogel structure that embeds the NPs and is responsible for steric stabilization above 
and around the critical polymer concentration. This structure prevents aggregation and 
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agglomeration of SPIONs [9, 39, 40]. It was reported that PVA has the capacity to bind to 
proteins through hydrogen-bonding interactions and this may be responsible for a reduced 
capacity of monocyte-derived human dendritic cells to process antigens, secrete cytokines 
and stimulate T cells after exposure to PVA-coated magnetic IONs [41, 42]. 
 
4.1.2. Poly(vinylpyrrolidone) (PVP) 
 
PVP is a synthetic water-soluble polymer produced from the monomer N-vinyl 
pyrrolidone. It has non-biodegradable properties, good biocompatibility and a safe, long-
standing record in biomedical and pharmaceutical applications. The main benefits of PVP 
for coating SPIONs are stability and safety in the use of SPIONs [43, 44]. 
 
4.1.3. Polyethylene glycol (PEG) 
 
PEG is a linear neutral polyether polymer that can be considered to reduce 
opsonization because it is hydrophilic, uncharged and non-immunogenic [9, 36]. In 
addition to steric stabilization of magnetic NPs, PEG non-fouling properties diminish 
interactions of the NPs with blood proteins permitting PEG-coated NPs to escape 
recognition by the mononuclear phagocyte system, in this way increasing NPs circulation 
in vivo [45, 46]. PEG-coated NPs are internalized efficiently by cells through amphiphilic 
affinity to lipid bilayers on plasma membranes and via fluid-phase endocytosis [9].  
PEG exhibits low immunogenicity and toxicity. It is excreted through kidneys (for 
PEG <30 kDa) and feces (for PEG >20 kDa) in an intact form [36]. 
 
4.1.4. Polyacrylic acid (PAA) 
 
PAA is a non-toxic polyanion where each repeating unit exhibits a carboxylic acid 
function [47]. In an aqueous solution at neutral pH, since PAA is a weak organic acid, 
many of its side chains lose their protons and obtain a negative charge [48]. PAA has 
been considered an endosomolytic polymer. It has been shown that the addition of PAA to 
polyethylenimine (PEI)-deoxyribonucleic acid (DNA) transfection complexes not only 
increased reporter gene expression but also reduced toxicity in vivo [49, 50]. 
 
4.1.5. Dextran 
 
Dextran has proven to be among the most commonly used coatings and is a 
water-soluble polysaccharide which has been clinically used for more than half a century. 
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Many commercially-available contrast agents are coated with dextran or carboxydextran 
such as Resovist®, Endorem®, Sinerem® and Supravist® [16, 51, 52].  
Dextran-coated USPIONs are described as offering beneficial properties in their 
absorption, biodistribution, biotransformation, metabolism and excretion. These agents 
have been reported to be rapidly and nonspecifically captured by phagocytic cells and 
accumulate in the RES such as lymph nodes, Kupffer cells of the liver and spleen [9, 53, 
54, 55]. It was reported that after intravenous infusion, approximately 70% of dextran was 
excreted into urine within a 24 hour period with the remaining 30% retained in the body for 
a few days [56]. Furthermore dextranase (an intracellular enzyme) cleaves the dextran 
component and consequently, the iron oxide is solubilized into iron ions, which are 
gradually incorporated into the hemoglobin pool [57]. However, one important limitation of 
polysaccharide coatings is that they are structurally unstable in highly acidic 
environments. Dextran is a huge macromolecule that is continually undergoing 
conformational changes and completely desorbs from the particle surface. In addition, in 
dextran-coated NPs, dextran is not strongly bound to the iron oxide core and can be 
effortlessly detached from the IONs surface, leading to their aggregation and even 
precipitation under physiological conditions [16, 23, 55]. Consequently, the NPs 
themselves are internalized very inefficiently given that low molecular-weight dextran is 
typically captured by fluid phase-mediated endocytosis, which is a fairly inefficient uptake 
process [23]. It was described that coatings such as mannan, citrate and silica permitted 
better internalization in macrophages compared to dextran [58, 59, 60]. As such, to 
guarantee the stability of the polymer coating in vivo, cross-linked IONs (CLIO) NPs have 
been conceived. CLIO NPs are dextran-coated SPIONs where the dextran chains are 
cross-linked chemically [61]. 
It was also reported that dextran coating may adsorb several plasma proteins, 
namely the C3 component, vitronectin and fibronectin [62]. Additionally, it was described 
that dextran caused allergic reactions. The fact that anti-dextran antibodies are present in 
few individuals has been related to the use of dextran coating in some USPIONs. Serious 
reactions linked to the use of dextrans 40 and 70 as a plasma substitute have been 
reported for considerable time. These reactions are caused at least in part, by dextran-
reactive IgG antibodies [63]. 
Carboxydextran is a derivative of dextran that has been used equally to coat IONs. 
It has been suggested that the carboxyl groups which carboxydextran presents, in 
addition to dextran, might lead to greater affinity to the cell membrane [64]. It was 
established that SHU555C (an ionic USPIONs with a size of 21 nm and a carboxydextran 
coating) is considerably better internalized into monocytes ex vivo compared to 
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ferumoxtran-10, which is a non-ionic USPIONs with a dextran coating and size of 20–50 
nm [65].  
Carboxymethyl-substituted dextran is another anionic dextran derivative that has 
been used as coating material for biosensors in both commercial and research settings 
due to the high density of carboxymethyl groups available for chemical conjugations. This 
coating is cleared from circulation at a low rate (compared to the unmodified form) and 
exhibits low fouling activity. This derivative also has the advantage of permitting covalent 
fixation of the polymer to the NPs’ surface which is favorable for the colloidal stability of 
the NPs [66]. 
4.1.6. Mannan 
Mannan is a cell wall component that exists on the surface of microorganisms and 
consists of D-mannose residues. Mannan in Saccharomyces cerevisiae is composed of α-
(1,3)-, α-(1,6)- and α-(1,2)-linkages between the two sugar monomers, being water 
soluble. Its recognition is done by mannan-binding lectins of the complement system and 
mannose receptors on antigen-presenting cells and RES, while circulating antigen-
presenting cells also opsonize the antigen present in circulation and thereafter migrate to 
the lymph nodes. For this reason, mannan–coated SPIONs may be used as an MRI 
contrast agent to target macrophages. These NPs are phagocytosed in the liver by 
Kupffer cells [59]. 
4.1.7. Poly(γ-glutamic acid) (PGA) 
PGA is a multifunctional and polyanionic polymer that is biosynthesized by Bacillus 
subtilis through fermentation and consists of repetitive glutamic acid units linked by γ-
amide linkages between γ –carboxyl and α-amino groups [67, 68]. It was described that 
PGA increases antibacterial activity towards Escherichia coli [67]. 
4.1.8. Chitosan 
Chitosan is a kind of cationic linear natural polysaccharide whose protonated 
amino groups can become positively charged under weak acidic conditions [69]. Chitosan 
is derived and can also be prepared by N-deacetylation of chitin, a poly [(1,4)-N-acetyl-D-
glucosamine]. Chitin is, after cellulose, the most abundant natural biopolymer and is 
removed from the shell of shrimp and crabs [70]. 
I. General Introduction
13
Recently, chitosan has been in the limelight thanks to its outstanding biological 
properties such as biodegradability, biocompatibility, wound healing and antibacterial 
activity [69]. It was described that the low molecular-weight chitosan may restrict tumor 
growth and present anti-transfer activity in tumor-bearing mice by lymphocyte factor 
activation and immune regulation enhancement [71, 72]. However, the application of 
chitosan and chitosan-based materials is in some way restricted due to their poor 
solubility, physical properties, reactivity and consequently, strong inter and intra-molecular 
hydrogen linking in aqueous medium. Besides, chitosan-coated NPs may be adsorbed 
onto normal tissues throughout the circulation process in vivo due to their good 
bioadhesive and mucoadhesive characteristics. This is evidently undesirable for a 
targetted drug delivery system [69, 73, 74]. 
To overcome these limitations, chemical modifications have been performed with a 
view to making chitosan derivatives more soluble in water, such as N-
carboxymethylchitosan, N-carboxymethylchitosan, O-carboxymethylchitosan, O-
sulfatechitosan, N-sulfatechitosan, O-succinyl-chitosan, hydroxypropylchitosan, N-
methylene phosphonic chitosan and N-trimethylchitosan, etc. [74, 75]. For example, the 
small hydrophilic size (<50 nm) of O-carboxymethylchitosans-coated SPIONs and their 
hydrophilic surface has been reported to significantly ameliorate suspension stabilization, 
decrease protein absorption and increase SPIONs surface hydrophilicity, thereby avoiding 
their detection and uptake by mouse macrophage cells [76].  
Recently, an association between chitosan and poly(N-isopropylacrylamide) has 
been described. This is one of the most widely described water-soluble polymers, known 
for having a lower critical solution temperature (32ºC). Above this temperature, a phase 
separation occurs. It is also possible to associate monomers with this coating in order to 
modify the critical solution temperature. This modification may make this coating useful for 
hyperthermia and drug delivery applications [77, 78, 79]. Given that poly(N-
isopropylacrylamide) is non-biodegradable, its association with chitosan renders it 
degradable in small fragments, which facilitates its removal by renal clearance [80]. 
 
4.1.9. Dimercaptosuccinic acid (DMSA) 
 
DMSA is a sulfur-containing chelating agent that is negatively charged. Today, 
DMSA is injected to patients with the aim of absorbing additional elements in their body. 
Using DMSA, an anionic coating is produced on the NPs surface which avoids 
opsonization and their removal by RES of liver and spleen. Consequently, as direct 
contact with the cells is decreased, their toxic effects are also reduced [9, 81, 82]. DMSA 
protects NPs from aggregation and due to its negative charge, establishes a strong 
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interaction with the positively charged regions of the plasma membrane [9]. Moreover, 
highly negatively charged SPIONs (as in the case of DMSA-coated IONs) interact 
repulsively with negative domains of the plasma membrane, induce local neutralization 
and unspecifically adsorb on the cell membrane with subsequent membrane bending and 
efficient capturing into endosomal compartments [58]. For this reason, DMSA-coated 
IONs were shown to be internalized by cells to a greater extent than dextran-coated IONs 
[83]. 
 
4.1.10. Inorganic NPs 
 
Inorganic compounds have been used to coat IONs. These compounds can 
greatly increase the antioxidant properties of non-coated IONs. IONs functionalized with 
inorganic compounds show great potential for application in biolabeling, catalysis and 
bioseparation. Coatings with inorganic materials comprise silica, sulfides, metal, non-
metal and metal oxides [34]. Additionally, precious metals (namely gold) may be used to 
offer protection to iron oxide cores against oxidation, given that these metals form highly 
stable NPs and with low reactivity [9]. 
 
4.1.10.1. Silica and aminosilane 
 
Silica (SiO2) is a coating material that is inert, prevents the aggregation of the iron 
oxide core in liquid media and increases their chemical stability [60]. Silica-coated NPs 
are stable and redispersible in aqueous conditions (even when pH changes occur) due to 
the negative charge of the silica shell and the surface silanol groups that may react with 
silane and alcohol coupling agents to create dispersions stable in non-aqueous solvents, 
and offer the ideal anchorage for covalent binding of specific ligands [9, 13, 36]. Silica-
coated NPs offer excellent control of interparticle interactions within structures and in 
solutions by varying the shell thickness. Silica-coated NPs present longer circulation 
times. Moreover, their hydrophilic and negatively charged surface offers ideal anchorage 
for covalent binding to ligands, being an exceptional platform for drug delivery [9]. 
Additionally, silica and other microporous inorganic materials have the advantage of being 
heat resistant with a high surface area and good mechanical strength. The porosity of 
silica, which efficiently encapsulates drugs at high concentrations, also allows a 
controllable drug release over a prescribed period of time at the target site [36]. 
Aminosilane (SiO2-NH2) is a derivative of silica that presents higher cellular 
labeling efficiency than silica. Under pH 7.4, aminosilane is positively charged and as 
plasma membranes possess huge negatively charged domains, their cationic surfaces 
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have been demonstrated to favor cellular internalization [84, 85]. This coating was shown 
to be effective in increasing survival in animals subjected to the tumor model when used in 
thermotherapy [86]. 
 
4.1.11. Polycationic transfection agents (PTA) 
 
PTA, such as PEI, poly(L-lysine) (PLL) or protamine sulfate have been used to 
facilitate interaction between the SPIONs and the surface of those cells which present 
negative charges, and consequently in endosomal absorption [25]. They are also utilized 
in cell transfection to form electrostatic complexes with the anionic phosphate backbone of 
DNA [87]. 
PEI is a synthesized cationic polymer. Due to its positive charge, PEI interacts with 
anionic proteoglycan at the cell surface, which facilitates the IONs entrance into the cells 
by endocytosis [88]. It was also reported that PEI interacts in an undetermined way with 
anionic molecules in the serum as well as with plasma proteins, namely opsonins [89, 90]. 
Protamines are arginine-rich proteins of low molecular-weight (~4000 Da), purified 
from the mature testes of fish. Protamine sulfate is a polycationic peptide approved by the 
Food and Drug Administration (FDA) and is mainly employed as an antidote for heparin 
anticoagulation [91, 92]. 
PLL is a synthetic positively charged polymer commonly used to increase cell 
adhesion to culture dish surfaces. Although its use has still not been accepted in humans, 
it was reported to be able to bind (through electrostatic interactions) to the dextran coat, 
modifying the distribution of anionic and cationic surface charges of ferumoxides that can 
adhere to the cell membrane [93, 94]. 
 
4.1.12. Folic acid 
 
Folic acid is a water soluble B vitamin which is synthesized by prokaryotes, plants 
and yeast to facilitate the digestion, utilization and synthesis of proteins in the body when 
they are necessary. It is required for red blood cells production and DNA synthesis [95, 
96]. 
Folate-receptor is a folate-binding and glycosylphatidylinositol-anchored protein 
highly expressed in various types of human tumors, namely colon, ovarian, lung, liver, 
kidney and breast cancers, where it functions by folate uptake to feed rapidly growing 
tumor cells in division. In contrast, the folate receptor expression level on other non-
tumoral cells is low and only restricted to some epithelial cells [97, 98]. IONs conjugated 
with folate have the capacity to enter the receptor-expressing cancer cells through folate 
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receptor-mediated endocytosis and evade nonspecific capture of NPs in normal tissues, 
producing their apoptotic effect solely in cancer cells [95, 99].  
 
4.2. Toxicity of coatings 
 
Although coatings are beneficial for the above-mentioned reasons, there are 
increasing reports concerning their toxicity. After NPs core coating, the acute toxicity 
experimented is ascribed to the physicochemical properties of the NPs surface, which is 
key for cellular uptake and particle-cell interactions. These properties comprise surface 
charge, hydrodynamic radius and toxicity inherent to the coating materials [9, 66]. 
It is known that positively charged SPIONs are usually more toxic due to the fact 
that positive charges tend to be firmly attached to the cell surface, compared to the 
anionic NPs. This occurs because the resting cell membrane potential is negative [100]. 
Following intravenous injection of positively charged SPIONs, nonspecific interactions and 
unspecific adsorptive endocytosis take place, which results in aggregates formed with 
plasma proteins and blood cells.  Therefore, cationic SPIONs will be more concentrated 
into the cells than anionic SPIONs. Cell membrane integrity was demonstrated to be more 
severely damaged and intracellular vesicles contained a higher concentration of SPIONs 
in the cells exposed to positively charged SPIONs [100]. Hoskins et al [101] reported that 
PEI-coated magnetic IONs decreased the viability of breast cancer (MCF-7), 
neuroblastoma (SH-SY5Y) and macrophage-like (U937) cell lines respectively. It was also 
reported that PEI-coated NPs increased reactive oxygen species (ROS) production which 
resulted in cellular stress [101]. The explanation for these toxic effects is that, by inserting 
the cationic SPIONs in an acidifying lysosomal compartment, the unsaturated amino 
groups are able to trap protons that are provided by the proton pump for cationic SPIONs 
digestion. One Cl- ion and one water molecule per proton are propagated in the lysosome 
vesicle. Owing to Coulombic interactions, more protons will be injected into the lysosome 
which will cause lysosomal swelling and consequent rupture, leading to NPs deposition in 
the cytoplasm and lysosomal content spillage [102, 103].  
Regarding polyethylene oxide (PEO), it was reported that the shortest tails of PEO 
are more toxic when compared to the longest tails. The shortest 0.75 kD tail triggered 
chromatin condensation, nuclear blebbing and formation of apoptotic bodies [16]. In the 
case of PAA, it was reported that PAA-coated IONs markedly reduced cell viability in 
OCTY mouse cells. Only 16% of cell viability was observed at an iron concentration of 400 
µg/mL after 72 hours of culture [104]. 
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5. Magnetization of IONs 
 
Superparamagnetism is a fundamental criteria of magnetic NPs in nanomedicine. 
This phemomenon arises from competition between thermal fluctuations of magnetic 
moments of NPs and the ordering effect on such NPs due to an external magnetic field 
[103]. 
When an external magnetic field is not present, ferromagnetic materials are not 
magnetized, given that the magnetization of the ferromagnetic domains is randomly 
oriented. Contrary to para- and dia- magnetic materials, elimination of the magnetic field 
will not lead to magnetism loss, but the NPs will still display a remnant magnetization 
given that the large Weiss domains (regions within a magnetic material which have a 
uniform magnetization) are still aligned along the original field. When the particles size is 
smaller than the diameter of the Weiss/ferromagnetic domains (about 30 nm) leading to 
NPs not showing any magnetic remanence (i.e. restoration of the induced magnetization 
to zero upon elimination of the external magnetic field), superparamagnetism occurs. 
Superparamagnetic IONs are the most widely applied NPs in the biomedical field. Each of 
the NPs may be considered a monomagnet and is regarded as a fully magnetized single 
Weiss monodomain, which is a direct consequence of the spinel structure of the NPs, 
permitting strong magnetic coupling and therefore a perfect alignment of the individual 
magnetic spins. The IONs saturation magnetization diminishes with particule size, which 
is unfavorable for the efficiency (relaxivity) of the IONs. This decline of saturation 
magnetization has been ascribed to surface effects, namely spin canting, which is a lack 
of full alignment of the spins at the surface in high magnetic fields [23, 28, 103, 105]. 
 
6. Biodistribution 
 
Biodistribution of IONs and their efficient delivery to a specific tissue depends on 
their chemical and physical characteristics. NPs may be characterized according to their 
surface coating, size, surface charge, density, surface hydrophobicity and pH of their 
suspensions [106]. These properties are particularly relevant and strongly influence blood 
circulation time, bioavailability and metabolism of the NPs within the body [9, 46]. The 
coating of IONs plays a relevant role in their biodistribution. Coating materials that restrict 
or hamper water access to the iron oxide core display significantly lower degradation 
rates, as demonstrated by the enhanced half-life of these NPs in the liver [107, 108]. The 
surface charge of SPIONs also plays a key role in their blood half-life. Cationic NPs tend 
to adhere unspecifically to cells. Strong negative charges result in increased liver uptake 
[109]. 
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Furthermore, the biodistribution of NPs is influenced by a myriad of factors 
including the route of administration and the physiological environment to which NPs are 
introduced [110]. NPs could straightforwardly pass through diverse tissue compartments 
and move rapidly and freely to target organs [111]. The characteristic biodistribution of 
NPs is 80–90% in liver, 5–8% in spleen and 1–2% in bone marrow [9].  
6.1. Route 
Magnetic NPs may be administered into the body via several routes. Although the 
preferred route for cancer therapy is intravenous injection, other routes are considered 
effective for drug delivery. For example, in the case of lymphatic targeting, interstitial 
injections (namely intradermal and subcutaneous) are chosen, since low doses of 
magnetic NPs reach high accumulation levels in the regional lymph nodes [36].  
6.2. Influence of size 
Particle size plays a fundamental role in the biodistribution of IONs. In general, 
larger particles circulate in blood for shorter time periods than smaller particles. It was 
described that larger particles greater than 200 nm in diameter are usually entrapped by 
the liver and spleen due to mechanical filtration. IONs over 50 nm are usually captured 
quickly by the RES in Kupffer cells of the liver and have a restricted uptake in lymph and 
bone tissues. They are eventually eliminated by the phagocytic cells which results in 
diminished blood circulation times [9, 112, 113]. Due to their greater half-life, USPIONs 
can pass through the capillary wall and present more extensive tissue distribution. For this 
reason, they are readily captured by phagocytic cells, namely the Kupffer cells of the liver, 
mononuclear T cells and circulating monocytes/macrophages, as well as reactive 
astrocytes, dendritic cells and microglia inside the brain, and can be found in phagocytic 
cells in the lymph nodes, bone marrow, liver and spleen. This does not occur with 
SPIONs, which are found almost exclusively in the liver and spleen [114, 115]. However, 
smaller NPs of diameters less than 10 nm are quickly eliminated via extravasation and 
renal clearance. Particles between 10 to 100 nm are consequently ideal for subcutaneous 
injection and display the most prolonged blood circulation times (in humans of 24 to 36 h 
and in rats approximately 5 h [116]), having been reported to accumulate in bone marrow, 
heart, kidney, intestine, spleen and stomach [13, 117]. The ability of these IONs to cross 
the blood-brain barrier (BBB) and move into the central nervous system (CNS) via the 
olfactory pathway was also described as well as the ability to penetrate stratum corneum 
and hair follicles, attaining viable skin epidermis [9, 18]. The NPs in this size interval are 
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sufficiently small to evade RES and in addition, enter the very small capillaries within the 
body tissues. For this reason, they may provide the most effective distribution in several 
tissues [13]. The capture of SPIONs into the RES is associated with protein adsorption on 
the particle surface and ensuing opsonization. Consequently, decreasing the particle size 
will reduce NPs phagocytosis, which results in a significant increase in plasma half-life 
and larger biodistribution [118, 119]. 
 
6.3. Half-life 
 
For all IONs, the blood half-life is dose-dependent. This feature is related to a 
gradual saturation of macrophage capture by the liver or other macrophage-rich organs, 
namely spleen and bone marrow [28]. The blood half-life of IONs is normally higher in 
humans than in animals. Although it was described that SPIONs are more appropriate for 
primary monocytes labeling, USPION are more frequently used for in vivo labeling due to 
their long blood pool half-life: the plasma half-life for USPIONs has been reported to range 
from 80 minutes to more than 24 hours, compared with only ~2 to 4 hours for standard 
SPIONs [28, 114, 120]. Ferumoxides interaction time with cells is reported to be 
approximately 6 minutes in vivo compared to 4 h in vitro [65]. The large variability in 
USPIONs circulation time is related to the composition of the surface coating used to 
stabilize the particle. In general, the extended circulation time for USPIONs derives from 
the particles not being immediately recognized by phagocytic cells of the RES [114]. 
Ferumoxtran-10 (15-30 nm) is reported to have a longer blood half-life (around 30 h in 
humans) without accumulating in specific tissues compared to ferumoxide AMI-25 (120-
180 nm) [28]. 
 
6.4. Circulation and homeostasis 
 
The destiny of NPs following intravenous administration is defined by their polymer 
coatings. After injection of NPs into the bloodstream, they are usually opsonized and this 
step is critical in dictating their outcome. Usually, opsonization makes the NPs 
recognizable by the RES. The liver macrophages and, to a lesser extent, the 
macrophages in circulation and of the spleen, play a significant role in the elimination of 
opsonized NPs [121]. IONs do not extravasate into the interstitium in most tissues. 
However, some extravasation was observed across the discontinuous endothelium of 
microvessels in the liver, spleen, lymph nodes and bone marrow [122]. In addition, when 
NPs are transported to the tumor site through the bloodstream, some extravasation can 
occur across hyperpermeable microvessels [123]. After clearing by the RES, there is the 
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possibility that magnetic NPs recirculate in the blood or inflammatory lesions, being 
transported by membrane vesicles which are released by apoptotic macrophages. 
Consequently, the vesicular traffic permits a dynamic intercellular redistribution of NPs 
[124]. 
Intracellular iron homeostasis involves a tightly regulated balance between the 
synthesis of transferrin receptors and the synthesis of intracellular ferritin molecules, 
responsible for cellular iron capture [125, 126]. Clear evidence has now emerged that 
once the USPIONs are ingested by macrophages, they are dissolved within the 
lysosomes by a succession of hydrolyzing enzymes with the low pH (~ 4.5) of the 
lysosome, where this low pH and heme oxygenase divides the iron oxide core into iron 
ions. These ions are subsequently incorporated into the hemoglobin pool and potentially 
into other iron requiring proteins such as apoferritin, ferritin and transferrin [36, 115, 127, 
128]. 
When cytoplasmic iron content rises, ferritin synthesis is triggered, which results in 
the entrapment of toxic iron (Fe2+) into the ferritin molecules [129]. However, it was 
described that elevated levels of free iron ions from magnetic NPs may trigger a 
disequilibrium in body homeostasis and lead to aberrant cellular responses including 
oxidative stress, DNA damage, epigenetic events and inflammatory processes [36]. 
 
6.5. Elimination 
 
The efficacy of NPs clearance exerted by RES depends on the chemical 
composition, size and surface chemistry of the magnetic NPs and may influence 
mechanisms of particle internalization as well as macrophage activation [9]. The most 
desirable excretion pathway for IONs is via the kidney (89%) given that this route implies 
minimal intracellular catabolism and reduces the probability of producing reactive oxygen 
species (ROS) and therefore, associated toxicity. Renal excretion is considered the safest 
route of excretion for IONs. However, the hydrodynamic size, shape, surface charge and 
surface coating of IONs play a key role in the regulation of their renal clearance [28, 35, 
130]. The rest of the iron is excreted slowly (84 days) in feces [131]. The presence of γ-
Fe2O3 NPs in podocytes has been reported, suggesting that they can cross the glomerular 
basement membrane and consequently, are filtered into the urine. This is also supported 
by the finding that NPs are present in lysosomes/endocytic vesicles in the cytoplasm of 
proximal tubular cells [132]. 
Regarding coating elimination, it has been suggested that the acidic environment 
of the lysosomal compartment (pH ~ 5.5) may cause the rupture of the dextran shell 
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(because of the existence of intracellular dextranases in macrophages) and liberate Fe3+ 
from IONs. Sulfatases are also lysosomal enzymes that break a variety of sulfated 
carbohydrates, being these compounds able to be used as IONs coating [133, 134]. 
 
6.6. Differences between normal and cancer cells 
 
Carcinoma and normal cells were shown to have different metabolism regarding 
iron uptake. Breast carcinoma cell metabolism, for example, is faster than in normal cells. 
As a result, carcinoma cells necessitate larger amounts of micronutrients (namely iron), 
which can be evidenced by the increase of transferrin receptors in these cells [135, 136]. 
Moreover, in fast-growing tumors, neovascularization is habitually deficient and 
associated with poor lymphatic drainage, which permits increased permeation and 
retention of therapeutic nanodrugs [137]. However, it was described that SPIONs are not 
phagocytosed by reticuloendothelial cells in tumoral lymphoid tissues because 
macrophages are replaced by cancer cells and consequently, these tissues lack 
reticuloendothelial cells [138, 139]. 
 
6.7. Cellular localization 
 
IONs have been described as having cytoplasmic localization in different cells, 
namely non-coated Fe3O4 NPs in HeLa cells [140], DMSA-coated Fe3O4 NPs in 
RAW264.7 cells [141, 142], pullulan-coated Fe3O4 NPs in fibroblasts [143] and citrate-
coated γ-Fe2O3 NPs in THP-1cells [124]. IONs seem to be grouped into clusters in the 
cytoplasm of the cells, in part around the nucleus and possibly localized in endocytotic 
vesicles (for example lysosomes) [124, 144, 145]. It was reported that in BEAS-2B cells, 
IONs are surrounded by mitochondria but do not have the capacity to penetrate them 
[145]. However, in monocytes NPs are described as entering into the mitochondria, 
having been found on the membrane and cristae, sometimes filling the matrix [146]. 
 
7. Internalization routes 
 
Diverse cellular internalization routes exist which include transcytosis and 
endocytosis (clathrin-mediated endocytosis, caveolae-mediated endocytosis, 
phagocytosis and macropinocytosis), among others. It is believed that all of these types of 
mechanisms are used by cells to internalize several substrates [9, 147]. 
The cellular internalization routes through which NPs enter into the cells depend 
on their surface properties which may be characterized according to their 
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hydrophilic/hydrophobic features, chemistry or surface energy. These surface 
characteristics determine the means by which NPs adsorb to the cell surfaces and more 
specifically, dictate the behavior of the cells in contact with them [46]. Size is also 
determinant for NPs internalization and efficacy of cellular uptake. For NPs in the interval 
10–30 nm, diffusion through membrane channels or across plasma membranes may 
occur [36]. Smaller NPs may also be internalized by pinocytosis while in the case of larger 
NPs, phagocytosis and receptor-mediated endocytosis seem to be the most common 
internalization pathways [148]. In phagocytic cells, smaller NPs are often internalized less 
effectively than larger NPs while in nonphagocytic T-cells, NPs with intermediate sizes 
were shown to be internalized more effectively than any other size [148]. 
 
7.1. Transcytosis 
 
Transcytosis is described as being the vesicular transendothelial transport 
mechanism. Endothelial vesicles represent the most important mediator of 
macromolecular transport via the capillary wall and are increased in inflamed tissues [149, 
150]. Endothelial transcytosis into the interstitium throughout the body has been described 
as a mechanism by which IONs uptake can occur. When USPIONs are in the 
bloodstream, they may cross the endothelium by transcytosis. Thereafter, USPIONs will 
be taken up by cells through endocytosis or other processes [28].  Transcapillary passage 
of the NPs through the venules into the medullary sinuses within the lymph nodes has 
been described, with subsequent phagocytosis by macrophages [151]. 
 
7.2. Endocytosis 
 
Most inorganic NPs are captured by cells through the endocytic route. 
Internalization via endocytosis (the process of capturing macromolecules into cells by 
including them in membrane vesicles) after cell membrane contact can occur through a 
variety of mechanisms: clathrin-mediated endocytosis, caveolae-mediated endocytosis, 
receptor-mediated endocytosis, phagocytosis, pinocytosis and macropinocytosis [152]. 
In endocytosis, NPs interact with the cell plasma membrane which encloses and 
traps them into vesicles. These vesicles are denominated early endosomes and are 
transported via the cytoplasm and fuse sequentially with late endosomes and lysosomes. 
In this process of cell internalization, NPs meet compartments with various enzymatic 
activities and continuously decreasing pH, ending up in lysosomes [153, 154]. The 
endocytic pathway was previously reported for anionic magnetic NPs after interacting with 
the plasma membrane via electrostatic interactions [124, 155]. It was also described that 
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PVA-coated SPIONs were endocytozed by monocyte-derived human dendritic cells in a 
dose-related manner, predominantly via an actin-dependent process [41]. Cellular uptake 
data showed that the uptake of long-circulating dextran-coated IONs was ever-present in 
several tumor cells and was not saturable, which suggests that fluid-phase endocytosis 
rather than receptor-mediated endocytosis is the uptake mechanism [156]. Improved 
endocytosis strategies may be sought, namely the use of transfection agents, antibody or 
receptor-mediated delivery or conjugated, cellular translocation signal peptides [4, 103]. 
 
7.2.1. Phagocytosis 
 
Phagocytosis is an actin-dependent endocytic mechanism which involves 
phagocytes such as dendritic cells, macrophages and neutrophils [157]. It is often 
triggered by particle opsonization and ensuing F-actin-driven pseudopods receptor-
mediated activation, which encloses the NPs in a phagosome present in the cytoplasm 
[158]. It was observed that phagocytic uptake of IONs increases when NPs size 
increases. USPIONs of sizes varying from 20–50 nm and monocrystalline IONs (MIONs) 
of 10–20 nm sizes were less efficiently phagocytized than SPIONs between 50–180 nm 
[115, 159]. Another study reported that phagocytosis was highest in response to 10 nm 
magnetite particles and minimal in response to 1 µm particles, which is not completely in 
line with the previous mentioned studies [160]. 
 
7.2.2. Macropinocytosis 
 
Macropinocytosis is a highly conserved endocytic process where extracellular fluid 
and its contents are enclosed into cells through macropinosomes. These are 
heterogeneous and large vesicles formed through direct actin polymerization near the 
plasma membrane, causing membrane ruffling [157, 161]. Rejman et al [147] 
demonstrated that efficient uptake of microspheres requires cholesterol in their plasma 
membrane which can indicate that macropinocytosis is in some way involved in the 
internalization of larger sized particles. Macropinocytosis, although not ubiquitous, may 
function in cells other than macrophages. It was described that magnetic NPs can be 
incorporated into A549 human lung endothelial cells by macropinocytosis [12, 162].  
 
7.2.3. Clathrin-mediated endocytosis 
 
IONs uptake can also occur via clathrin-mediated endocytosis. It is known that 
some cells (such as macrophages) express clathrin, and clathrin forms clusters at these 
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NPs capture areas. Clathrin assembly triggers the generation of coated pits of 
approximately 150 nm. Internalization occurs when the clathrin coating on the plasma 
membrane creates invaginations in the membrane, leading to clathrin-coated vesicles 
budding. Following internalization, the clathrin coating is recycled, leading to the fusion of 
the vesicle with an endosome where the sorting (which is mediated by microtubules) and 
dissociation of potential receptors takes place. Thereafter, degradation in lysosomes takes 
place and further transportation to the final destination occurs [142, 163, 164]. 
Lunov et al [165], having detected by transmission electron microscopy (TEM) that 
SPIONs and USPIONs are incorporated inside vesicles of approximately 100 nm in 
diameter, used monodansyl cadaverine, which is a specific inhibitor of clathrin-mediated 
endocytosis, and demonstrated that macrophages capture the carboxydextran-coated 
NPs though a clathrin-mediated endocytosis mechanism. Yang et al [166] using 
phenylarsine oxide (another inhibitor), reached a similar conclusion with Ferucarbotran. 
Likewise, Ayala et al [66] using dansylcadaverine also showed that 
carboxymethylsubstituted dextran-coated IONs were internalized using this mechanism. 
Internalization by this mechanism was attributed in this last case to the formation of a 
protein corona surrounding NPs. This protein corona is formed through non-specific 
interactions between serum proteins and NPs that are usually internalized via clathrin-
mediated and caveolae-mediated endocytosis [66].  
7.2.4. Caveolae-mediated endocytosis 
Caveolae (of diameter 50–100 nm) are invaginated, flask-shaped plasma 
membrane domains which are present in diverse cell types but particularly abundant in 
endothelial cells. Their structure is sustained by caveolins, which are a family of 
cholesterol-binding proteins. In addition to caveolin, caveolae are enriched in 
sphingomyelin, cholesterol and glycosphingolipids [147, 167]. Prijic et al [168] suggest 
that SPIONs uptake by mouse L929 fibroblasts cells, human melanoma SK-MEL-28 cells 
and human mesothelial MeT-5A cells occurs by caveolae-mediated endocytosis. 
Moreover, DMSA-coated SPIONs uptake in RAW264.7 cells was also reported to be 
caveolae-mediated [142]. Likewise, Ayala et al [66] using fillipin (which is a specific 
inhibitor of caveolae-mediated endocytosis), showed that carboxymethylsubstituted 
dextran-coated IONs were also internalized using this mechanism for the reason outlined 
above in 7.2.3. 
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7.2.5. Receptor-mediated endocytosis 
7.2.5.1. Transferrin receptor 
It has been described that the transferrin receptor is the most important route for 
iron transport through the capillary endothelium luminal membrane. It is possible that iron 
passes through the luminal membrane and in the form of Fe2+, enters the interstitial fluid 
[169]. Chen et al [170] hypothesized that gambogic acid loaded on magnetic IONs 
permeated the cell membrane through binding to the transferrin-binding site of transferrin 
receptor and endocytosis, which were potential routes for IONs uptake into cells. 
7.2.5.2. Scavenger receptor (SR)-A 
Among the several receptor types involved in the endocytic process, macrophage 
SRs are an attractive family which has been thoroughly studied. These receptors were 
firstly identified as macrophage receptors involved in the recognition of modified 
lipoproteins. Presently, they comprise a family of eight different pattern recognition 
receptor subclasses, binding to a diversity of ligands, namely modified low density 
lipoproteins (LDL), polysaccharides, proteins, RNA and environmental particles, while 
playing a fundamental role in immunity and host defense [165, 171]. Under physiological 
conditions, SRs scavenge or clean up cellular debris as well as other similar materials and 
exert an important role in host defense. Under pathological conditions, SRs intervene in 
the recruitment, activation and transformation of several cells which may be correlated 
with the development of atherosclerosis and other disorders provoked by accumulation of 
the denatured materials, such as Alzheimer disease or multiple sclerosis [172]. It has 
been described that SPIONs uptake is mediated by SR-A [122, 173]. Raynal et al [173] 
used the SR-A inhibitors fucoidan and polyinosinic acid in competition experiments and 
observed that there was a dose-related inhibition of ferumoxides uptake, which clearly 
demonstrates that a SR-A-mediated endocytic pathway is implicated in IONs uptake by 
macrophages. SPIONs uptake into hepatocytes was also shown to be independent of 
caveolae, dynamin and clathrin-coated pits and mediated principally by a SR other than 
SR-A [174]. 
7.2.5.3. Mac-1 receptor 
Another receptor possibly implicated in NPs capture is Mac-1 [175]. Both SPIONs 
and USPIONs are eliminated from the circulation by mononuclear phagocyte system cells 
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through adsorptive endocytosis in a monocyte integrin Mac-1 receptor-mediated process, 
which is also involved in the adhesion of leukocytes, activation of complement and 
phagocytosis [159]. Von Zur Muhlen et al [175] reported that, after human monocytes 
stimulation with PMA, the capture of Ferumoxtran-10 and amino-PVA-coated USPIONs 
(with a mean hydrodynamic size of 30 nm) was significantly enhanced for Ferumoxtran-10 
and amino-PVA SPIONs but was inhibited by antibodies to Mac-1 (CD11b/CD18) in 
human monocytes. 
 
7.2.5.4. Other receptors 
 
Mannose receptors are possibly involved in mannan-coated SPIONs uptake. It 
was described that recognition of mannan-coated SPIONs was efficiently performed by 
mannose receptors which were expressed on human monocyte-derived macrophages 
[59]. Also, it was reported that ION coated with folic acid can be internalized by folate 
receptor, which is useful for tumor imaging [176, 177]. 
 
8. NPs available in the market 
 
Currently, a wide range of IONs formulas are available in the market (table 1). 
Despite the fact that these formulas were initially conceived for imaging lesions in RES 
organs like spleen, liver and lymph nodes, they have also been used for cell labeling. 
These formulas differ in surface coating materials and size, which is a determining factor 
for uptake rate and cell retention [178]. 
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Table 1. IONs available in the market. 
 
Name Type Coating agent Applications 
Ferumoxides 
 
Endorem® (Europe) 
 
Feridex® (USA, 
Japan – withdrawn 
from the market) 
 
AMI-25® 
SPIONs Dextran 
- liver and spleen imaging 
[28, 115, 133] 
- monitorization of dendritic 
cells in melanoma patients 
and neural stem cells in 
traumatic brain injury [179, 
180] 
Ferucarbotran 
 
Resovist® (Europe, 
America, Japan and 
Australia – 
withdrawn from the 
market in America 
and Australia) 
 
Supravist® 
 
SPIONs 
(Resovist®) 
and USPIONs 
(Supravist®) 
Carboxydextran 
- imaging of liver and central 
nervous system tumors 
[115] 
- pancreatic islet grafts in 
type I diabetic patients 
[181] 
Ferumoxytol 
 
Feraheme® 
USPIONs Polyglucose sorbitol carboxymethylester  
- iron replacement therapy 
in patients with chronic 
renal failure [115, 182] 
- CNS imaging applications 
[115] 
Ferumoxtran-10 
 
Combidex® (USA) 
 
Sinerem® (Europe) 
USPIONs Low molecular weight dextran 
- Imaging of CNS, lymph 
node, brain, kidney, 
osteoarticular tissues, 
inflammatory cells, 
atherosclerotic plaques, 
etc. [57, 115, 122] 
Ferumoxsil 
 
Lumiren® 
 
AMI-121® 
USPIONs Silicone - bowel imaging [183] 
Feruglose 
 
Clariscan® 
(discontinued) 
USPIONs Carbohydratepolyethylene glycol 
- MRI angiography [184] 
VSOP-C184 USPIONs Citrate - MRI [178] 
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9. Concentration
The ingestion of dietary iron amounts to about 10–30 mg per day in adult humans 
while the mucosa absorbs approximately 0.6–1.5 mg per day [185]. In therapeutic 
situations, the IONs concentration may vary according to the IONs formula used as well 
as the purpose for which they are being used. Table 2 summarises the recommended 
doses reported in the literature. 
Table 2. Recommended doses of IONs used for medical purposes. 
Name Dose 
Resovist® 
0.42−0.65 mg Fe/kg (in humans when 
used for liver-specific magnetic 
resonance contrast agent) [186] 
USPIONs 2.6 mg Fe/kg [187, 188] 
Sinerem® 
2.6 mg/kg (for MRI detection of human 
atherosclerotic plaques) [189] 
Endorem® 
0.588 mg/mL (for liver MRI, intravenously) 
[190] 
Fe2O3 NPs 
45 µmol Fe/kg (for human MRI in CNS 
and in carotid atherosclerotic plaque) [57] 
10. Applications
Due to their chemical, physical, mechanical and thermal properties, IONs are of 
high interest for in vivo applications.  
10.1. Magnetic resonance imaging (MRI) 
The advantages of MRI, when compared to other imaging techniques are that it is 
noninvasive; it provides superior spatial resolution and tissue contrast, principally in soft 
tissues; it can screen cellular events in living animals in vivo; it may be performed 
repeatedly and continuously in real time; and it does not involve the use of radioactive 
isotopes [191]. 
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MRI contrast agents are sorted by the several changes in relaxation times after 
their injection and are divided into two categories. Positive contrast agents (bright on MRI) 
provoke a decrease in the T1 spin lattice relaxation time (increased signal intensity on T1 
weighted images). These agents are usually low molecular weight compounds which 
contain manganese, gadolinium or iron as their active element. Negative contrast agents 
(dark on MRI) such as USPIONs typically consist of a crystalline iron oxide core which 
contains thousands of iron atoms and a polymer shell. These mainly produce spin 
relaxation effects (local field inhomogeneities), resulting in shorter T2 relaxation times 
[192]. SPIONs are also mainly used as a T2 contrast agent in MRI although this agent 
may shorten T1 and T2/T2* relaxation processes [183]. However, to date only few 
examples have been published where IONs are used as a T1 contrast agent. An 
important example corresponds to the well-known blood pool contrast agents, which are 
applied to the imagiology of particular vessel structures in MR angiography and offer a 
longer blood half-life when compared to the other classes [193, 194, 195]. 
 
10.1.1. Labeling and imaging 
 
A huge diversity of SPIONs has been prepared to date and experimented for 
several preclinical applications, and in clinical trials. Hepatic imaging was the first clinical 
application for IONs. Several studies have demonstrated that IONs are captured by 
macrophages to a greater extent than other cell types although most of the cells are 
possibly capable of capturing them to a certain degree [62, 196]. After intravenous 
injection, IONs are quickly captured by the Kupffer cells (specialized hepatic 
macrophages), which results in a decrease in magnetic resonance signal intensity and 
consequently in hypointense images [28]. It was reported that monocytes are labeled 
more effectively by utilizing SPIONs rather than USPIONs mainly due to the larger 
diameter of SPIONs compared to that of USPIONs. However, the long blood pool half-life 
of USPIONs (greater than 24 hours in humans) makes them the most commonly used 
ION for in vivo labeling [28, 120]. 
The different composition and size of IONs (which impacts their biodistribution) 
caters for diverse clinical applications: SPIONs with high macrophage capture are used 
mainly for liver imaging [28]; USPIONs with extended blood half-life are efficient for 
macrophage imaging and metastatic lymph node as well as blood pool agents utilizing a 
T1 sequence for angiography, tumor blood volume and tumor permeability or utilizing a 
T2/T2* sequence for vessel size index and steady-state cerebral blood volume 
measurements [28]. 
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IONs administered intravenously have been applied as a MRI contrast agent to 
analyse liver pathology, namely in the identification and characterization of focal hepatic 
lesions. They have also been proposed for use in monitoring patients undergoing surgical 
procedures for focal hepatic malignancies and in the follow-up stage of patients with liver 
cirrhosis for hepatocellular carcinoma detection [197, 198, 199, 200]. Additionally, they 
have been used as an ex vivo cell labeling agent for diverse types of mammalian cells 
which after labeling, may be used as in vivo MRI probes. IONs have been successfully 
used to label T cells [201], cancer cells [139], stem cells [58] and dendritic cells [202] as 
well as detect functional and anatomic renal abnormalities [203, 204, 205]. 
IONs alone or conjugated with target-specific ligands (namely antibodies or 
proteins) have been utilized in the selective imaging of tumors in vivo as well as for gene 
delivery and therapy [37]. In fact, one strategy to perform specific and efficient cell labeling 
with magnetic NPs is to alter the NPs surface by recurring to a ligand, which could be 
effectively captured by target cells through receptor-mediated endocytosis. A diversity of 
ligands has been conjugated to NPs surfaces to favor the receptor-mediated endocytosis 
of the NPs, namely monoclonal antibodies. Targeting agents (for instance, albumin, 
insulin, transferrin and growth factors, etc.) have been shown to preferentially target the 
cell surface, given that the receptors for these ligands are usually overexpressed on the 
mammalian cells surface [13]. For example, it was described that HER2/neu antibody 
conjugated poly(amino acid)-coated IONs derivatives can be used for breast cancer 
SKBR-3 cells molecular MR imaging [206]. 
IONs were also hypothesized as being useful for vascular compartment imaging 
(magnetic resonance angiography) as in the case of pullulan-modified IONs [143]. 
Labeling mouse insulinoma cells with IONs is also feasible. Citrate-coated MIONs were 
described to be internalized in all insulinoma cell lines experimented, although at low 
concentration [207]. 
Apart from these applications, SPIONs are intensively explored in neuromedicine 
because they can cross the BBB [208]. The use of IONs conjugated to a glioblastoma 
specific antibody in glioblastoma tumors imaging has been described as has the 
application of IONs in the study of neuroinflammation following stroke [209, 210]. Some 
studies demonstrated that transplanted oligodendrocyte progenitors [211], neural stem 
cells [212], Schwann cells [213], olfactory ensheathing cells [213], bone marrow stromal 
cells [214] and undifferentiated embryonic stem cells [214] can be located using MRI in 
CNS and non-CNS tissue in vivo through intracellular labeling with IONs [215]. 
IONs have been employed to image inflammatory processes, angiogenesis or 
atherosclerosis [175, 216]. Small SPIONs were described as being able to navigate 
through the tight interstitial endothelial pores and have been used in imagiology with 
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macrophages in in vivo studies [159]. It has been demonstrated by experimental research 
in an atherosclerotic animal model using hyperlipidemic rabbits that USPIONs enter 
atherosclerotic plaques with an enhanced endothelial permeability and accumulate in 
atheroma with high macrophage content [217, 218]. 
SPIONs have also been successfully used to label transplanted cells for in vivo 
monitoring by high resolution MRI [37]. Mesenchymal stem cells also called mesenchymal 
stromal cells (MSC), have the potential to migrate after systemic transplantation along 
chemokine gradients to diseased tissues where they engraft and differentiate into the 
defective cell type and/or induce regenerative processes through paracrine mechanisms 
[58, 219, 220]. IONs are useful in tracking the transplantation of stem cells and immune 
cells with the aim of regenerating, repairing or restoring the functionality of diverse tissues 
or organs. These have been in the limelight for the treatment of a variety of diseases such 
as cancer, leukemia, muscle damage, neural degenerative diseases, spinal cord injuries, 
stroke, myocardial infarction and bone fractures. Numerous studies have already 
demonstrated the in vivo tracking of SPIONs-labeled MSC by MRI in various tissues such 
as brain, liver, kidney, spinal cord, myocardial heart and muscle tissue [58, 219]. 
IONs may also be useful in the identification of tumor cell apoptosis markers using 
MRI. Numerous markers can be used to identify apoptotic cells including DNA 
fragmentation, morphological changes and caspase activation. The flipping of 
phosphatidylserine from the plasma membrane bilayer inner leaflet to the outer surface is 
a relatively early event in the apoptotic process, which can be detected by the protein 
annexin V binding to surface phosphatidylserine [221, 222, 223]. It was reported that a 
conjugation of annexin V to CLIO enabled the detection of apoptosis with MRI both in vitro 
and in vivo [224]. It was also shown that the C2A-GST (domain of synaptotagmin I; 
glutathione S-transferase) fusion protein could also be used to detect apoptotic tumor 
cells in vivo and in vitro in T2-weighted MRI experiments, when directly conjugated to 
SPIONs [221, 225]. 
 
10.1.2. Cell sorting 
 
Cell labelling with IONs is an increasingly widespread method for in vivo cell 
separation given that the labelled cells may be detected by MRI. Most recent labelling 
techniques apply one of these two approaches: 1) engulfment of biocompatible magnetic 
NPs by receptor-mediated endocytosis, fluid phase endocytosis or phagocytosis or 2) 
binding of magnetic NPs to the cell surface [13]. The immunomagnetic poly(glycidyl 
methacrylate) (PGMA)-coated IONs conjugated with a specific monoclonal antibody with 
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CD4 molecules expressed on CD4+ lymphocytes were reported to be highly efficient and 
specific in CD4+ lymphocytes separation from whole blood, which can be applied in 
diverse biomedical applications namely diagnosis, treatment and monitoring of illnesses 
[226]. 
 
10.2. Tissue repair 
 
IONs can be used to promote tissue repair. In fact, they were described (in the 
presence of the nerve growth factor) to synergistically instigate neurite outgrowth and 
upregulate a neural specific marker protein [227]. 
The possibility of using magnetic NPs in osteoporosis treatment has also been 
reported [228, 229]. The ability of these NPs (principally maghemite) to instantaneously 
enhance bone density and give rise to a further increase in osteoblast functions at the 
disease site was underlined. In addition, the magnetic properties of these NPs can be 
applied to guide drug molecules that were previously attached to the NPs under a 
magnetic field to targeted bone sites [228, 229]. 
 
10.3. Drug delivery 
 
Magnetic NPs were used for the first time as delivery systems for drug delivery in 
cancer treatment in the late 1970s [168]. The magnetic properties of SPIONs permit their 
mechanic manipulation by a magnetic field gradient. This capacity of “acting at a distance” 
in combination with the intrinsic capacity that magnetic fields have to penetrate into 
human tissue, increases the specificity and selectivity of the therapy, enabling these 
particles to be conducted or held to a certain place through a magnetic field and heated to 
induce drug release or generate tissue hyperthermia [123, 230]. Therefore, the main 
benefits sought through use of nanovectors over simple drugs are: protection of the drug 
from their natural inhibitors, such as enzymatic degradation; specific and effective delivery 
of large quantities of therapeutic drugs utilizing biorecognition targets; pharmacokinetic 
and drug tissue distribution profile control; increased drug absorption into a selected 
tissue via increased retention effect and permeability; amelioration of intracellular 
penetration; avoidance of damage to healthy cells when cancer cells are killed and; low 
toxicity and immunogenicity [231, 232, 233]. 
SPIONs can work as vehicles for several molecules such as alkylating agents, 
plant alkaloids, antitumor antibiotics, antimetabolites, cytokines and monoclonal 
antibodies. Therefore, they function as delivery systems for therapeutic purposes [137, 
168, 169]. A potential application is the conjugation of thrombin to IONs for use in the 
I. General Introduction
33
promotion of wound healing, given that thrombin is necessary for the conversion of 
fibrinogen to fibrin, whose action is critical and necessary for the early and late stages of 
wound healing [234]. 
IONs can be used to solve the problem of lack of sensitivity of tumor cells to 
cytotoxic drugs, which occurs in tumor treatment. Indeed, some reports have proven the 
synergistic effect of IONs on the delivery of anticancer drugs [5, 170, 235, 236], namely 
increasing the accumulation of the drug daunorubicin in leukemia cells. This accumulation 
could be related to the capacity of the IONs to block glycoprotein P function [237]. 
Previous investigation has demonstrated that daunorubicin and 5-bromotetrandrine 
attached to magnetic IONs revealed a considerable cytotoxicity effect on drug resistant 
leukemia K562/A02 cells [238]. SPIONs and USPIONs can be further modified by 
incorporation of a photosensitizer that has proven capable of generating singlet oxygen 
(1O2), useful in cancer therapy [239]. 
To achieve drug-targeting, SPIONs are frequently combined with targeting ligands 
such as antibodies, small molecules or peptides. This will target them for specific sites 
and allow rapid accumulation of SPIONs as well as the drugs they carry into the regions of 
interest. Some examples are folic acid, given that the folate receptor is usually 
overexpressed solely in cancer cells, namely in ovary, breast, kidney, colon and lung, and 
restricted in normal tissues [4, 97, 98]. Antisense oligonucleotides coupled with silica-
coated magnetic IONs are also described as being a significantly attractive targeting 
delivery system for selective tumor targeting and specific cellular uptake [240]. Recently, 
Seabra et al [241] reported that IONs coated with DMSA or mercaptosuccinic acid may be 
nitrosated in their thiol groups. This formation of S-nitroso groups on the surface of IONs 
permits the release of nitric oxide, which can be useful in anticancer therapies. 
 
10.4. Hyperthermia 
 
Hyperthermia is a therapeutic practice that relies on the enhancement of 
temperature in body tissues with the aim of changing the functionality of the cellular 
structures [86]. The earliest use of magnetic hyperthermia on tumors was described in 
1957 by Gilchrist et al [242]. This author showed with in vitro assays that 5 mg of 20–100 
nm diameter Fe2O3 NPs in lymph nodes (47 mg of Fe2O3 per gram of tissue) were able to 
trigger a temperature enhancement of 14 ºC in an alternating magnetic field of 200–240 
Oe at 1.2 MHz [242]. However, the first prospective study for biomedical purposes in 
humans was described only in 1993. In 2010, magnetic hyperthermia trials involving the 
use of magnetic NPs passed preclinical stages and obtained regulatory authorization as a 
new clinical therapy denominated thermotherapy [243]. Recently, many IONs have been 
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developed to be used in hyperthermia, namely γ-Fe2O3 NPs coated with L-3,4-
dihydroxyphenylalanine (L-DOPA) and tetra-methylrhodamine-5/6-isothiocyanate [162]. 
In this process, heat is produced as a result of magnetic hysteresis loss. When 
NPs are submitted to a high frequency AC magnetic field, they become heated due to 
Neel or Brownian relaxation losses in single-domain particles, which results in localized 
destruction of the cells [9, 35]. 
This local enhancement in temperature may be applied in medical treatments to 
destroy tumor cells and this is favored by the fact that cancer cells are more sensitive to 
abrupt rises in temperature above 43ºC than normal cells [86, 244]. In fact, the increase in 
temperature alters the performance of many structural and enzymatic cellular proteins, 
triggering repair enzyme inhibition, as well as alterations in DNA synthesis and 
conformation, together with alterations in differentiation and cell growth, which may lead to 
apoptosis. Hyperthermia may also trigger alterations in cell membrane which leads to a 
fall in transmembrane transport and provokes a destabilization of its potential [86]. 
Exposure of tumor cells to moderately high temperatures renders them sensitive to 
radiation and chemotherapy and may diminish their viability, depending on the exposure 
time and temperature [245]. Apart from killing cancer cells with heat, a host immune 
response is induced. Nevertheless, conventional hyperthermia systems encompass 
treatment solely once or twice per week, performed at intervals greater than 48 h to avoid 
thermotolerance provoked by the expression of heat shock proteins [245]. In addition, it is 
difficult to heat the local tumor region to the desired temperature without provoking 
damage in the normal tissue [245]. However, hyperthermia using magnetite NPs has 
proven to be efficient in animals with different types of tumor, including T-9 rat glioma, B16 
mouse melanoma, VX-7 squamous cell carcinoma in rabbit tongue, Os515 hamster 
osteosarcoma and MM46 mouse mammary carcinoma [245]. 
10.5. Transfection 
Transfection or gene therapy implies the introduction of genetic materials namely 
small interference RNA, oligonucleotides, plasmid DNA, messenger RNA and double-
stranded DNA into tissues or target cells to express knockdown mutated deleterious 
genes, heterogeneous gene products, and substitute with functional genes. Gene delivery 
has demonstrated great promise in genetic disease treatments such as thalassemia, 
cystic fibrosis, influenza A, Huntington’s disease, Parkinson’s disease, cancer, inherited 
color blindness, etc. The gene carrier (usually denominated as a vector) is required to 
transfer the genetic sequences for gene expression into the cellular compartment. Vectors 
can be generally classified into two groups: nonviral and viral [103, 246, 247]. 
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Magnetofection is a process whereby magnetic NPs linked to DNA are, under the 
influence of an external magnetic field, transfected into cells [9, 13]. NPs present 
numerous advantages as gene vectors over viral carriers, namely they:  
- do not induce immune responses, since they are not biological materials;  
- have limited genotoxicity and cytotoxicity; 
- are able to mediate the introduction of foreign genes into the DNA of host 
chromosomes and consequently, foreign genes are expressed stably; 
- have the ability to protect foreign genes from host enzymes and complement;  
- may kill or destroy some viruses [248]. 
NPs cannot effectively label the required cells because of the repulsive electric 
interaction between the NPs and cell membrane, given that both the SPIONs and cell 
membrane possess a negatively charged surface. Therefore, a complex composed of 
SPIONs and transfection agents is frequently used to increase its labeling efficiency. The 
use of transfection agents is beneficial in transferring SPIONs to the target cells. The 
commonly used transfection agents such as PLL, lipofectamine, PEI and protamine 
sulphate are predominantly cationic [87, 103, 249, 250]. Positively charged magnetic NPs 
are endocytozed in the tight fitting vesicles due to the electrostatic interaction between 
positive charged magnetic NPs and the anionic cell membrane. Subsequently, the 
unsaturated amino groups trap the pumped-in-protons by the ATPase located on the 
endosomal membrane, which conducts to Cl- ions retention and water molecules in the 
endosome. When water retention accumulates, swelling and bursting of the endosomes 
occur which results in the genetic material and magnetic NPs being released into the 
cytoplasm [103]. 
Therefore, NPs have the potential to be used in magnetofection. It has been 
reported that CLIO-Tat may be used to transfect CD34q hematopoietic T cell precursors 
and offers a suitable combination for effective T lymphocytes loading [251]. CLIO which 
show polyethylene glycol moiety and covalently linked branched PEI, mediates efficient 
and rapid transfection in primary vascular human umbilical vein endothelial cells (HUVEC) 
and effectively inhibits plasminogen activator inhibitor-1 expression which is responsible 
for several vascular dysfunctions, such as atherosclerosis and vascular inflammation. For 
this reason, these IONs offer a possible approach to transfect highly sensitive HUVEC 
[252]. 
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10.6. DNA detection 
 
IONs readily interact with proteins and as such, it is possible to combine several 
hydrophilic macromolecules (namely peptides and nucleotides) with IONs, which could be 
applied for highly sensitive detection of the DNA sequence [253, 254]. 
 
10.7. Tissue soldering 
 
SPIONs may be used for tissue soldering [108]. For this purpose, their specific 
size requires an assessment for optimized heating ability given that these SPIONs may be 
“tuned” with their corresponding electromagnetic frequency, also called Neél and 
Brownian relaxation [108, 255]. 
 
10.8. Biofilm treatment and antibacterial activity 
 
IONs may provide some supplementary advantages for biofilm treatment since iron 
restriction is intimately connected to the physiological onset of biofilm formation for 
common pathogenic bacteria, namely Staphylococcus aureus, S. epidermidis and 
Pseudomonas aeruginosa [229]. Inhibition of a bacterial colony formation even when the 
SPIONs concentration is 10 µg/mL has been described [229]. In vitro antimicrobial activity 
of magnetic poly(γ-glutamic acid)-coated NPs was also reported against S. enteritidis, E. 
coli and S. aureus [67]. It was also illustrated that IONs may be able to enhance the 
antibacterial activity of the bacitracin, which results in a lower dosage with a subsequent 
reduction in side effects associated with the antibiotics [256]. 
 
10.9. Vaccine carriers 
 
The potential of IONs as potential vaccine carriers has also been reported. 
However, further work is being carried out to induce antibody responses in vivo [257]. Hu 
et al reported an ocular mucosal administration of IONs containing DNA vaccine pRSC-
gD-IL-21 as promising in the inhibition of herpes stromal keratitis due to the efficient 
transport of plasmid DNA vaccine into target cells [258]. More recently, it was reported 
that IONs could be linked to polyinosinic-polycytidylic acid, an activator of Toll-like 
receptors 3 which is described as being a promising adjuvant for vaccines. Given that this 
receptor is expressed by tumor cells of several cancers, this system could prove an 
alternative in cancer treatment [259]. 
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10.10. Peroxidase activity 
 
Magnetic IONs were reported to have peroxidase behavior which is an attractive 
property apart from their superparamagnetism. Since IONs can compete with natural 
enzymes due to their robustness, ease of preparation and stability in adverse conditions, 
they may constitute robust, simple, easy-to-make and cost-effective biosensors in the 
future. For example, the capacity to catalyze the organic substrates oxidation to generate 
a color change and/or to diminish their toxicity is regularly employed as a detection tool or 
in the treatment of wastewater [260, 261, 262]. However, one of the most usual 
peroxidase-relevant applications is related to the oxidation reaction by hydrogen peroxide. 
Glucose detection is frequent in the laboratory or in clinics and is a common application of 
peroxidase. IONs also exhibit high sensitivity in glucose detection particles [261]. 
 
11. Final notes 
 
IONs (USPIONs, <50 nm and SPIONs, >50 nm) encompass electrical, thermal, 
mechanical and imaging properties that gain relevance regarding their use in biomedicine. 
Due to these properties, several commercial formulations of these NPs (namely 
Ferumoxides, Ferucarbotran, Ferumoxtran-10, among others) have been extensively used 
in MRI. Tissue repair, drug delivery, hyperthermia and transfection among other 
biomedical applications mentioned in this review also represent other applications of this 
type of NPs. The number of applications of IONs is growing exponentially and this growth 
is estimated to increase endlessly in the future. New types of IONs are coming to market 
and significant research is being directed towards developing new types of IONs with 
different sizes and coatings for innovative applications in biomedicine. However, and 
despite the importance and enormous utility of these NPs in biomedicine, it will be 
important in the near future to evaluate their safety and the way in which the different 
types of existing and prospective IONs interact with the human body. Equally important 
will be the need to create a toxicology database for better control of the less beneficial 
effects of these NPs. 
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12. List of Abbreviations 
 
1O2 – Singlet oxygen 
BBB – Blood-brain barrier 
C2A-GST – Domain of synaptotagmin I; glutathione S-transferase 
CLIO – Cross-linked iron oxide nanoparticles 
CNS – Central nervous system 
DMSA – Dimercaptosuccinic acid 
DNA – Deoxyribonucleic acid 
FDA – Food and Drug Administration 
HUVEC – Human umbilical vein endothelial cells 
IONs – Iron oxide nanoparticles 
LDL – Low density lipoproteins 
L-DOPA – L-3,4-Dihydroxyphenylalanine 
MIONs – Monocrystalline iron oxide nanoparticles 
MRI – Magnetic resonance imaging 
MSC – Mesenchymal stem cells 
NPs – Nanoparticles  
PAA – Polyacrylic acid 
PEG – Polyethylene glycol 
PEI – Polyethylenimine 
PEO – Polyethylene oxide 
PGMA – Poly(glycidyl methacrylate) 
PLGA – Poly(lactic-co-glycolic acid) 
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PLL – Poly(L-lysine) 
PTA – Polycationic transfection agents 
PVA – Polyvinyl alcohol 
PVP – Poly(vinylpyrrolidone)  
RES – Reticuloendothelial system 
ROS – Reactive oxygen species 
SPIONs – Superparamagnetic iron oxide nanoparticles 
SR – Scavenger receptors 
TEM – Transmission electron microscopy 
USPIONs – Ultra-small superparamagnetic iron oxide nanoparticles 
TEM – Transmission electron microscopy 
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I.1.2. TOXICOLOGICAL AND PRO-INFLAMMATORY MECHANISMS OF IRON OXIDE
NANOPARTICLES 
Nanoparticles (NPs) are becoming available in the market with exponential increase. 
In particular, iron oxide nanoparticles (IONs) have been extensively used for biomedical 
purposes, namely in  magnetic resonance imaging [1,2], tissue repair [3,4], drug delivery 
[5,6], hyperthermia [7,8], transfection [9,10], tissue soldering [11], antibacterial activity [4], 
vaccine delivery [12] and peroxidase activity [13,14]. However, and despite all the 
possible biomedical applications, recent studies report that these IONs are not so 
innocuous as it was thought before. In fact, the small size of IONs may induce toxic 
effects that are not observed in their bulk material states due to the increase in surface 
area per unit mass, ability to cross cell and tissue barriers, and resistance to 
biodegradation [15,16]. Moreover, IONs can affect cells even when no internalization 
occurs, through the release of material used as coating agent, which can be toxic, the 
release of toxic metal ions or by interaction with proteins, leading to the formation of 
protein–NPs complexes and subsequent aggregation [17,18]. The safety of 
nanotechnology requires the evaluation of concentration-dependent effects of IONs on 
cellular function and toxicity, as well as the interactions between IONs and biological 
structures and the influence of size, morphology and agglomeration [19]. However, it is 
believed that activation of oxidative stress and inflammatory signaling, leading to 
apoptosis and genotoxicity are the key paradigm(s) of nanotoxicity [15]. Apart from the 
potential involvement in Fenton reaction, IONs can cause structural damage to 
mitochondria, which could potentially result in anomalous functioning of these organels, 
including altered membrane potential, cytochrome c release, superoxide radical (O2•-) 
production, and uncoupling of oxidative phosphorylation, which may also contribute to the 
underlying mechanisms associated with cytotoxicity [20]. Putative toxicity of IONs may 
become associated with multiple neurodegenerative disorders, including multiple 
sclerosis, Alzheimer’s and Parkinson’s diseases that occur due to the generation of free 
radicals in the brain resulting from iron deposition [15]. It was also described that α-Fe2O3 
NPs are able to disrupt the adherens junctions of cell lines due to interaction of IONs with 
membrane proteins and phospholipids [21]. The mechanisms of cytotoxicity and apoptotic 
death that may be caused by IONs are presented in this part of the introductory chapter. 
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I.1.2.1. MECHANISMS OF CYTOTOXICITY
The effects of IONs on the viability and/or cytotoxicity of several cells are variable 
according to the type of IONs, coating, concentration, interaction with different types of 
cells, and have been described in several studies. The mechanisms behind the IONs 
cytotoxicity are not completely established and various mechanisms are proposed (figure 
1), as discussed in the following chapter. 
Figure 1. Possible mechanisms underlying the cytotoxic effects of IONs (ATP:  Adenosine 
triphosphate; Cyt c: Cytochrome c; IONs: Iron oxide nanoparticles; RNS: Reactive 
nitrogen species; ROS: Reactive oxygen species; TNF-α: Tumor necrosis factor α). 
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I.1.2.1.1. REACTIVE OXYGEN SPECIES, REACTIVE NITROGEN SPECIES AND
PEROXIDASE ACTIVITY
ROS are defined as molecules containing one or more oxygen atoms, which are more 
reactive than molecular oxygen. RNS, mainly peroxynitrite anion (ONOO-), nitrogen 
dioxide, and its sub-products, derive from reactions between superoxide radical (O2•-) and 
nitric oxide radical (•NO) [22]. It has been reported that the potential mechanism of IONs 
cytotoxicity involves the formation of ROS such as hydrogen peroxide (H2O2), hydroxyl 
radical (HO•), hydroperoxyl radical (HO2•), and O2•-, among others. When produced in 
abundance, ROS can lead to oxidative stress, given that they disturb the balance between 
oxidative pressure and antioxidant defense, which results in damage to biomembranes 
[20] (figure 1). As a good example, exposure of PC12 cells to Fe3O4 NPs was shown to
induce a significant increase of intracellular ROS, which was associated to the release of
cytochrome c from mitochondria, resulting in initiation of the intrinsic apoptosis pathway
[23]. In another study, the free radical scavenger edaravone, abolished caspase 3
activation and apoptosis in Kupffer cells of in mice treated with Resovist®
[carboxydextran-coated superparamagnetic IONs (SPIONs)] [24].
After internalization, IONs are presumably degraded into iron ions within the 
lysosomes by hydrolysing enzymes, at low pH. Free iron ions can potentially cross the 
nuclear or mitochondrial membrane and induce redox cycling and catalytic chemistry via 
Fenton reaction [H2O2 + Fe2+ → Fe3+ + HO− + HO•], the most prevalent source of ROS in 
biological systems, and thus catalyze the formation of the highly reactive HO• that 
damages cellular membranes, depolymerizes polysaccharides, causes deoxyribonucleic 
acid (DNA) strand breaks, inactivates enzymes, and initiates lipid peroxidation [15,20,25]. 
In Fe3O4 NPs, iron is present as a mixture of Fe3+ and Fe2+ ions, and it is possible that 
surface Fe2+ ions contribute to the Fenton reaction. On the other hand, in Fe2O3 NPs, iron 
ions are mostly in the ferric state; thus maghemite would produce less radicals [26]. 
IONs are also known to be phagocytosed by neutrophils and other phagocytes. Upon 
formation of the phagolysosome nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidases are activated, generating O2•- and this generation of O2•- would lead to the 
production of other ROS. It is also possible that NPs-induced damage of the mitochondria 
could determine Ca2+ release into the cytosol, where Ca2+-dependent enzymes, such as 
nitric oxide synthase, become activated, resulting in production of •NO and ONOO- [27,28] 
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(figure 2). Depending on the type of IONs used, the time at which maximal ROS and RNS 
levels are generated can vary greatly, from approximately 4 h for citrate-coated IONs to 
24–32 h for dextran-coated ones [29]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. IONs-induced production of ROS and RNS (H2O2: Hydrogen peroxide; HO•: 
Hydroxyl radical; HOCl: Hypochlorous acid; iNOS: Inducible nitric oxide synthase; IONs: 
Iron oxide nanoparticles; NADPH: Nicotinamide adenine dinucleotide phosphate; •NO: 
Nitric oxide radical; NOS: Nitric oxide synthase; 1O2: Singlet oxygen; O2•-: Superoxide 
radical; ONOO-: Peroxynitrite anion). 
 
There are several studies performed to evaluate the effect of different types of IONs 
on ROS and RNS production in different types of cells and results indicate that the effect 
on these cells depends on the different characteristics of the IONs (namely coating, 
concentration and type of IONs) and the different interaction of these IONs with the 
different cells and their receptors. For example, Fe2O3 NPs was reported to increase ROS 
production and inhibit catalase in Hep-2 human epithelial cells [30], while FeRex® 
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(dextran-coated SPIONs) had no effects on ROS production in bone marrow dendritic 
cells [31]. In these circumstances, detoxifying enzymes such as superoxide dismutase 
(SOD), catalase and glutathione peroxidase can be produced in order to prevent ROS-
induced damage and the extent of ROS production and consequent damage may be 
dependent on the production of these enzymes, whose expression and activities vary from 
cell to cell [27].  
The techniques used to assess ROS and RNS production may be responsible for the 
different results reported in the literature. Fe3O4 NPs was shown to increase ROS 
production in human lung cancer A549 cells [32,33], while Guadagnini et al [34] reported 
that the same IONs did not induce ROS production in the same cell line. The fact that 
Konczol et al [32] and Ahamed et al [33] presented contradictory results when compared 
to the results presented by Guadagnini et al [34] may be related to the different probes 
used: while Konczol et al [32] and Ahamed et al [33] used dichlorodihydrofluorescein 
diacetate, a probe that detects H2O2, HO•, •NO and ONOO-, Guadagnini et al [34] used 
hydroethidine, a probe that only detects O2•- [35]. 
IONs peroxidase-like activity has as well been described as one of the potential 
mechanisms involved in the cytotoxicity of IONs. In fact, IONs may catalyze H2O2 to react 
with various intracellular molecules including proteins, lipids, and nucleic acids through 
peroxidase-like activity, thus causing irreversible cell damage. On the contrary, when 
IONs have catalase-like activity, they would rather protect cells from oxidative stress 
through decomposition of H2O2 into H2O and O2. When IONs are located in lysosomes, 
the acidic environment contributes to their peroxidase-like activity rather than catalase-like 
activity [36].  
 
I.1.2.1.2. DISRUPTION OF THE CYTOSKELETON 
 
IONs are described as being capable of affecting the actin cytoskeleton. The 
cytoskeleton is a dynamic network consisting of actin polymers, microtubules, and 
associated proteins. Actin, in particular, plays an important role in cell shape, adhesion, 
and motility. Increasing evidence shows that the actin cytoskeleton is essential to 
endocytotic processes, including pseudopod extension, phagocytotic engulfment, cell 
surface remodeling for vesicle formation and movement as well as to the maintenance of 
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the cell morphology and their effect on signaling pathways monitoring several parameters 
such as cell death, migration and differentiation [37,38]. It is described that the formation 
of cytoplasmic vacuoles containing internalized IONs disrupts the cytoskeleton and cell 
membrane by either chemically or physically impeding actin microfilament formation [39]. 
In fact, Miller et al [40] suggested that NPs could interact with the extracellular domain of 
integrins (proteins that promote actin assembly) and thereby affect their activation and 
intracellular signalling cascade. It is reported that IONs affect the morphology and actin 
cytoskeleton and the formation and maturation of focal adhesion complexes in porcine 
aorthic endothelial cells [41], human blood outgrowth endothelial cells [42,43], as well as 
human mesenchymal stem cells [44]. Wu et al [45] reported that citrate-coated Fe3O4 NPs 
interfere with the polymerization and depolymetrization of the tubulin in human umbilical 
vein endothelial cells, and induce disruption of F-actin and microtubules, resulting in a 
disorganization of the cytoskeleton. Gupta et al [46] reported also a rapid disruption of 
actin and microtubule structures in human fibroblasts as well as Apopa et al [47] reported 
that Fe2O3 NPs induced the activation of protein kinase B (Akt) and inhibited glycogen 
synthase kinase-3β in a phosphoinositide-3-kinase dependent manner in human 
microascular endothelial cells, which results in microtubule remodeling. 
 
I.1.2.1.3. INTERFERENCE WITH ATP PRODUCTION 
 
IONs were also described as exerting a decrease in ATP production in mitochondria 
[48]. In fact, it is described that Fe2O3 NPs decreased the activity of Mg2+-ATPase in a 
dose-dependent manner in brains of rats, which may hamper the ATP synthesis and thus 
lead to mitochondrial disorganization [49]. The same authors also reported that Fe2O3 
NPs decreased the activities of total, Na+-K+, and Ca2+-ATPases in a dose-dependent 
manner in brains of rats, possibly due to the interaction of these IONs with the enzymes 
and suggest that the observed decreased in the activity of Na+-K+-ATPases may cause 
alterations in the cell-membrane permeability, presumably resulting in impaired iono-
regulatory activity as well as cause an imbalance in cellular functions, while the decrease 
in the activity of Ca2+-ATPases may conduct to disturbances in numerous cellular 
processes, such as exocytosis, cell proliferation, gene transcription, cell differentiation, 
synaptic maturation, neurotransmitter release, intracellular signaling, muscle contraction 
and cell survival [49]. 
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I.1.2.1.4. PARAMETERS THAT AFFECT THE CYTOTOXICITY OF IRON OXIDE 
NANOPARTICLES  
 
I.1.2.1.4.1. CELL TYPE 
 
It is important to consider that IONs cytotoxicity depends on diverse parameters. One 
of them is the cell type. For example, Horie et al [50] reported that Fe2O3 NPs caused a 
decrease in the viability of human keratinocyte HaCaT cells, while for similar conditions 
and concentrations, Sun et al [51] reported that Fe2O3 NPs did not cause decrease in the 
viability of human cardiac microvascular endothelial cells. It is also possible to verify that 
certain cells are more propense to IONs toxicity. For example, in lymphocytes, there are 
many studies performed that indicate that IONs trigger a decrease in viability [52-54], 
while most of the authors that studied the effect of IONs on mesenchymal stem cells came 
to the conclusion that they do not exert cytotoxicity [55-59]. Although there is not any 
specific explanation for these facts, possible explanations could be the presence of 
distinct cell surface receptors in these cell types leading to differential downstream 
signalling events, discrepancy of NPs uptake, differences in the sensitivity of cellular 
organelles to IONs induced insult (lysosomal/mitochondrial damage), differential handling 
of NPs after uptake and different inherent capacity to deal with oxidative stress [34]. 
Noteworthy, for most of the cells, ROS production appeared to be directly related to the 
quantity of lysosomes formed following SPIONs exposure [60]. 
 
I.1.2.1.4.2. COATING OF IONs 
 
The coating used also influence cytotoxity of IONs. In fact, the interaction of the IONs 
coating with proteins may change their biological reactivities [50], although coatings with 
known biocompatible compounds do not always exclude an unexpected increase in 
cytotoxicity or pro-inflammatory response [34]. For example, oleate itself and non-coated 
Fe3O4 NPs were not found to be toxic to TK6 cells and lymphocytes, while oleate-coated 
Fe3O4 NPs were found to be cytotoxic to the same cellular lines [61]. Likewise, Zhu et al 
[62] reported that, while aminosilane, dextran and non-coated SPIONs did not resulted in 
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decreased cell viability, silica-coated SPIONs decreased cell viability in RAW 264.7 cells. 
In fact, coordination of the coating agent with the nanostructure influences the entry into or 
interaction of both the nanostructure and surface chemicals with cells, thereby magnifying 
any interactions (positive or negative) with cellular components; a second, alternative 
explanation for this fact is the variance in the effectiveness of the coatings to shield the 
nanostructures from potentially adverse interactions with cellular components [39,63]. 
Shen et al [64] reported that the cytotoxicity of NPs with amine groups on their surface 
stems from the strong electrostatic interaction between the positively charged NPs and 
the negatively charged cell membranes. On the other hand, the absence of cytotoxic 
effects attributable to poly(L-lysine) (PLL)-Endorem® (dextran-coated SPIONs) could be 
explained by the delayed release of free iron into the intracellular environment due to the 
slower degradation of their double-coating [65]. In a similar way, Fan et al [66] reported 
that, while Fe3O4 NPs decreased cell viability in hepatic cell line LO2, O-carboxymethyl 
chitosan-coated Fe3O4 NPs, folic acid-carboxymethyl chitosan-coated Fe3O4 NPs and 
dextran-coated SPIONs did not trigger the same effect. In this case, coatings were able to 
reduce Fe3O4 NPs cytotoxicity. For example, it is known that O-carboxymethylchitosan-
coated Fe3O4 NPs have carboxyl groups that are bound to the surface of Fe3O4 by 
covalent bonds of “O” of the hydrous Fe3O4 NPs. These carboxyl groups will confer a 
negative charge to Fe3O4 NPs, which prevents agglomeration by the electrostatic 
repulsion. Moreover, this coating may increase the surface hydrophilicity, minimizing 
adherence to cell membranes by hydrophobic interaction, which minimizes phagocytosis 
[66]. 
 
I.1.2.1.4.3. TYPE OF IONs 
 
Several types of IONs can be synthetized, magnetite (Fe3O4), hematite (α-Fe2O3) and 
maghemite (γ-Fe2O3) being the most common [15,67]. The type of IONs may also 
influence their cytotoxicity. For example, Karlsson et al [68] described that Fe2O3 NPs 
caused a slight decrease in viability of A549 cells, while Fe3O4 NPs did not cause the 
same effect. However, Park et al [69] reported that, in a MH-S cell line, Fe3O4 NPs caused 
a greater cell viability decrease than Fe2O3 NPs. Likewise, Chen et al [36] reported that, 
while 2,3-dimercaptosuccinic acid (DMSA)-coated γ-Fe2O3 NPs are not cytotoxic to 
human neuronal glioblastoma U251 cells, DMSA-coated Fe3O4 NPs decreased cell 
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viability at a lower concentration in the same cellular line. In Fe3O4 NPs, iron is present in 
the form of Fe3+ and Fe2+ ions, while in Fe2O3 NPs iron is mostly in the form of Fe3+ ions 
[26]. In fact, Fe2+ is released into the solution much faster than Fe3+ because the bonds 
between the reduced iron and O2− ions of the crystalline lattice are weakened [70]. 
However, materials only containing Fe3+ at the surface, such in the case of Fe2O3 NPs, 
may also release HO• through a Fenton-like reaction that requires previous reduction of 
Fe3+ to Fe2+ by endogenous molecules such as ascorbic acid or by reaction of Fe3+ and 
H2O2 with HO2• as the propagating intermediate, which may increase cytotoxicity [70,71]. 
 
I.1.2.1.4.4. SOLUBILITY OF IONs 
 
The solubility of IONs has recently been shown to directly affect its cytotoxicity [72]. It 
is known that the low pH of endosomes/lysosomes can solubilize the iron core within a 
few days, releasing ferric iron Fe3+ into the cytoplasm and consequently the cytotoxicity 
may increase [73]. However, IONs of extremely low solubility may also be cytotoxic 
because they will be persistent within the biological system and may provoke a range of 
long-term effects involving carcinogenic, mutagenic, or teratogenic influence in the 
organism [72]. 
 
I.1.2.1.4.5. SURFACE CHARGE OF IONs 
 
The surface charge of IONs influences their stability as well as the cellular 
internalization and trafficking pathways, therefore influencing their cytotoxicity [9,74]. It is 
generally accepted that the NP-protein “corona”, a dynamic layer of proteins and other 
biomolecules that adsorbs to NP surfaces immediately upon contact with living systems, 
mediates the interaction of IONs with the cellular machinery [18]. Generally, the surface 
charges of the IONs are negative due to their interaction with the hydroxyl groups of the 
water molecules, and these surface charges originate an electric field that attracts 
counterions [75]. IONs, due to their strong van der Waals forces, have a significant 
interaction with the surrounding environment, which alters the physical properties of the 
NPs, depending upon the presence of ionic (salt) and biomolecules in their vicinity, 
gravitation, diffusion, convection forces, cell type, pH and protein composition, either in 
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culture media or in body fluids, and the extent of agglomeration [76,77]. Proteins such as 
albumin, immunoglobulin, fibrinogen, and apolipoproteins were found to play an important 
role in the agglomeration of IONs [78]. Simberg et al [79] reported that IONs have the 
ability to bind to mouse plasma proteins, namely histidine–proline rich glycoprotein, high 
molecular weight kininogen, plasma prekallikrein, mannose-binding lectins (MBL), 
mannose-binding lectin-associated serine proteases, apolipoproteins, beta-2 glycoprotein, 
clotting factors coagulation factor XI (FXI) and coagulation factor XII (FXII), hemoglobin, 
hemoglobin-binding hemopexin (proteoglycan-4), vinculin, tubulin-1 and talin-1. The fact 
that kallikrein, kininogen, FXI and FXII can be bound to IONs surface may potentially 
initiate the activation of the intrinsic pathway of blood clotting [79].  
IONs have also been described as causing disruption of microvilli, through disruption 
of the adherens junctions [21,80]. In fact, protein fibrillation may occur due to protein-NPs 
interactions [18]. It was also found that interaction of Fe3O4 NPs with amyloid aggregates 
led to a decrease of the amount of amyloids by depolymerization of amyloid structures 
and inhibition of lysozyme aggregation [81]. IONs can also disturb the electronic and/or 
ionic transport chains due to the strong affinity of the NPs for the cell membrane [82]. 
Therefore, the immediate environment of the NPs (presence of biomolecules, chemical 
composition, and physiological properties of the liquid in which they are suspended) may 
modulate their toxicity on the basis of agglomeration, that may depend on the surface 
chemistry and charge of IONs [77]. 
It is reported that IONs do not need to enter into the cells to exert cytotoxicity. In the 
case of non-coated IONs, as they have a negative charge and the cell membrane also 
has a negative charge, there is a slight electrostatic repulsion between cells and the non-
coated-IONs, which influence the interaction between cells and IONs. However, cell 
membrane receptors have different aminoacid compositions that comprise negative, 
neutral, and positive charges; therefore, the effect of charge on the interaction between 
transmembrane receptors or channels and IONs continuously changes according to the 
type of IONs, coating, surface charge, among many other previously mentioned factors 
[48,61]. The different charge might also influence the interactions with other compounds 
present in medium, such as serum proteins, as well as with cell membranes, and thus 
could have impact on internalization of NPs and toxicity [61].  
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I.1.2.1.4.6. SIZE OF IONs 
 
IONs size is also a parameter that influences their cytotoxicity. Ying et al [52] reported 
that 50 nm IONs were more toxic than 10 nm IONs to A3 human T lymphocytes. Likewise, 
Faust et al [83] reported that 78 nm α-Fe2O3 NPs are more toxic to BeWo b30 plancentary 
epithelial cell line than 50 nm α-Fe2O3 NPs, the 15 nm α-Fe2O3 NPs being not toxic to the 
same cellular line. Larger particles possess larger effective interaction area with more 
functional groups for accessing to the cell, in comparison with smaller NPs. Within this 
specific area, there are more functional groups on the individual large particle [52,84]. 
Larger aggregates, as it occurs in the case of non-coated IONs, are considered more 
cytotoxic, as they may mechanically damage the cell and also deform the nucleus on the 
entry into the cell [61,85]. However, it is also reported that smaller NPs are more toxic. 
This is, probably, due to their large specific surface area and hence larger surface 
reactivity toward biological systems [86]. According to this theory, Zhang et al [21] 
reported that α-Fe2O3 NPs with 26 nm were more cytotoxic to CaCo-2 cells than α-Fe2O3 
NPs with 53, 76 and 98 nm. 
Also, size may influence the uptake of IONs by phagocytic cells. In fact, IONs with 
dimensions superior to 50 nm are usually phagocytized by cells of the reticuloendothelial 
system in liver and spleen, being eliminated in a short period of time, while IONs with 
dimensions inferior to 50 nm are able to move through the capillary wall and be 
phagocytozed by phagocytic cells that are also in other organs, namely bone marrow and 
lymph nodes [87,88]. However, when IONs are smaller than 10 nm, they may be 
eliminated via extravasation and renal clearance [15]. 
 
I.1.2.1.4.7. EXPERIMENTAL CONDITIONS 
 
Some erroneous factors derived from the experimental conditions have to be taken 
into account. The adsorption of the components of the culture media onto IONs induces a 
starvation state of cells in vitro. Thus, the adsorption effect that occurs when cytotoxicity 
experiments are performed may influence their toxicity in vitro [50]. These effects of 
adsorption are expected to be proeminent when the NPs are smaller, given that the 
adsorption ability of NP increases as the particle size decreases [50]. 
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It is also important to have into account that the techniques used to determine 
cytotoxicity can biase the toxicological results obtained. Factors such as exact protocols 
with respect to the source of cells, the cell number, cell culture medium, and incubation 
times are all factors of extreme importance for validation of results and to enable 
comparison between studies [89]. DMSA-coated Fe3O4 NPs were reported to decrease 
cellular viability in RAW 264.7 cells by Liu et al [90] when 5x104 cells/mL were used. 
However, when the same author used 1x106 cells/mL, no cytotoxicity was observed using 
the same cellular line for the same concentration of the IONs [91]. This evidence shows 
how the number of cells utilized in the experiments may influence the results obtained, as 
the number of IONs/cell will vary considerably. 
In a similar way, Liu et al [23] reported that Fe3O4 NPs decreased cell viability in PC12 
cells, while Xue et al [92] reported the opposite, even at a higher concentration. Again, the 
different experimental conditions led to different results: although both authors used MTT 
assay, Liu et al used RPMI 1640 cell medium and 1x104 cell/mL, while Xue et al used high 
glucose DMEM culture medium and 2x105 cell/mL. Therefore, all these variables may lead 
to different results. 
In vivo studies also need a careful description, for which animal species, strains, age, 
sex, methods of applying NPs and vehicles used, will be of main importance. Particularly, 
for both in vitro and in vivo toxicology methods, there is a need for the inclusion of the 
appropriate controls to test possible effects of solvents, adherence of the analyzed 
proteins to NPs, effects caused by ions released by the NPs, potential contamination of 
samples, optical interference of the NPs with the method used, and many other factors 
[89]. As an example, Baratli et al [93] reported that while Fe3O4 NPs did not show to alter 
3-month Wistar rats liver mitochondrial activity the same IONs were able to impair liver 
mitochondrial activity and the activity of the mitochondrial complexes I, II, III and IV in 18-
month rats from the same strain. This fact reflects the importance of age in the toxic effect 
of IONs. The authors attributed these age differences to the fact that, with the time, the 
fragility of mitochondria increases, which leads to iron accumulation. As it was previously 
mentioned, iron accumulation results in HO• formation through Fenton reaction, which 
may trigger oxidative damage [94] and, consequently, impairment of the mitochondrial 
complexes. Concerning gender, Srinivas et al [95] reported that there is a difference in the 
recovery of inflammatory and oxidative stress parameters in male and female Wistar rats, 
namely in the number of neutrophils present in bronchoalveolar lavage fluid (BALF). 
However, the cause responsible for these differences remains to be elucidated. 
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Therefore, it is possible to conclude that the final response of a cell to NPs results 
from a chain of events that depend upon the genetic make-up of the cell, determining the 
specificity of the intracellular environment (e.g. the spectrum and actual levels of plasma 
proteins, the activity of repair enzymes, etc.), as well as upon the size and surface 
chemistry of the given NP. The latter, as reported before, may influence not only the 
efficiency of IONs internalization, but also the route and speed of their intracellular 
degradation with the subsequent release of free iron and, last but not least, the choice of 
particular pathways leading to ROS generation and subsequent damage to biomolecules 
[65]. 
The cytotoxic effect of different types of IONs on the several types of cells evaluated 
so far are summarized in table 1. 
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Table 1. Toxic effects of IONs in several cell types and tissues. 
 
Type of cell/tissue Type and concentrations of 
nanoparticles 
Cytotoxic effects 
Endothelial cells   
Human endothelial cells PLL and carboxydextran-coated 
Fe2O3 NPs (50 μg/mL) 
Decrease in cell viability [96] 
Human endothelial cells PLL-coated SPIONs (25 μg/mL) No evidence of cytotoxicity  [97] 
Human blood outgrowth endothelial 
cells 
Resovist® (600 µg/mL) and 
Endorem® (400 µg/mL) 
Cellular cytoskeleton and morphology 
were affected  [43] 
Human microvascular endothelial cells Fe2O3 NPs (50 μg/mL) No evidence of cytotoxicity  [47] 
Human cardiac microvascular 
endothelial cells 
Fe2O3 NPs (100 μg/mL) and Fe3O4 
NPs (100 μg/mL) 
No evidence of cytotoxicity  [51] 
Human aortic endothelial cells DMSA-coated Fe2O3 NPs (0.05 
mg/mL) 
Decrease in cell viability [98] 
Human aortic endothelial cells Fe3O4 NPs (100 μg/mL) and Fe2O3 
NPs (2 μg/mL) 
Decrease in cell viability, cytoplasmic 
vacuolation, mitochondrial swelling and 
cell death  [99] 
Human aortic endothelial cells γ-Fe2O3 NPs (50 μg/mL) No evidence of cytotoxicity [100] 
Porcine aortic endothelial cells Ultra-small SPIONs (USPIONs) (0.5 
mg/mL) 
Decrease in cell viability and actin 
cytoskeleton disruption  [37] 
Porcine aortic endothelial cells Dextran and polyethylene glycol 
(PEG)-coated USPIONs (0.5 
mg/mL) 
No evidence of cytotoxicity [37] 
Human umbilical vein endothelial cells γ-Fe2O3 NPs (10 μg/mL) Long-term toxicity in human endothelial 
cells by a necrotic process [101] 
Human umbilical vein endothelial cells Citrate-coated Fe3O4 NPs (1 mM) Decrease in cell viability [45] 
Human umbilical vein endothelial cells Citrate-coated Fe2O3 NPs (10 mM) No evidence of cytotoxicity  [55] 
Human umbilical vein endothelial cells Thermally cross-linked (TCL) 
SPIONs (1 mg/mL) and  
monocrystalline IONs (MION)-47 (1 
mg/mL) 
No evidence of cytotoxicity  [102] 
Human umbilical vein endothelial cells Citric acid-coated IONs (35 μg/mL) Decrease in cell  viability [103] 
Murine brain endothelial cell line Citrate-coated Fe3O4 NPs (100 
μg/mL) 
Decrease in cell viability [104] 
Murine brain endothelial cell line Cross-linked IONs (CLIO) Fe3O4 
NPs (10 mg/mL) 
No evidence of cytotoxicity [104] 
Mouse brain-derived microvessel 
endothelial cell bEnd.3 line 
Aminosilane-coated Fe3O4 NPs 
(224 μg/mL) and 
carboxyaminosilane-coated Fe3O4 
NPs (224 μg/mL) 
No evidence of cytotoxicity [105] 
Human cerebral endothelial cells Oleic acid-coated Fe3O4 NPs (75 
μg/cm2) 
Decrease in cell viability [106] 
Endothelial progenitor cells Fe3O4 NPs (20 µg/mL) No evidence of cytotoxicity  [107] 
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Table 1. Toxic effects of IONs in several cell types and tissues (continuation). 
 
Type of cell/tissue Type and concentrations of 
nanoparticles 
Cytotoxic effects 
Placentary cells   
Placental choriocarcinoma cell line 
BeWo b30 
Fe3O4 NPs (0.12 μg/cm2) and sodium 
oleate-coated Fe3O4 NPs (0.12 
μg/cm2) 
Decrease in cell viability [108] 
BeWo placentary epithelial cell line α-Fe2O3 NPs (100 μg/mL) Decrease in cell viability [83] 
Dendritic cells   
Antigen-presenting dendritic cells Chitosan-coated IONs (200 μg/mL) Decrease in cell viability [109] 
Dendritic cells Endorem® (400 μg/mL) Decrease in cell viability  [110] 
Primary mouse bone marrow-derived 
dendritic cells 
Feridex® (dextran-coated SPIONs) 
(200 μg/mL) 
No evidence of cytotoxicity [31] 
Intestinal cells   
CaCo-2 cells  Carboxymethyldextran-coated Fe3O4 
NPs (0.90 mg/mL) 
Decrease in cell viability [111] 
CaCo-2 cells  α-Fe2O3 NPs (100 μg/mL) Disruption of microvilli structures [21] 
CaCo-2 cells  Fe2O3 NPs (10 ppm) Decrease in microvilli and membrane 
disruption [80] 
Breast cancer and mammary cells   
Breast cancer cell line SKBR3 Poly(aminoacid)-coated Fe3O4 NPs 
(1mg/mL) 
No evidence of cytotoxicity  [112] 
Human ductal breast epithelial tumor 
T47D cell line 
Tetramethylammonium 11-
aminoundecanoate-coated Fe3O4 NPs 
(100 μg/mL) 
Slight decrease in cell viability  [82] 
Human breast cancer MCF-7 cells Folic acid-coated Fe3O4 NPs (400 
μg/mL) 
No evidence of cytotoxicity [113] 
Human breast cancer MCF-7 cells PEG-coated Fe3O4 NPs (500 μg/mL) No evidence of cytotoxicity  [114] 
Human breast cancer MCF-7 cells Poly(lactide-co-glycolide)-coated 
Fe3O4 NPs (1 mM) and cellulose-
coated Fe3O4 NPs (1 mM) 
No evidence of cytotoxicity  [58] 
Human breast cancer MCF-7 cells Lauric acid-coated Fe3O4 NPs (2000 
μM) 
No evidence of cytotoxicity  [115] 
Human breast cancer MCF-7 cells Fe2O3 NPs (0.5 mM) No evidence of cytotoxicity  [116] 
Human breast cancer MCF-7 cells Fe2O3 NPs (30 μg/mL) Decrease in cell viability [117] 
MDA-MB-435S breast cancer-bearing 
mouse 
Lauric acid-coated Fe3O4 NPs (2000 
μM) 
No evidence of cytotoxicity  [115] 
Keratinocytes and epidermal cells   
Human keratinocyte HaCaT cells Fe2O3 NPs (100 μg/mL) Decrease in cell viability [50] 
Human melanoma cells (SK-MEL-28) Silica-coated γ-Fe2O3 NPs (200 
μg/mL) 
Slight decrease in cell viability  [9] 
Human melanoma cells (SK-MEL-28) PLL-γ-Fe2O3 NPs (10 μg/mL) No evidence of cytotoxicity [118] 
KB (human epidermoid carcinoma) 
cells 
Poly(glycidyl methacrylateco-PEG 
methyl ether methacrylate)-coated 
Fe3O4 NPs (1 mg/mL) 
No evidence of cytotoxicity [119] 
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Table 1. Toxic effects of IONs in several cell types and tissues (continuation). 
 
Type of cell/tissue Type and concentrations of 
nanoparticles 
Cytotoxic effects 
KB (human epidermoid carcinoma) 
cells 
Folic acid-PEG-polyethylenimine 
(PEI)-coated Fe3O4 NPs (100 μg/mL) 
No evidence of cytotoxicity [120] 
Human epithelial cell line A-431 Fe3O4 NPs (25 μg/mL) Decrease in cell viability [33] 
Mouse melanoma cell line B16F10 Dopamine-coated Fe/Fe3O4 NPs (10 
μg/mL) 
Decrease in cell viability  [121] 
Monocytes and macrophages   
RAW264.7 cells TCL SPIONs (50 μg/mL) and MION-47 
(50 μg/mL) 
Reduction in the population of healthy 
cells and collapse of the mitochondrial 
membrane potential [102] 
RAW 264.7 cells Aminosilane-coated SPIONs (200 
μg/mL) 
No evidence of cytotoxicity [62] 
RAW 264.7 cells SPIONs (200 μg/mL) No evidence of cytotoxicity [62] 
RAW 264.7 cells Dextran-coated SPIONs (200 μg/mL) No evidence of cytotoxicity [62] 
RAW 264.7 cells Silica-coated SPIONs (10 μg/mL) Decrease in cell viability [62] 
RAW 264.7 cells Alginate-coated Fe3O4 NPs (100 
μg/mL) 
No evidence of cytotoxicity [122] 
RAW 264.7 cells Pluronic F127-coated Fe3O4 NPs (60 
μg/mL) 
Decrease in cell viability [123] 
RAW 264.7 cells Poly(glycidyl methacrylateco-PEG 
methyl ether methacrylate-coated 
Fe3O4 NPs (1 mg/mL) 
No evidence of cytotoxicity  [119] 
RAW 264.7 cells DMSA-coated Fe3O4 NPs (100 μg/mL) Decrease in cell viability  [90] 
RAW 264.7 cells DMSA-coated Fe3O4 NPs (100 μg/mL) No evidence of cytotoxicity  [91] 
RAW 264.7 cells DMSA-coated γ-Fe2O3 NPs (50 
μg/mL) 
No evidence of cytotoxicity  [124] 
RAW 264.7 cells γ-Fe2O3 NPs (6.25 μg/mL) Decrease in cell viability and in ATP 
production and alteration of organelles 
such as the Golgi apparatus, 
endoplasmic reticulum, and 
mitochondria and formation of 
autophagosome-like vacuoles [48] 
RAW 264.7 cells Ferucarbotran (carboxydextran-coated 
IONs) (100 μg/mL) 
No evidence of cytotoxicity  [125] 
THP-1 cells DMSA-coated Fe3O4 NPs (100 μg/mL) No evidence of cytotoxicity  [91] 
Human monocyte-macrophages Ferumoxtran-10 (low  molecular 
weight dextran-coated USPIONs) (10 
mg/mL) 
Decrease in cell viability  [126] 
Human monocyte derived 
macrophages 
Silica-coated Fe3O4 NPs (100 μg/mL) Decrease in cell viability  [127] 
U937 Human leukemic monocyte 
lymphoma cells 
Fe2O3 NPs (2 μg/mL) and Fe3O4 NPs 
(20 μg/mL) 
Decrease in cell viability  [99] 
Murine macrophage J774 cells PEG2000-coated Fe3O4 NPs (200 
μg/mL) 
Decrease in cell viability  [128] 
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Table 1. Toxic effects of IONs in several cell types and tissues (continuation). 
 
Type of cell/tissue Type and concentrations of 
nanoparticles 
Cytotoxic effects 
Murine macrophage J774 cells PEG1100-coated Fe3O4 NPs (200 
μg/mL) and PEG350-coated Fe3O4 
NPs (200 μg/mL) 
No influence of cytotoxicity  [128] 
Murine macrophage J774 cells Tween-80-coated SPIONs (200 
μg/mL) 
Decrease in cell viability [129] 
J774A.1 murine macrophages High density lipoprotein-coated FeO 
NPs (4 μg/mL) 
No evidence of cytotoxicity  [130] 
Macrophage cell line J7442 Carbon-coated IONs (10 μg/mL) Decrease in cell viability [131] 
Human macrophages Resovist® (100 μg/mL) and 
Supravist® (carboxydextran-coated 
USPIONs) (0.1 μg/mL) 
Decrease in cell viability  [132] 
Human monocytes Endorem® (1000 μg/mL) and 
Sinerem® (low  molecular weight 
dextran-coated USPIONs) (1000 
μg/mL) 
No evidence of cytotoxicity  [133] 
Human monocytes CLIO-680 (100 μg/mL) No evidence of cytotoxicity [134] 
Murine peritoneal macrophages Resovist® (200 μg/mL) No evidence of cytotoxicity [135] 
Bone marrow-derived macrophages PEG-coated Fe3O4/FeO NPs (0.3 
μg/mL) 
Decrease in cell viability [136] 
Mouse bone marrow-derived 
macrophages 
Fe3O4 NPs (200 μg/mL) No evidence of cytotoxicity [137] 
Cardiac cells   
Cardiac-derived stem cells PLL-coated Ferumoxides (dextran-
coated SPIONs) (25 μg/mL) 
No evidence of cytotoxicity  [138] 
Human cardiac myocytes Carboxyethylsilanetriol-coated 
SPIONs (8 mg/mL) 
Decrease in cell viability [60] 
Rat heart Fe3O4 NPs (500 µg/mL) No alteration of mitochondrial 
respiratory chain complexes I, II, III and 
IV activities [139] 
Rat heart GEH121333 (hydroxyphosphonate–
PEG-coated Fe3O4 NPs) (200 mg/kg) 
No evidence of cytotoxicity [140] 
Mesenchymal stem cells   
Mesenchymal stem cells Citrate-coated Fe2O3 NPs (10 mM) No evidence of cytotoxicity [55] 
Human mesenchymal stem cells Feridex® (100 μg/mL), Resovist® (100 
μg/mL) and MION-47 (100 μg/mL) 
No evidence of cytotoxicity  [56] 
Human mesenchymal stem cells Protamine sulfate-coated Feridex IV® 
(50 μg/mL) 
No evidence of cytotoxicity  [141] 
Human bone marrow-derived 
mesenchymal stem cells 
Poly(vinylpyrrolidone) (PVP)-coated 
SPIONs (1600 μg/mL) and Feridex 
IV® (1600 μg/mL) 
No evidence of cytotoxicity  [142] 
Human bone marrow-derived 
mesenchymal stem cells 
Resovist® (400 μg/mL) and chitosan-
coated SPIONs (400 μg/mL) 
Decrease in cell viability  [143] 
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Table 1. Toxic effects of IONs in several cell types and tissues (continuation). 
 
Type of cell/tissue Type and concentrations of 
nanoparticles 
Cytotoxic effects 
Human bone marrow mesenchymal 
stromal cells 
PLL-coated γ-Fe2O3 NPs (15.4 
μg/mL), mannose-coated γ-Fe2O3 NPs 
(15.4 μg/mL), PLL-coated Endorem® 
(15.4 μg/mL), Endorem® (15.4 μg/mL) 
and γ-Fe2O3 NPs (15.4 μg/mL) 
Decrease in cell viability  [65] 
Human amniotic membrane-derived 
mesenchymal stem cells 
Resovist® (28 μg/mL) Decrease in cell viability and loss of 
morphology [144] 
Mouse mesenchymal stem cells Protamine-coated Feridex® (25 
μg/mL) 
No evidence of cytotoxicity  [57] 
Mouse mesenchymal stem cells Poly(lactide-co-glycolide)-coated 
Fe3O4 NPs (1 mM) and cellulose-
coated Fe3O4 NPs (1 mM) 
No evidence of cytotoxicity  [58] 
Rat mesenchymal stem cells PEI-polyacrylic acid (PAA)-coated 
Fe3O4 NPs (100 μg/mL) 
No evidence of cytotoxicity [59] 
Pulmonary cells   
Human lung epithelial cells BEAS-2B Tetramethylammonium hydroxide-
coated Fe3O4 NPs (6.0 x 1012 NP/mL) 
No evidence of cytotoxicity  [89] 
Human lung epithelial cells BEAS-2B α-Fe2O3 NPs (50 μg/mL) Decrease in cell viability [77] 
Human lung epithelial cells BEAS-2B Fe2O3 NPs (50 μg/cm2) Decrease in cell viability [145] 
Human lung cancer A549 cells Fe2O3 NPs (80 μg/mL) Decrease in cell  viability [68] 
Human lung cancer A549 cells Fe3O4 NPs (80 μg/mL) No evidence of cytotoxicity [68] 
Human lung cancer A549 cells Poly (ethylene oxide)-block-poly(γ-
methacryloxypropyl trimethoxysilane)-
coated IONs (0.5 mg/mL) 
No evidence of cytotoxicity [146] 
Human lung cancer A549 cells α-Fe2O3 NPs (100 μg/cm2) No evidence of cytotoxicity [70] 
Human lung cancer A549 cells Fe2O3 NPs (10 mg/mL) Decrease in cell viability [50] 
Human lung cancer A549 cells Fe3O4 NPs (0.5 μg/mL) Decrease in cell viability [147] 
Human lung cancer A549 cells Fe3O4 NPs (200 μg/mL) Decrease in cell viability [66] 
Human lung cancer A549 cells Carboxyethylsilanetriol-coated 
SPIONs (114 μg/mL) 
Decrease in cell viability [60] 
Human lung cancer A549 cells IONs (25 μg/mL) Decrease in cell viability and loss of 
mitochondrial membrane potential 
[148] 
Human lung cancer A549 cells Fe3O4 NPs (25 μg/mL) Decrease in cell viability [33] 
Human lung cancer A549 cells Sodium oleate-coated Fe3O4 NPs (3 
μg/cm2) and Fe3O4 NPs (37.5 μg/cm2) 
Decrease in cell viability [34] 
Human lung cancer A549 cells Sodium oleate-coated Fe3O4 NPs (0.6 
mM), sodium oleate and PEG-coated 
Fe3O4 NPs (0.35 mM), sodium oleate, 
PEG and poly(lactide-co-glycolic acid)-
coated Fe3O4 NPs (0.1 mM) 
Decrease in cell viability [149] 
Human lung cancer A549 cells Fe3O4 NPs (200 μg/cm2) Slight loss of mitochondrial membrane 
potential [32] 
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Table 1. Toxic effects of IONs in several cell types and tissues (continuation). 
 
Type of cell/tissue Type and concentrations of 
nanoparticles 
Cytotoxic effects 
Human lung fibroblast IMR-90 cells IONs (100 μg/mL) No evidence of cytotoxicity [148] 
Human lung fibroblast IMR-90 cells Fe2O3 NPs (10 μg/cm2) Decrease in cell viability [145] 
Rat BALF Fe3O4 NPs (aerosol concentration of 
640 mg/m3 for 4 hours) 
Decrease in cell viability [95] 
Rat BALF γ-Fe2O3 NPs (90 μg/m3 for 6 hours 
during 3 days) 
No evidence of cytotoxicity  [150] 
Rat BALF γ-Fe2O3 NPs (57 µg/m3 for 6 hours 
during 3 days) 
No evidence of cytotoxicity [151] 
Mouse lung alveolar type II (C10) 
epithelial cells 
Carboxy-coated Fe3O4 NPs (10 
µg/mL) 
Decrease in cell viability [152] 
Mouse lung alveolar type II (C10) 
epithelial cells 
Amine-coated Fe3O4 NPs (200 µg/mL) No evidence of cytotoxicity [152] 
Human lung embryonic HEL 12469 
cells 
Sodium oleate-coated Fe3O4 NPs (0.6 
mM), sodium oleate and PEG-coated 
Fe3O4 NPs (0.35 mM), sodium oleate, 
PEG and poly(lactide-co-glycolic acid)-
coated Fe3O4 NPs (0.1 mM) 
Decrease in cell viability [149] 
Human bronchial 16HBE epithelial 
cells 
Sodium oleate-coated Fe3O4 NPs (7.5 
μg/cm2) and Fe3O4 NPs (15 μg/cm2) 
Decrease in cell viability [34] 
Human lung adenocarcinoma ASTC-a-
1 
PLL-coated SPIONs (50 μg/mL) Decrease in cell viability  [153] 
Lewis lung carcinoma cell line Poly(3-(Trimethoxysilyl)propyl 
methacrylate -r-PEG monomethyl 
ether methacylate)-coated Fe3O4 NPs 
(100 μg/105 cells) 
No evidence of cytotoxicity  [154] 
Rat lung Fe3O4 NPs (500 µg/mL) No alteration of mitochondrial 
respiratory chain complexes I, II, III and 
IV activities [139] 
Osteoblast cells   
Human osteosarcoma (U2OS) Carbon-coated IONs (100 μg/mL) Decrease in cell viability [131] 
Brain cells   
Human neuronal glioblastoma U251 
cells 
DMSA-coated γ-Fe2O3 NPs (100 
μg/mL) 
No evidence of cytotoxicity [36] 
Human neuronal glioblastoma U251 
cells 
DMSA-coated Fe3O4 NPs (25 μg/mL) Decrease in cell viability [36] 
Human neuronal glioblastoma U251 
cells 
Tetramethylammonium 11-
aminoundecanoate-coated Fe3O4 NPs 
(100 μg/mL) 
Decrease in cell viability [82] 
Human neuronal glioblastoma U251 
cells 
Protamine sulfate-coated Feridex IV® 
(100 μg/mL) 
No evidence of cytotoxicity [155] 
Human primary glioblastoma cell line 
U87 
Tetramethylammonium 11-
aminoundecanoate-coated Fe3O4 NPs 
(100 μg/mL) 
No evidence of cytotoxicity [82] 
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Table 1. Toxic effects of IONs in several cell types and tissues (continuation). 
Type of cell/tissue Type and concentrations of 
nanoparticles 
Cytotoxic effects 
U87MG glioblastoma cells USPIONs (0.03 μmol/mL) and 
arginine-glycine-aspartic acid-coated 
USPIONs (0.03 μmol/mL) 
No evidence of cytotoxicity [156] 
U87MG glioblastoma cells Fe3O4 NPs (25 µg/mL) Protection from H2O2-induced 
cytotoxicity [157] 
Human neural stem cell line HB1F3 Feridex IV® (25 μg/mL), MION-47(25 
μg/mL) , CLIO-NH2 (25 μg/mL) and tat-
CLIO (25 μg/mL) 
No evidence of cytotoxicity [158] 
Neuro-2A mouse neuroblastoma Fe3O4 NPs (200 μg/mL) No evidence of cytotoxicity [159] 
Human glioma cell line D54MG Tetramethylammonium 11-
aminoundecanoate-coated Fe3O4 NPs 
(100 μg/mL) 
Decrease in cell viability [82] 
Human brain tumor cell G9T/VGH Tetramethylammonium 11-
aminoundecanoate-coated Fe3O4 NPs 
(100 μg/mL) 
Decrease in cell viability [82] 
Glioma cell line SF126 Tetramethylammonium 11-
aminoundecanoate-coated Fe3O4 NPs 
(100 μg/mL) 
No evidence of cytotoxicity [82] 
Human isolated from brain epithelium 
U373 
Tetramethylammonium 11-
aminoundecanoate-coated Fe3O4 NPs 
(100 μg/mL) 
No evidence of cytotoxicity [82] 
Oligodendroglia OLN-93 cells DMSA-coated IONs (4 mM) Loss of the initial bipolar shape and 
bright intracellular vesicles [160] 
Oligodendroglial OLN-93 cells DMSA-coated IONs (1000 μM) No evidence of cytotoxicity [161] 
BV2 microglial cells α-Fe2O3 NPs (0.2 mmol/L) and γ-
Fe2O3 NPs (0.2 mmol/L) 
Large number of cellular vesicles, 
proliferation of lysosome, swelling of 
endoplasmic reticulum and 
disappearance of mitochondrial cristae 
[162] 
Human brain-derived endothelial cells Amino polyvinyl alcohol (PVA)-coated 
SPIONs (200 μg/mL) and Fe3O4 NPs 
(200 μg/mL) 
No evidence of cytotoxicity [163] 
Human brain-derived endothelial cells Oleic acid-coated Fe3O4 NPs (150 
μg/mL) 
Decrease in cell viability [163] 
C17.2 neural progenitor cells Resovist® (150 µg/mL) and 
Endorem® (200 µg/mL) 
No evidence of cytotoxicity [43] 
Chick cortical neurons FluidMAG-Amine (aminosilane-coated 
Fe3O4 NPs (100 μg/mL) 
No evidence of cytotoxicity [19] 
Chick cortical neurons FluidMAG-D (dextran-coated Fe3O4 
NPs) (50 μg/mL) 
Decrease in cell viability [19] 
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Table 1. Toxic effects of IONs in several cell types and tissues (continuation). 
 
Type of cell/tissue Type and concentrations of 
nanoparticles 
Cytotoxic effects 
Chick cortical neurons FluidMAG-PEA (poly- 
(dimethylamine-co-epichlorhydrin-co-
ethylendiamine)-coated Fe3O4 NPs) 
(10 μg/mL) 
Decrease in cell viability due to 
remotion of plasma membrane of the 
neurons [19] 
PC12 cells Citrate-coated very small SPIONs 
(VSOP) (400 μg/mL) 
Decrease in the formation of 
intercellular contacts and in the growth 
of neurites upon nerve growth factor 
exposure [17] 
PC12 cells Aminopropyltriethoxysilane-coated 
Fe3O4 NPs (100 μg/mL) 
Decrease in cell viability [164] 
PC12 cells IONs (40 μg/mL) Slight decrease in cell viability [165] 
PC12 cells DMSA-coated Fe2O3 NPs (1.5 mM) Decrease in cell viability, decreased 
ability to respond to nerve growth factor 
and to generate neuritis, reduction in 
the formation of actin microfilaments 
[39] 
PC12 cells Fe3O4 NPs (50 µg/mL) Decrease in cell viability [23] 
PC12 cells Fe3O4 NPs (0.5 mg/mL) No evidence of cytotoxicity [92] 
A172 cells Carboxyethylsilanetriol-coated 
SPIONs (8 mg/mL) 
Decrease in cell viability [60] 
BE-2-C brain cells Carboxyethylsilanetriol-coated 
SPIONs (4 mg/mL) 
Decrease in cell viability [60] 
Rat neural progenitor cells Feridex® (100 µg/mL) No evidence of cytotoxicity [166] 
Rat brain Fe3O4 NPs (500 µg/mL) No alteration of mitochondrial 
respiratory chain complexes I, II, III and 
IV activities [139] 
Rat brain Combidex® (10 mg/kg) (low  
molecular weight dextran-coated 
USPION), Ferumoxytol (polyglucose 
sorbitol carboxymethylester-coated 
USPIONs) (10 mg/kg) and Feridex IV® 
(10 mg/kg) 
No evidence of cytotoxicity [167] 
Rat brain Fe2O3 NPs (1000 mg/kg) Inhibition of acetylcholinesterase [49] 
Mouse hippocampus α-Fe2O3 NPs (130 μg per day for 30 
days) 
Decrease in the contents of 
monoamine neurotransmitter and 
related metabolites [168] 
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 Table 1. Toxic effects of IONs in several cell types and tissues (continuation). 
 
Type of cell/tissue Type and concentrations of 
nanoparticles 
Cytotoxic effects 
Mouse brain α-Fe2O3 NPs (6.5 g/L per day for 40 
days) and γ-Fe2O3 NPs (6.5 g/L per 
day for 40 days) 
Morphological changes: irregular 
arrangement of neuron cells or 
neuronal loss in olfactory bulb, 
decrease in number of intact neuronal 
cells in the region I of hippocampus 
proper, cellular swelling, vacuolar 
degeneration, nuclear chromatin 
condensation and fragmentation [162] 
Murine microglial cells Resovist® (50 µg/mL) No evidence of cytotoxicity [169] 
Rat astrocytes Dextran-coated Fe3O4 NPs (500 
μg/mL) 
No evidence of cytotoxicity [170] 
Rat astrocytes DMSA-coated IONs (1 mM) Slight decrease in cell viability [171] 
Mouse primary astrocytes Aminosilane-coated Fe3O4 NPs (224 
μg/mL) 
Decrease in cell viability [105] 
Mouse primary astrocytes Carboxyaminosilane-coated Fe3O4 
NPs (100 μg/mL) 
Decrease in cell viability [105] 
Mouse primary neurons Aminosilane-coated Fe3O4 NPs (224 
μg/mL)  
Decrease in cell viability [105] 
Mouse primary neurons Carboxyaminosilane-coated Fe3O4 
NPs (150 μg/mL) 
Decrease in cell viability [105] 
Mouse olfactory bulb  α-Fe2O3 NPs (130 μg per day for 30 
days) 
Slightly dilated rough endoplasmic 
reticulum, degeneration of 
neurodendron, disruption of 
membranous structure, and increase of 
lysosome of nerve cells [168] 
Lymphocytes   
Human peripheral lymphocytes Oleate-coated Fe3O4 NPs (75 μg/cm2) Decrease in cell viability [61] 
A3 human T lymphocytes Amine-coated IONs (25 μg/mL) and 
carboxyl-coated IONs (25 μg/mL) 
Decrease in cell viability [52] 
Jurkat cells Poly(maleic anhydride-alt-1-
octadecene and methoxy-PEG-coated 
Fe3O4 NPs (150 μg/mL) 
Decrease in cell viability [54] 
Jurkat cells Carboxyethylsilanetriol-coated 
SPIONs (8 mg/mL) 
Decrease in cell  viability [60] 
TK6 lymphoblastoid cells Oleate-coated Fe3O4 NPs (45 μg/cm2) Decrease in cell viability [61] 
Cervical cancer cells   
Human cervical cancer HeLa cells Polymeric liposomes-coated Fe3O4 
NPs (1200 μg/mL) 
No evidence of cytotoxicity [172] 
Human cervical cancer HeLa cells PLL-coated Ferumoxides (50 μg/mL) No evidence of cytotoxicity [173] 
Human cervical cancer HeLa cells Fe3O4 NPs (10 μg/mL) Decrease in cell viability [75] 
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Table 1. Toxic effects of IONs in several cell types and tissues (continuation). 
Type of cell/tissue Type and concentrations of 
nanoparticles 
Cytotoxic effects 
Human cervical cancer HeLa cells Protamine-sulfate Feridex IV® (50 
μg/mL) 
No evidence of cytotoxicity [141] 
Human cervical cancer HeLa cells Carboxyethylsilanetriol-coated 
SPIONs (8 mg/mL) 
Decrease in cell viability [60] 
Human cervical cancer HeLa cells Dextran-coated Fe3O4 NPs (500 
μg/mL), aminodextran-coated Fe3O4 
NPs (500 μg/mL) and DMSA-coated 
Fe3O4 NPs (500 μg/mL) 
No evidence of cytotoxicity [174] 
Human cervical cancer HeLa cells Fe3O4 NPs (50 µg/mL), arginine and 
chitosan-coated Fe3O4 NPs (50 
µg/mL) and arginine and PEG-coated 
Fe3O4 NPs (50 µg/mL) 
No evidence of cytotoxicity [175] 
Human cervical cancer HeLa cells Carbon-coated IONs (100 μg/mL) Decrease in cell viability [131] 
Adipose cells 
Human adipose derived stem cells Protamine sulphate, PEG and dextran-
coated γ-Fe2O3 NPs (15 mM)  
No evidence of cytotoxicity [176] 
Rat adipose derived stem cells Protamine sulphate-coated 
Ferumoxides (100 μg/mL) 
No evidence of cytotoxicity [177] 
Pancreatic cells 
Beta‐TC‐6 cells PVP‐coated SPIONs and Feridex® 
(200 µg/mL) 
No evidence of cytotoxicity [178] 
Panc-1 cells Carboxyethylsilanetriol-coated 
SPIONs (8 mg/mL) 
Slight decrease in cell viability [60] 
Capan-2 cells Carboxyethylsilanetriol-coated 
SPIONs (8 mg/mL) 
Slight decrease in cell viability [60] 
Murine insulinoma βTC3 Citrate-coated γ-Fe2O3 NPs (20 
µg/mL) 
No evidence of cytotoxicity [179] 
βTC-tet cells Citrate-coated γ-Fe2O3 NPs (20 
µg/mL) 
No evidence of cytotoxicity [179] 
Spleen 
Mouse splenocytes Resovist® (100 µg/mL) No evidence of cytotoxicity [180] 
Ovarian cells 
Ovarian carcinoma (MLS) cells USPIONs, arginine-glycine-aspartic 
acid-coated USPIONs (0.03 μmol/mL) 
No evidence of cytotoxicity [156] 
Chinese Hamster Ovary (CHO-K1) 
cells 
SPIONs (80 µg/mL) Decrease in cell viability [181] 
Liver cells 
Human hepatocytes Endorem® (150 µg/mL) Decrease in cell viability and in albumin 
production [182] 
Human primary hepatocytes Chitosan and linoleic acid-coated 
Fe3O4 NPs (100 µg/mL) 
Slight decrease in cell viability [183] 
HepG2 hepatocytes High density lipoprotein-coated FeO 
NPs (4 μg/mL) 
No evidence of cytotoxicity [130] 
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Table 1. Toxic effects of IONs in several cell types and tissues (continuation). 
 
Type of cell/tissue Type and concentrations of 
nanoparticles 
Cytotoxic effects 
HepG2 hepatocytes Carboxyethylsilanetriol-coated 
SPIONs (8 mg/mL) 
Decrease in cell viability [60] 
Normal mouse liver NCTC 1469 cell 
line 
Resovist® (0.5 mM) Decrease in cell viability [184] 
Rat liver derived BRL 3A cell line Fe3O4 NPs (250 µg/mL) Decrease in cell viability [185] 
Hepatic cell line LO2 O-carboxymethyl chitosan-coated 
Fe3O4 NPs (1000 µg/mL), folic acid-
carboxymethyl chitosan-coated Fe3O4 
NPs (1000 µg/mL) and dextran-coated 
Fe3O4 NPs (1000 µg/mL) 
No evidence of cytotoxicity [66] 
Hepatic cell line LO2 Fe3O4 NPs (200 µg/mL) Decrease in cell viability [66] 
Mouse liver Fe3O4 NPs (10 mg/kg per day for 1 
week) 
Cell expansion, liver cords broadening, 
liver sinuses contraction and hepatic 
damage [186] 
Murine hepatocytes Fe2O3 NPs (250 µg/mL) Decrease in cell viability [187] 
Rat liver Fe3O4 NPs (500 µg/mL) No alteration of mitochondrial 
respiratory chain complexes I, II, III and 
IV activities [139] 
Rat liver Fe2O3 NPs (500 mg/kg) Increase in aspartate aminotransferase 
(AST), alanine aminotransferase (ALT) 
and lactate dehydrogenase (LDH) 
levels [49] 
Rat liver GEH121333 (200 mg/kg) No evidence of cytotoxicity [140] 
Rat liver Sodium oleate-coated Fe3O4 NPs 
(0.0364 mg/kg) 
Diffuse necrosis and mild lipidosis [188] 
Fibroblasts   
Human fibroblasts DMSA-coated γ-Fe2O3 NPs (10 µg/L) Decrease in cell viability and in 
metabolic mitochondrial activity [189] 
Human fibroblasts MION-47 and TCL SPIONs (1 mg/mL) No evidence of cytotoxicity [102] 
Human fibroblasts PAA and bacitracin-coated Fe3O4 NPs 
(400 µg/mL) 
No evidence of cytotoxicity [190] 
Human skin fibroblast Poly(γ–glutamic acid)-coated Fe3O4 
NPs (1 mg/mL) 
No evidence of cytotoxicity [191] 
Human diploid fibroblast Gelatin-coated Fe3O4 NPs (600 
µg/mL) 
No evidence of cytotoxicity [192] 
Human diploid fibroblast Fe3O4 NPs (300 µg/mL) Decrease in cell viability [192] 
Mouse fibroblast adhesive cells (L929) Fe3O4 NPs (20 mM) Decrease in cell viability [193] 
Mouse fibroblast adhesive cells (L929) PVA-coated Fe3O4 NPs (80 mM) No evidence of cytotoxicity [193] 
Mouse fibroblast adhesive cells (L929) Fe3O4 NPs (100 mM) Decrease in cell viability [194] 
Mouse fibroblast adhesive cells (L929) PVA-coated Fe3O4 NPs (400 mM) No evidence of cytotoxicity [194] 
Mouse fibroblast adhesive cells (L929) Alginate-coated Fe3O4 NPs (100 
µg/mL) 
No evidence of cytotoxicity [122] 
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Table 1. Toxic effects of IONs in several cell types and tissues (continuation). 
 
Type of cell/tissue Type and concentrations of 
nanoparticles 
Cytotoxic effects 
Mouse fibroblast adhesive cells (L929) Poly(L-lactide)-PEG-poly(L-lactide)-
coated Fe3O4 NPs (1 mg/mL) and 
Fe3O4 NPs (2 mg/mL) 
No evidence of cytotoxicity [195] 
Mouse fibroblast adhesive cells (L929) Dextran-coated SPIONs (1 mg/mL) Decrease in cell viability [196] 
Mouse fibroblast adhesive cells (L929) Surfactin-coated Fe3O4 NPs (400 
μg/mL) and 
rhamnolipid-coated Fe3O4 NPs (400 
μg/mL) 
Decrease in cell viability [197] 
Mouse fibroblast adhesive cells (L929) PEG-coated Fe3O4 NPs (400 μg/mL) 
and 
dextran-coated Fe3O4 NPs (400 
μg/mL) 
No evidence of cytotoxicity [197] 
Mouse fibroblast adhesive cells (L929) Silica-coated γ-Fe2O3 NPs (200 
µg/mL) 
Slight decrease in cell viability [9] 
Telomerase immortalised primary 
human fibroblasts (h-TERT BJ1) 
Fe3O4 NPs (50 µg/mL) Decrease in cell viability [46] 
Telomerase immortalised primary 
human fibroblasts (h-TERT BJ1) 
Pullulan-coated Fe3O4 NPs (2 mg/mL) No evidence of cytotoxicity [46] 
Telomerase immortalised primary 
human fibroblasts (h-TERT BJ1) 
Lactoferrin and sodium oleate-coated 
Fe3O4 NPs (1 mg/mL) and 
ceruloplasmin and sodium oleate-
coated Fe3O4 NPs (1 mg/mL) 
No evidence of cytotoxicity [198] 
Telomerase immortalised primary 
human fibroblasts (h-TERT BJ1) 
Fe3O4 NPs (250 µg/mL) Decrease in cell viability [198] 
Telomerase immortalised primary 
human fibroblasts (h-TERT BJ1) 
Fe3O4 NPs (50 µg/mL) and dextran-
coated Fe3O4 NPs (50 µg/mL) 
Decrease in cell viability and cell 
morphology/cytoskeletal organisation 
and cell motility changes [199] 
Telomerase immortalised primary 
human fibroblasts (h-TERT BJ1) 
Fe3O4 NPs (50 µg/mL) Appearance of vacuoles in the cell 
body and aberrations on the cell 
membrane [200] 
3T3 cell mouse embryo fibroblast cells Oleate-coated γ-Fe2O3 NPs (0.7 
µg/mL) 
No evidence of cytotoxicity [201] 
3T3 cell mouse embryo fibroblast cells Poly(glycidyl methacrylate-co-PEG 
methyl ether methacrylate-coated 
Fe3O4 NPs (1 mg/mL) 
No evidence of cytotoxicity [119] 
3T3 cell mouse embryo fibroblast cells Silica-coated Fe3O4 NPs (1 mg/mL) No evidence of cytotoxicity [6] 
3T3 cell mouse embryo fibroblast cells Oleic acid-coated Fe3O4 NPs (19.7 
μg/cm2) 
Decrease in cell viability [202] 
3T3 cell mouse embryo fibroblast cells Fe3O4 NPs (316 μg/mL) and 
Endorem® (316 μg/cm2) 
No evidence of cytotoxicity [202] 
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Table 1. Toxic effects of IONs in several cell types and tissues (continuation). 
 
Type of cell/tissue Type and concentrations of 
nanoparticles 
Cytotoxic effects 
3T3 cell mouse embryo fibroblast cells Fe3O4 NPs (50 µg/mL), arginine and 
chitosan-coated Fe3O4 NPs (50 
µg/mL) and arginine and PEG-coated 
Fe3O4 NPs (50 µg/mL) 
No evidence of cytotoxicity [175] 
Embryo fibroblast cells (NIH/3T3) Fe3O4 NPs (50 µg/mL) Decrease in cell viability [203] 
Embryo fibroblast cells (NIH/3T3) PVP-coated Fe2O3/Fe3O4 NPs (10 
mM) 
No evidence of cytotoxicity [204] 
Embryo fibroblast cells (NIH/3T3) Fe2O3 NPs (100 µg/mL) Decrease in cell viability, focal 
adhesion and regulation of actin 
cytoskeleton, lipid biosynthetic process 
and the cellular lipid metabolic process 
alterations [205] 
Embryo fibroblast cells (NIH/3T3) Carbon-coated IONs (100 μg/mL) Decrease in cell viability [131] 
Human lung fibroblast cell line MRC-5 α-Fe2O3 NPs (6.25 µg/mL) Decrease in cell viability [27] 
Nasopharingeal cells   
Human nasopharyngeal epidermoid 
carcinoma cells (KB cells) 
Citrate-coated Fe3O4 NPs (2 mg/mL) No evidence of cytotoxicity [206] 
Human nasopharyngeal epidermoid 
carcinoma cells (KB cells) 
Acetic anhydride and 3-
aminopropyltrimethoxysilane-coated 
Fe3O4 NPs (100 µg/mL) 
No evidence of cytotoxicity [64] 
Human nasopharyngeal epidermoid 
carcinoma cells (KB cells) 
Succinic anhydride and 3-
aminopropyltrimethoxysilane-coated 
Fe3O4 NPs (10 µg/mL) and 3-
aminopropyltrimethoxysilane-coated 
Fe3O4 NPs (10 µg/mL) 
Decrease in cell viability [64] 
Human nasopharyngeal epidermoid 
carcinoma cells (KB cells) 
Pluronic F127 and PAA-coated Fe3O4 
NPs (1 mg/mL) 
No evidence of cytotoxicity [207] 
Human nasopharyngeal epidermoid 
carcinoma cells (KB cells) 
Oleic acid and PEG-coated Fe3O4 NPs 
(200 µg/mL) 
No evidence of cytotoxicity [208] 
Human nasopharyngeal epidermoid 
carcinoma cells (KB cells) 
Fe3O4 NPs (100 µg/mL) Decrease in cell viability [66] 
Human nasopharyngeal epidermoid 
carcinoma cells (KB cells) 
O-carboxymethyl chitosan-coated 
Fe3O4 NPs (1 mg/mL) and dextran-
coated Fe3O4 NPs (1 mg/mL) 
No evidence of cytotoxicity [66] 
Erythrocytes   
Rabbit erythrocytes Alginate-coated Fe3O4 NPs (570 
µg/mL) 
No evidence of cytotoxicity [122] 
Rat erythrocytes Fe2O3 NPs (500 mg/kg) Inhibition of acetylcholinesterase [49] 
Human erythrocytes Tetramethylammonium hydroxide-
coated Fe3O4 NPs (0.1 M) 
Increase in hemolysis [209] 
Human erythrocytes Acetic anhydride and 3-
aminopropyltrimethoxysilane-coated 
Fe3O4 NPs (400 µg/mL) 
No evidence of cytotoxicity [64] 
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Table 1. Toxic effects of IONs in several cell types and tissues (continuation). 
Type of cell/tissue Type and concentrations of 
nanoparticles 
Cytotoxic effects 
Human erythrocytes Succinic anhydride and 3-
aminopropyltrimethoxysilane-coated 
Fe3O4 NPs (400 µg/mL) and 3-
aminopropyltrimethoxysilane-coated 
Fe3O4 NPs (400 µg/mL) 
Increase in hemolysis [64] 
Human erythrocytes Poly(L-lactide)-PEG-poly(L-lactide)-
coated Fe3O4 NPs (20 mg/mL) and 
Fe3O4 NPs (20 mg/mL) 
Increase in hemolysis [195] 
Human erythrocytes Folic acid-PEG-PEI-coated Fe3O4 NPs 
(400 μg/mL) 
No evidence of cytotoxicity [120] 
Kidney cells 
Human embryonic kidney 293T cell 
line 
Carboxyethylsilanetriol-coated 
SPIONs (8 mg/mL) 
Decrease in cell viability [60] 
Human embryonic kidney 293T cell 
line 
PEI-PAA-coated Fe3O4 NPs (200 
µg/mL) 
No evidence of cytotoxicity [210] 
Cos-7 monkey kidney cells Tetramethylammonium hydroxide-
coated Fe3O4 NPs (23.05 mM) 
No evidence of cytotoxicity [209] 
MDCK (canine distal tubule) epithelial 
cell line 
Oleic acid-coated Fe3O4 NPs (235 
µg/mL) 
Decrease in cell viability [211] 
LLC-PK (porcine proximal tubule) 
epithelial cell line 
Oleic acid-coated Fe3O4 NPs (235 
µg/mL) 
Decrease in cell viability [211] 
Human urinary bladder carcinoma cells 
UM-UC-3 
Poly(ε-caprolactone)-b-poly(propargyl 
methacrylate-co-poly- 
(ethylene glycol) methyl ether 
methacrylate)-coated SPIONs (1 
mg/mL) 
No evidence of cytotoxicity [212] 
Renal NRK cells Dextran-coated Fe3O4 NPs (500 
μg/mL) 
No evidence of cytotoxicity [170] 
Mouse kidney Fe3O4 NPs (5 mg/kg per day for 1 
week) 
Large reduction of tubular space and 
extreme edema of epithelial cells in 
glomeruli [186] 
Mouse kidney PAA-coated γ-Fe2O3 NPs (10 mg/kg) No evidence of cytotoxicity [213] 
Rat kidney Fe3O4 NPs (500 µg/mL) No alteration of mitochondrial 
respiratory chain complexes I, II, III and 
IV activities [139] 
Rat kidney Fe2O3 NPs (500 mg/kg) Decrease in AST and ALT levels [49] 
Rat kidney Fe2O3 NPs (1000 mg/kg) Decrease in LDH levels [49] 
Rat kidney GEH121333 (200 mg/kg) No evidence of cytotoxicity [140] 
Muscular cells 
C2C12 cells Protamine sulfate-coated Feridex® (30 
μg/mL) 
No evidence of cytotoxicity [214] 
Embryonic cells 
Embryonic stem cells PLL-coated SPIONs (50 μg/mL) No evidence of cytotoxicity [215] 
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 Table 1. Toxic effects of IONs in several cell types and tissues (continuation). 
 
Type of cell/tissue Type and concentrations of 
nanoparticles 
Cytotoxic effects 
Retina epithelial cells   
ARPE-19 cells 
 
Feraheme® (polyglucose sorbitol 
carboxymethylester-coated USPIONs) 
(0.1 mg/mL) 
Decrease in metabolic activity [216] 
Blood   
Rat serum Fe2O3 NPs (1000 mg/kg) Increase in AST and LDH levels [49] 
Rat serum Fe2O3 NPs (2000 mg/kg) Increase in ALT levels [49] 
Rat blood Fe2O3 NPs (0.8 mg/kg) Prolongation of prothrombin time and 
activated partial thromboplastin time 
and elevation of the average 
concentration of fibrinogen [217] 
Concentrations in parenthesis represent the lowest concentration where an effect was observed. When no 
effect was observed, concentration in parenthesis represents the highest concentration tested. 
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I.1.2.2. PROGRAMMED CELL DEATH INDUCED BY IRON OXIDE 
NANOPARTICLES 
 
Apoptosis is a highly organized process characterized by the progressive activation of 
precise pathways leading to specific biochemical and morphological alterations, namely 
cytoplasmatic blebbing, cell shrinking and intense condensation of chromatin in the 
nucleus [218,219]. Two of those pathways are the mitochondrial-mediated or intrinsic and 
the receptor-mediated or extrinsic [218]. In both pathways (intrinsic and extrinsic), the 
initiator caspases (caspase 8 in extrinsic and caspase 9 in intrinsic pathway) activate 
downstream effector caspases, mainly caspase 3 (cysteine-aspartic acid protease 
belonging to the family of effector caspases [132]), by proteolytic induction of its inactive 
zymogen form. Effector caspases cleave cytoplasmic and nuclear components, and 
promote DNA degradation and cell dismantling, which converges in the demise of the cell 
[219,220] (figure 3). It was reported that IONs have the ability to induce caspase 3 
activation: Resovist® and Supravist® induced caspase 3 activation in human 
macrophages (greater for Supravist®) [132], Resovist® in mouse hepatic tissues [24], 
Fe3O4 NPs in human hepatoma BEL-7402 cells [221], in PC12 cells [23], in Jurkat cells 
[222] and in A-431 epithelial and A549 cell lines [33], oleic acid-coated Fe3O4 NPs in 
human hepatoma BEL-7402 cells [221], Fe2O3 NPs in human breast cancer MCF-7 cell 
line [117] and in murine hepatocytes [187], and DMSA-coated Fe3O4 NPs and DMSA-
coated Fe2O3 NPs in rat sciatic nerve [223]. It was also described that Fe3O4 NPs 
enhanced the caspase 3 induction caused by daunorubicin in K562/A02 [224] and 
gambogic acid in K562 cells [225]. However, it was also reported that citrate-coated 
VSOP or Resovist® did not cause a measurable increase in caspase 3 activity in THP-1 
cells [226]. 
Caspase 9 was also reported to be affected by IONs. Khan et al [227] reported that 
Fe3O4 NPs cause a decrease in the expression of caspase 9, both at ribonucleic acid and 
protein levels, in HeLa cells. However, Fe3O4 NPs induced the activation of caspase 9 in 
PC12 cells [23], in Jurkat cells [222] and in A-431 epithelial and A549 cell lines [33] and 
Fe2O3 NPs in murine hepatocytes [187]. 
Regarding caspase 8, Zhang et al [228] demonstrated that tetraheptylammonium-
coated Fe3O4 NPs have the capacity to increase the ability of daunorubucin to induce 
apoptosis in K562 cells through caspase 8 activation. 
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One of the earliest indications of apoptosis is the translocation of the membrane 
phospholipid phosphatidylserine from the inner to the outer leaflet of the plasma 
membrane. Annexin V has a high affinity for phosphatidylserine and consequently may be 
used to reveal this phospholipid exposed on the outer surface of cells. This event 
precedes the loss of membrane integrity, resulting in cell death in the later stages [147]. In 
fact, after being activated, caspase 3 cleaves and activates Xk-receptor protein 8 (Xkr8). 
This protein is a scramblase which will be responsible for the translocation of 
phosphatidylserine to the outer leaflet [229] (figure 3). There are many studies reporting 
the translocation of phosphatidylserine induced by IONs, namely caused by Resovist® in 
human macrophages [132], dextran-coated Fe3O4 NPs in rat peripheral blood 
mononuclear cells [170], Fe3O4 NPs in human hepatoma BEL-7402 cells [221] and Fe3O4 
NPs in PC12 cells [23], in human hepatoma BEL-7402 cells [221] and in Jurkat cells [222]. 
Besides that, some studies demonstrated that Fe3O4 NPs have the ability to enhance 
apoptosis induced by cancer drugs, namely daunorubicin in K562/A02 cells [224,230] and 
gambogic acid in K562 leukemia cells [225]. Although apoptosis may be beneficial for the 
killing of cancer cells and in the case of proliferative diseases, such as lymphoproliferative 
syndrome, IONs-triggered apoptosis also showed to trigger apoptosis in normal cells, 
which may be detrimental to the organism and harmful to the human health, given that it is 
known that excessive apoptosis is involved in various ischemia-associated injuries, 
autoimmune diseases and neurodegenerative diseases [231]. On the other hand, other 
IONs were not able to induce apoptosis as this was the case of PVA-coated  Fe3O4 NPs in 
L929 cells [232], Feridex® in rat neural progenitor cells [166] and γ-Fe2O3 NPs in mouse 
bone marrow dendritic cells [233]. 
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Figure 3. IONs influence on intrinsic and extrinsic apoptotic pathways (AIF: Apoptosis 
inducing factor; Apaf 1: Apoptotic protease-activating factor 1; FADD: Fas-associated 
death domain; IONs: Iron oxide nanoparticles; PS: Phosphatidylserine; TNF-α: Tumor 
necrosis factor α; TNFR: Tumor necrosis factor receptor; TRADD: Tumor necrosis factor 
receptor associated domain; Xkr8: Xk-receptor protein 8). 
 
I.1.2.2.1. MITOCHONDRIA AND APOPTOTIC-RELATED PROTEINS 
 
As mitochondria and the events that occur in this organelle are intimately linked to 
apoptosis, it is crucial to evaluate IONs effects in mitochondria. It was observed that 
Fe2O3 NPs and Fe3O4 NPs induced mitochondrial swelling, decrease or disappearance of 
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mitochondrial cristae and vacuolization in human aortic endothelial cells [99] and PLL-
coated SPIONs markedly decreased the number of mitochondria and induced 
mitochondrial swelling in ASTC-a-1 cells [153]. A decrease in mitochondrial membrane 
potential is usually indicative of cellular apoptosis and has also been described for Fe3O4 
NPs in A549 cells [32] and in human hepatoma BEL-7402 cells [221], for oleic acid-coated 
Fe3O4 NPs in human hepatoma BEL-7402 cells [221] and for and PLL and 
carboxydextran-coated Fe2O3 NPs in human endothelial cells [96]. 
IONs are also able to affect survival proteins. It was observed that phosphorylation of 
Akt, a pro-survival protein, was decreased in γ-Fe2O3 NPs exposure to human umbilical 
vein endothelial cells [101], as well as in Fe2O3 NPs exposure to murine hepatocytes 
[187]. This last author showed that quercetin, a natural antioxidant, was able to revert the 
decrease in Akt phosphorylation, which demonstrates that apoptosis triggered by IONs 
may be mediated by ROS [187]. Moreover, the up-regulation of the pro-apoptotic protein 
Bad triggered by these IONs was also reverted by quercetin [187]. Fe3O4 NPs increased 
the gambogic acid mediated downregulation of the expression of antiapoptotic genes such 
as Bcl-2 and survivin of K562 cells, whereas the pro-apoptotic protein bax was 
upregulated [225]. Fe2O3 NPs also showed to decrease the level of antiapoptotic protein 
Bcl-2 in murine hepatocytes, which resulted in mitochondrial membrane potential 
reduction [187]. Liu et al [23] reported also that Fe3O4 NPs induced an increase in the 
Bax/Bcl-2 ratio and a decrease in heat shock proteins 70 and 90 in PC12 cells. Kai et al 
[221] also reported that oleic acid-coated Fe3O4 NPs and Fe3O4 NPs decreased 
cytochrome c and increased Bax expression in human hepatoma BEL-7402 cells. 
p53 can be also involved in apoptosis, given that its activation leads to the expression 
of Bax and Noxa, two pro-apoptotic proteins that induce an increase in mitochondrial 
permeability, leading to the release of cytochrome c, apoptosis inducing factor (AIF) and 
Diablo/Smac and the consequent mitochondrial apoptotic pathway [218]. Wu et al 
[164,234] reported that aminopropyltriethoxysilane-coated Fe3O4 NPs induced p53 gene 
expression and increased phosphorylation levels of p53 in PC12 cells, and that this 
activation is associated with increased levels of Bax and decreased levels of Bcl-2. Fe3O4 
NPs also showed to increase the expression of p53 when in association with adriamycin 
and daunorubicin in Raji cells [235] and with daunorubicin in K562/A02 cells [224]. 
However, the opposite was also reported by Huang et al [236], reporting slight 
decreases in p53 expression in Ferucarbotran-labeled human mesenchymal stem cells, 
as well as it was also reported by Chen et al [224] that Fe3O4 NPs do not change the 
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expression of p53 messenger ribonucleic acid (mRNA) in K562/A02 cells. It is possible to 
conclude that the effect of IONs on p53 activation varies according to the cell which IONs 
interacts. 
c-Jun-N-terminal kinase (JNK) plays a critical role in death receptor-initiated extrinsic- 
as well as mitochondrial intrinsic-apoptotic pathways. JNK activates apoptotic signaling by 
the upregulation of pro-apoptotic genes via the transactivation of specific transcription 
factors or by directly modulating the activities of mitochondrial pro- and anti-apoptotic 
proteins through distinct phosphorylation events [237]. It is reported that exposure of 
human macrophages to Resovist® [132] and of PC12 cells to aminopropyltriethoxysilane-
coated Fe3O4 NPs [164] induces prolonged activation of JNK, leading to apoptosis. 
 
I.1.2.3. GENOTOXICITY 
 
Genotoxins are chemicals or agents that can cause DNA or chromosomal damage 
[238]. IONs have been extensively described to induce genotoxicity in several types of 
cells. The exact mechanisms of genotoxic effects of IONs are still unknown. It is 
suggested that the following factors can potentially affect genotoxicity of nanocarriers: 
composition, size, molecular weight, particle geometry, and surface charge [181]. This 
latter, for example, may influence not only the efficiency of SPIONs internalization, but 
also the route and speed of their intracellular degradation with the subsequent release of 
free iron and the choice of particular pathways leading to ROS generation and subsequent 
damage to biomolecules [65]. 
Genotoxicity can be also indirectly influenced by the interaction between IONs and the 
culture growth medium, which comprises an array of proteins, nutrients and growth 
factors. Both in vitro and in vivo, the IONs-protein corona is a complex transient in nature 
dependent of extracellular environment, as well as the physicochemical properties of the 
IONs themselves and the complexes formed between the protein and IONs [239]. 
Konczol et al [32] reported that Fe3O4 NPs induced DNA damage in human lung 
cancer A549 cells that was attenuated by the antioxidants N-acetyl-cysteine and butylated 
hydroxyanisole. Similarly, dextran-coated γ-Fe2O3 NPs induction of DNA damage in 
human B-lymphoblastoid MCL5 cells was diminished by N-acetylcysteine [239] and Alarifi 
et al [117] attributed the DNA damage triggered by Fe2O3 NPs in human breast MCF-7 
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cell line to the elevated ROS production. It is known that ROS interact with cellular 
biomolecules such as proteins, membrane lipids and even DNA which could be oxidized, 
destructured and ultimately became non-functional [33]. In fact, it is thought that the 
enhanced production of ROS caused by mitochondria or membrane-bound NADPH 
oxidases in response to their interaction with IONs might be a possible mechanism 
involved, causing damage to both purine and pyrimidine bases as well as the DNA 
backbone [32,240]. Moreover, iron ions released from IONs participate in Fenton reaction, 
originating HO•, which is highly reactive, leading to an increase in DNA damage, attacking 
a multitude of oxidized bases, namely DNA base guanine to form 8-hydroxy-2′-
deoxyguanosine adducts, which are known to have mutagenic potential, abasic sites, 
single and double-strand breaks [33,77,239]. An example of this has been described by 
Ma et al [186]:  Fe3O4 NPs increased 8-hydroxy-2′-deoxyguanosine adducts in mouse 
hepatic and renal tissues. RNS are also able to induce DNA damage: •NO can react with 
O2•-, producing ONOO-, which in turn can generate other RNS to interact with proteins and 
nucleic acids [241]. 
The coating and the extent of uptake are described as exerting a determinant role 
concerning genotoxicity. Singh et al [239] stated that cellular internalization of IONs is 
positively correlated with the induction of genotoxicity. This author also showed that, while 
dextran-coated γ-Fe2O3 NPs induced DNA damage in human B-lymphoblastoid MCL5 
cells, γ-Fe2O3 NPs, dextran-coated Fe3O4 NPs and Fe3O4 NPs did not exert the same 
effect [239]. Similarly, Hong et al [242] reported that, in mouse fibroblast adhesive cells 
(L929), (3-aminopropyl)trimethoxysilane-coated Fe3O4 NPs, tetraethyl orthosilicate-(3-
aminopropyl)trimethoxysilane-coated Fe3O4 NPs and citrate-coated Fe3O4 NPs triggered 
DNA damage, while non-coated Fe3O4 NPs and tetraethyl orthosilicate-coated Fe3O4 NPs 
did not exert such effect. The fact that (3-aminopropyl)trimethoxysilane-coated Fe3O4 NPs 
and tetraethyl orthosilicate-(3-aminopropyl)trimethoxysilane-coated Fe3O4 NPs induce 
genotoxicity is probably due to the fact that these positively charged IONs are more 
concentrated within the cells and enter into the nucleus through the nuclear pore and 
interact directly with the DNA, which is negatively charged due to its phosphate groups 
[242]. Citrate-coated Fe3O4 NPs are shown to penetrate through nuclear membrane, 
generating highly reactive HO• in close proximity to DNA, leading to DNA attack [242]. 
Chen et al [195] reported that both poly(L-lactide)–PEG–poly(L-lactide)-coated Fe3O4 NPs 
and Fe3O4 NPs increased micronuclei in Chinese Hamster Ovary (CHO-K1) cells, 
although this increase has been more pronounced in the case of Fe3O4 NPs. The authors 
defend that this polymer coating may reduce the DNA damage caused by the IONs, 
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affecting the physical presence and/or disturbance of the NPs around the mitotic 
apparatus [195]. Likewise, Magdolenova et al [61] found that oleate-coated Fe3O4 NPs 
induced DNA damage in human peripheral lymphocytes and TK6 lymphoblastoid cells but 
Fe3O4 NPs did not exerted the same effect. Nevertheless, the authors reported that 
oleate-coated Fe3O4 NPs exhibited lower cellular uptake than Fe3O4 NPs. This fact proves 
that augmented IONs internalization is not always synonym of increased genotoxicity. 
Coating of Fe3O4 NPs with oleate was found to change the genotoxic potential of the 
Fe3O4 NPs, probably by inducing changes in features of the IONs related to cellular 
uptake and binding to extracellular receptors or transmembrane channels [61]. Non-
coated IONs have also demonstrated to be cytotoxic: Fe2O3 NPs induced DNA damage in 
human lung fibroblasts IMR-90 cells and human lung epithelial cells BEAS-2B [77,145]. 
Fe3O4 NPs induced DNA damage in human lung cancer A549 cells and human epithelial 
cell line A-431 [33,68]. In effect, the cells involved and the type of interactions between the 
cells and ION may be determinant for the genotoxicity. 
Besides that, it is also known that genotoxicity may suffer interindividual variations. 
Novotna et al [65] reported that, although PLL-coated γ-Fe2O3 NPs, PLL-coated 
Endorem®, mannose-coated γ-Fe2O3 NPs, poly(N,N-dimethylacrylamide)-coated γ-Fe2O3 
NPs and γ-Fe2O3 NPs have induced DNA damage in human bone marrow mesenchymal 
stromal cells of the two individuals studied, Endorem® only induced DNA damage in one 
of the individuals, demonstrating not to be genotoxic in the other individual tested. 
 
I.1.2.4. PRO-INFLAMMATORY EFFECTS OF IRON OXIDE NANOPARTICLES 
 
Many studies have been performed in the last few years to evaluate the impact and/or 
the effect of IONs on the different cells and animal models regarding inflammation 
[180,243,244]. The interaction between NPs and immune cells and the consequences of 
such interactions are relevant issues in addressing the potential impact of IONs on 
inflammatory processes [245]. It is important to remember that the cellular recruitment 
processes are mediated by a battery of proinflammatory cytokines, including interleukin 
(IL)-8, IL-6, tumor necrosis factor α (TNF-α), etc. that induce increased microvascular 
caliber, enhance vascular permeability, leukocyte recruitment, and release of 
inflammatory mediators (figure 1). This process is of relatively short duration, lasting from 
several minutes to a few days. However, when inflammation becomes chronic, it can 
result in tissue destruction and lead to organ dysfunction in pathological situations 
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[246,247]. IONs have been described as being involved in the different stages of the 
inflammatory process. Therefore, in this chapter, the effect of IONs on the most relevant 
inflammatory pathways, as well as in the cytokine production, is reviewed. 
 
I.1.2.4.1. MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) PATHWAY 
 
MAPK signaling pathways relay, amplify and integrate signals from a diverse range of 
extracellular stimuli, thereby controlling the genomic and physiological response of a cell 
to changes in the environment. It is a critical link between cell surface signal transduction 
and nuclear processes, including cell proliferation, differentiation and migration, 
development, inflammatory response and apoptosis [248]. Mammalian cells express at 
least four distinctly regulated groups of MAPK, specifically extracellular signal-related 
kinases (ERK)-1/2, JNK1/2/3, p38 proteins (p38 α/β/γ/δ) and ERK5, which are activated 
by different MAPK kinases (MKK) [249]. 
Liu et al [90] reported that DMSA-coated Fe3O4 NPs activate several members of the 
MAPK family in RAW264.7 cells. DMSA-coated Fe2O3 NPs, however, decreased MAPK-
14 (or p38α) expression in human aortic endothelial cells [98], showing the differential 
responses that may occur when different cells as well as different type of IONs are 
studied.  
ERK1/2 are distributed throughout quiescent cells, but upon stimulation, a significant 
population of ERK1/2 accumulates in the nucleus. In fact, upon receptor activation, 
membrane-bound Ras recruits one of the Raf kinases into a complex where it becomes 
activated. Afterwards, Raf phosphorylates two serine residues on the kinase mitogen 
protein kinase kinase (MEK) 1 and 2, which in turn activate ERK1/2 by tandem 
phosphorylation of threonine and tyrosine residues on the dual-specificity motif. While the 
mechanisms involved in nuclear accumulation of ERK1/2 remain elusive, nuclear 
retention, dimerization, phosphorylation, and release from cytoplasmic anchors have been 
shown to play a role. Activated ERK1 and ERK2 phosphorylate numerous substrates in all 
cellular compartments, including several MKK [250,251]. Moreover, stimulation of 
inflammatory cells and ROS also triggers protein phosphorylation, where MKK are 
activated via phosphorylation by MKK kinases (MAPKKK), and these MKK, usually MKK 3 
or 6, lead to phosphorylation of p38 MAPK and JNK [252]. JNK and p38 represent one 
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subgroup of MAPK that is activated primarily by cytokines and exposure to environmental 
stress. A major target of the these signaling pathways is the activation of the activator 
protein 1 (AP-1) transcription factor that is mediated, in part, by the phosphorylation of c-
Jun and related molecules, such as activating transcription factor 2 (ATF-2) and c-Fos, 
resulting in the production and secretion of pro-inflammatory cytokines, such as IL-1β and 
TNF-α [248,252]. AP-1 levels were shown to be increased by dextran-coated Fe3O4 NPs 
in the JB6 P+ murine epidermal cell line [253]. Therefore, in this case and in the most of 
the cases above mentioned, a pro-inflammatory response is expected to be increased. It 
is also described that Resovist® significantly induced ERK1/2 and Akt phosphorilation in 
pancreatic β cells [254]. In fact, ERK1/2 are components of the mechanism by which 
glucose stimulates insulin gene expression, which is mediated by the activation of 
transcription factors (pancreatic and duodenal homeobox 1, neurogenic differentiation 1 
and E47) [255]. It was also described that PEG-coated Fe3O4 NPs increased the 
phosphorylation of ERK1/2 in PC12 cells in the presence of nerve growth factor [165] and 
γ-Fe2O3 NPs and Fe3O4 NPs increased p-ERK levels in RAW 264.7 cells [48]. ERK1 is 
also essential for regulation of energy homeostasis together with p62 [256] and, for this 
reason Park et al [48] suggest that the increase in p-ERK triggered by γ-Fe2O3 NPs was 
activated for cell survival. Moreover, Resovist® and Supravist®-induced JNK activation in 
human macrophages was associated with an increase in apoptosis, given that it is known 
that JNK may lead to formation of the proapoptotic Bid protein [132]. Fe3O4 NPs was also 
shown to activate JNK in a ROS-independent manner in A549 cells [32], although Park et 
al [48] reported that γ-Fe2O3 NPs and Fe3O4 NPs decrease the levels of p-JNK in RAW 
264.7 cells.  
 
I.1.2.4.2. NUCLEAR FACTOR kB (NF-kB) SIGNALING PATHWAY 
 
NF-kB is a pivotal mediator, which is involved in multiple cellular responses. This 
transcription factor could be activated by a variety of stimuli, including cytokines and ROS, 
and regulates the transcription of various pro- and inflammatory mediators, namely 
cytokines (IL-1β, TNF-α, and IL-6), chemokines [IL-8 and macrophage inflammatory 
protein 2 (MIP-2)], adhesion molecules [vascular cell adhesion molecule 1 (VCAM-1), 
intercellular adhesion molecule 1 (ICAM-1), and E-selectin], and enzymes [inducible nitric 
oxide synthase (iNOS)] [32,257,258]. In unstimulated cells, NF-kB is retained in the 
cytosol by inhibitor of kB (IkB). Stimulation with TNF-α or foreign agents leads to 
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degradation of IkB which then dissociates from NF-kB enabling it to translocate to the 
nucleus where it exerts its transcriptional function, increasing the transcription of several 
cytokines, such as TNF-α, IL-1, IL-6 and IL-8 [32,259]. Zhou et al [150] reported a slight 
increase in NF-kB-DNA binding activity caused by Fe2O3 NPs in rat lung. However, Fe3O4 
NPs did not trigger any alteration on NF-kB activity in rat primary microglia [92], human 
lung cancer A549 cells [32], occurring a decrease and delay in the IkB degradation in the 
latter. Therefore, in most of the cases above mentioned, NF-kB does not seem to be an 
inflammatory pathway largely activated by IONs, as it occurred for MAPK pathways. 
Consequently, cytokine production triggered by IONs seems to be due to the involvement 
of other pathways, namely MAPK pathways. 
 
I.1.2.4.3. CYTOKINES 
 
Cytokines are a group of soluble proteins, peptides or glycoproteins regulators of host 
responses to infection, immune responses, inflammation, and trauma. There are several 
cytokines that are produced in our organism in the events above mentioned, namely 
human TNF-α, interferon γ (IFN-γ), IL-1, IL-6, among others [260]. Cytokines may be 
produced via regulation of transcription factors, namely NF-kB and MAPK pathways as 
well as due to monocyte/macrophage activation in response to microbial products, which 
gives rise to the activation of T-cell immunity. Classical activation of macrophages, 
defined as macrophages subset 1 (M1) activation, may promote the differentiation of T-
helper lymphocytes 1 (Th1) cells, whereas macrophages subset 2 (M2) activation could 
promote T-helper lymphocytes 2 (Th2)-type responses. In both types of responses, there 
is cytokine production. M1 activation is activated by IFN-γ and characterized by elevated 
phagocytic ability to kill pathogens, microorganism and tumour cells, elevated expression 
of major histocompatibility complex (MHC) class II, generation of ROS, and production of 
the Th1 cytokines, such as IL-12 and TNF-α. M2 macrophages activation down-regulates 
Th1 responses and stimulates Th2 responses, with production of Th2 cytokines such as 
IL-4 and IL-6, scavenge debris, and promote angiogenesis, tissue remodelling and repair 
[261,262]. 
TNF-α, a pro-inflammatory cytokine, is synthesized and secreted by several types of 
cells, but especially by macrophages. TNF-α mediates a wide range of biological 
responses including inflammation, infection, injury, and apoptosis and has a strong anti-
tumor effect, markedly inhibiting tumor growth by inducing tumor cell necrosis [263,264]. 
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This cytokine is also involved in IL-6 as well as IL-8 production, being this latter the most 
potent known chemotactic agent for neutrophils [260,265,266]. Several IONs showed to 
activate TNF-α, namely Fe3O4 NPs in mouse BALF [267] and Resovist® in THP-1 cell line 
[268]. 
IFN-γ is a type-II IFN secreted by several immune cells (dendritic cells, Th1, T cells, 
and natural killer) with anti-viral, anti-tumor, and immunoregulatory effects that can be 
exerted at several levels. IFN-γ regulates class I and II antigen presentation through the 
expression of key genes related to MHC class I and II-dependent antigen-presentation 
[269]. IONs showed to increase this cytokine, namely Fe3O4 NPs in mouse peripheral 
blood [244] and Fe2O3 NPs in mouse BALF [270]. 
IL-1 activates a cascade of cytokine production and induces the production of a broad 
range of immunomodulatory cytokines. IL-6 is among the mediators regulated by IL-1 and 
is frequently increased in inflammatory processes [260,271]. In fact, some IONs have 
shown to activate IL-1β, as it is the case of DMSA-coated Fe2O3 NPs in rat sciatic nerve 
[223], Fe3O4 NPs in mouse BALF [267] and citrate-coated γ-Fe2O3 NPs in human gingival 
fibroblasts [272] and also IL-6, as it is the case of dextran-coated Fe3O4 NPs in human 
epidermal keratinocytes [253] and Fe2O3 NPs in mouse BALF [270], which demonstrates 
IONs involvement in pro-inflammatory responses. However, IL-1β may be involved in 
other mechanisms. In effect, IL-1β released by microglia induces the proliferation of 
astrocytes, stimulates neovascularization and promotes repair of the central nervous 
system in brain injury. Wu et al [169] showed that Resovist® attenuated IL-1β production 
in murine microglial cells by suppressing the secretory lysosomal functionality in LPS-
stimulated microglia through cathepsin B activity attenuation, which may indicate that 
IONs promote brain injury. 
Transforming growth factor beta (TGF-β) is a large family of cytokines that includes 
activins, inhibins, bone morphogenetic proteins and nodal and growth differentiation 
factors. These ligands of the TGF-β signaling pathways bind to a diversity of cell-surface 
receptors and cause signal transduction through the SMADs [273,274]. TGF-β1 is the 
most important mediator that influences collagen synthesis and other matrix molecules, 
activating the gene transcription of collagens I, III, IV, VI, and VII, proteoglycans and 
matrix metalloproteinases [272,275]. TGF-β activation has been triggered by Fe3O4 NPs in 
mouse BALF [267]. 
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IL-10, as well as IL-4, is a cytokine considered to have an anti-inflammatory role. IL-
10 antagonizes a subset of genes activated by Toll-like receptors signaling, such as TNF-
α, IL-6, and numerous chemokine mRNA [276]. In fact, some IONs were shown to induce 
IL-10, inhibiting inflammatory cytokines such IL-1β, IL-6 and IFN-γ. Blank et al [277] 
reported that PVA-coated SPIONs triggered a decrease in IL-1β, IL-6, TNF-α and IFN-γ 
and increase in IL-10 levels in human monocyte-derived dendritic cells in the presence of 
LPS and tetanus toxoid [277].  
The influence of IONs in cytokine production has been described in other different cell 
types [95,108,125,278,279]. The studies performed so far indicate that IONs may have 
several effects on cytokine production, depending on the several factors. In fact, it is 
known that IONs can modulate cytokine profile and this modulation may be the result of 
distinct mechanisms of IONs uptake by the cells. Once inside the cell, the fate of the IONs 
in terms of subcellular location/translocation is different depending on the IONs and on the 
cell. Consequently, the interactions established between the IONs and the receptors 
and/or the cellular machinery are different, depending on many factors such as surface 
charge, coating, type of IONs, among other factors. All these factors may lead to immune-
suppression or immune-stimulation, modifying the mode how the antigen is handled in 
cells [277,280]. The animal model used may also influence the results obtained, 
determining the regulation of cytokine expression. Siglienti et al [281] reported that, in 
mouse macrophages, Resovist® and SH U 555C (carboxydextran-coated USPIONs) 
increased IL-10 levels, while in rat macrophages, the same IONs decreased IL-10 and 
TNF-α levels.  
I.1.2.4.4. ION-INDUCED ACTIVATION OF MACROPHAGES AND T CELLS
In inflammation, the major role of monocytes/macrophages is to recognize and 
eliminate foreign material. For this purpose, they have three major functions: antigen 
presentation, phagocytosis, and immunomodulation through production of various 
cytokines and growth factors [89,247]. It is known that NPs in biological fluids and tissues, 
as other foreign agents, are frequently covered with biological molecules, namely proteins 
that can facilitate their interaction with monocytes/macrophages, as well as their 
degradation and clearance from the bloodstream [282,283]. For example, Valois et al 
[282] clearly demonstrated an uptake of DMSA-coated Fe2O3 NPs by
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monocyte/macrophage cells, indicating that this may be a mechanism of NP clearance 
used by the lung in order to avoid further damage. It is described that IONs have the 
potential to modify monocytes’ ability to respond to other activating stimuli, as well as to 
alter monocytes’ activity, namely in the recruitment, adhesion and migration into the 
subendothelial layer of the intima, representing a considerable risk factor for promoting 
early events in the development of atherosclerosis [99].  
T lymphocytes include three major functional subsets: T-helper lymphocytes, T-
suppresser lymphocytes, and T-cytotoxic lymphocytes [243]. The immune response 
depends on the balance of cytokines produced by two Th cell subsets, Th1 and Th2. Th1 
cells secrete Th1 cytokines such as IL-2 and INF-γ, promote cytotoxic and inflammatory 
functions by activating macrophages, natural killer cells and cytotoxic CD8+ T 
lymphocytes. Th2 cells secrete Th2 cytokines such as IL-4, IL-6 and IL-10, which can 
trigger the humoral immune mechanism, including antibody production and eosinophil 
proliferation [284]. 
There are several studies concerning the role of IONs on T cell activation. In fact, it 
has been described that magnetic IONs have the ability to generate a significant number 
of exosomes in the alveolar region of mice. In turn, the immune activation in splenic T 
cells is simultaneously induced [285]. Fe3O4 NPs were shown to increase CD8+ T cells 
activation and decrease CD4+ T cells activation [267]. 
When mixed lymphocyte reaction was evaluated, Endorem® revealed an inability to 
interfere with the dendritic cells activation of the CD8+ T cells [110], CD4+ T cells [286] and 
protamine sulphate-coated Feridex IV® showed an inability to interfere with the THP-1 
cells activation of the CD4+ T cells [287]. However, Pawelczyk et al [288] observed, 
performing the same experiment, suppression of bone marrow stromal cells activation of 
alloreactive T-cells by protamine sulphate-coated Feridex IV®. Here, the different type of 
cell may have contributed for the different results. 
It was described, by Zhu et al [285], that, in ovalbumin-sensitized rats, magnetic IONs 
have the ability to increase the percentages of Th1 and T-cytotoxic lymphocytes 1, 
decreasing at the same time the percentages of Th2 and T-cytotoxic lymphocytes 2, 
which suggest that magnetic IONs are able to skew the immune response toward Th1 
responses. Other authors reported that Fe3O4 NPs increase Th1 immunity in a greater 
extent than they increase Th2 immunity [244]. In accordance, Ban et al [289] reported that 
Fe2O3 NPs inhibited the ovalbumin-induced Th2 response in mice. Zhu et al [261] 
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reported that IONs-induced exosomes triggered classical peritoneal macrophages 
activation to M1. Laskar et al [278] also reported that Resovist® induces a phenotypic shift 
of THP1 M2 macrophages towards M1 subtype. Shen et al [245], however, showed that 
Resovist® has a decreasing effect in the ovalbumin-induced production of immunoglobulin 
G1 and immunoglobulin G2a in mice, which demonstrates the suppressing effect of this 
IONs on Th2 and Th1 cell type responses, respectively, in vivo. The fact that the exposure 
times were different between this study and other in vivo mentioned studies may be the 
reason for this difference. However, further studies would be necessary to elucidate this 
question, namely studying the influence of IONs in ovalbumin-induced inflammatory 
responses at different time points under the same conditions. 
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I. General Introduction
The main objective of this dissertation was to assess the biological effects of PAA-
coated and non-coated magnetite IONs in in vitro and in vivo experimental models. For 
this purpose we evaluated the effects of these IONs on human leukocytes, as well as on 
other blood cells, in vitro, namely on the induction of oxidative burst, death and pro-
inflammatory pathways and genotoxicity, as well as the effects of PAA-coated IONs in 
vivo concerning their pro-inflammatory and toxicological effects in male CD-1 mice. 
The following specific objectives were established: 
 To evaluate the effects of PAA-coated and non-coated IONs on human
neutrophils, namely their capacity to activate the oxidative burst and to modify their
lifespan through necrosis and/or apoptosis;
 To evaluate the ability of PAA-coated and non-coated IONs to induce cytokine
production (IL-1β, TNF-α, IL-6, IL-8, IFN-γ and IL-10) by ex-vivo human blood cells
and assess the pathways (p38 MAPK, JNK and NF-kB) involved in this induction;
 To evaluate the ability of PAA-coated and non-coated IONs to induce genotoxicity
in human T lymphocytes through influence on cell cycle progression and on the
induction of chromosome aberrations;
 To evaluate the ability of PAA-coated and non-coated IONs to exert cumulative
effect with the iron-dependent genotoxic agent BLM in human T lymphocytes;
 To evaluate the biodistribution of PAA-coated IONs in male CD-1 mice after
intravenous administration;
 To evaluate the effect of acute intravenous PAA-coated IONs administration on
male CD-1 mice, namely their ability to induce pro-inflammatory processes and
induce liver and kidney toxicity.
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II. Original Research
II.1. INTERACTION OF POLYACRYLIC ACID COATED AND NON-COATED IRON
OXIDE NANOPARTICLES WITH HUMAN NEUTROPHILS
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Polyacrylic acid-coated iron oxide nanoparticles increase neutrophils’ apoptosis.
Non-coated iron oxide nanoparticles prevent neutrophils’ apoptosis.
Both nanoparticles trigger neutrophils’ oxidative burst by NADPH oxidase activation.
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a b s t r a c t
Iron oxide nanoparticles (ION), with different coatings and sizes, have attracted extensive interest in the
last years to be applied in drug delivery, cancer therapy and as contrast agents in imagiologic techniques
such as magnetic resonance imaging. However, the safety of these nanoparticles is still not completely
established, particularly to host defense systems that are usually recruited for their clearance from the
body. In this paper, given the importance of neutrophils in the immune response of the organism to
nanoparticles, the effect of polyacrylic acid (PAA)-coated and non-coated ION on human neutrophils was
evaluated in vitro, namely their capacity to activate the oxidative burst and to modify their lifespan.
II. Original Researcheywords:
anotoxicology
xidative burst
poptosis
uman neutrophils
ron oxide nanoparticles
The obtained results showed that the studied PAA-coated and non-coated ION triggered neutrophils’
oxidative burst in a NADPH oxidase dependent manner, and that PAA-coated ION increased —while non-
coated ION prevented — apoptotic signaling and apoptosis. These effects may have important clinical
implications in biomedical applications of ION.olyacrylic acid coating
. Introduction
Nanotechnology is nowadays at the forefront in the devel-
pment of new therapeutic and diagnostic tools in all areas of
edicine (Shubayev et al., 2009). A good example of nanotechnol-
gy applications is brought by the use of iron oxide nanoparticles
ION), due to their multifunctional properties, conferred by their
mall size, superparamagnetism, and biocompatibility (Mou et al.,
011). In fact, ION have the potential to be extensively used for
he improvement of site-speciﬁc drug delivery to cells, tissues, or
∗ Corresponding author. Tel.: +351 220428675.
E-mail address: egracas@ff.up.pt (E. Fernandes).
378-4274/$ – see front matter © 2013 Elsevier Ireland Ltd. All rights reserved.
ttp://dx.doi.org/10.1016/j.toxlet.2013.11.020© 2013 Elsevier Ireland Ltd. All rights reserved.
even organs, as well as in the enhancement of magnetic resonance
imagingcontrast, hyperthermia treatments in cancer therapy,mag-
netofection, stem cell therapy and gene delivery (Hong et al., 2011;
Muller et al., 2007; Naqvi et al., 2010; Shubayev et al., 2009).
To prevent the precipitation of iron oxide cores, ION for medical
imaging are always coated with a layer of protective and bio-
compatible colloid, usually a polymer that acts as a steric and/or
electrostatic stabilizer (Roohi et al., 2012). In particular, the poly-
acrylic acid (PAA) coating is an aqueous soluble polymer with
a high density of reactive functional groups that make it very
attractive in biomedicine, mainly due to its capability to form
ﬂexible polymer chain-protein complexes trough electrostatic,
hydrogen bonding or hydrophobic interactions (Pineiro-Redondo
et al., 2011).
134
5 ogy Le
l
2
6
u
s
n
l
s
I
a
m
t
I
e
g
t
e
t
s
b
p
2
l
i
T
c
a
t
2
e
h
o
o
t
n
f
6
p
t
o
W
s
n
s
d
t
d
t
a
e
i
l
w
o
b
(
t
w
a
n
t
viously reported in (Freitas et al., 2008). RPMI 1640 supplemented8 D. Couto et al. / Toxicol
Surface coating and size affect biodistribution, plasma half-
ife, and extent of cellular uptake of nanoparticles (Muller et al.,
007; Roohi et al., 2012). In vivo, large ION (comprised between
0 and 100nm) are rapidly phagocytosed by cells of the retic-
loendothelial system in the liver and spleen, having thereby a
hort blood half-life. On the other hand, small ION (<60nm) are
ot readily phagocytosed, which results in a longer plasma half-
ife and higher availability to other cells and organs of the immune
ystem (Matsushita et al., 2011; Muller et al., 2007). Although
ON may represent extremely useful tools in biomedicine, there
re still few studies assessing their possible effects in the above
entioned host defense systems that are usually recruited for
heir clearance from the body. It was previously reported that
ON have the ability to decrease the monocytes’ viability (Zhu
t al., 2011), as well as to induce the production of reactive oxy-
en species (ROS) on macrophages and decrease their viability,
hrough apoptosis, in a concentration-dependent manner (Lunov
t al., 2010a,b;Naqvi et al., 2010).However, theeffectof IONonneu-
rophils is still to be clariﬁed, this being the purpose of the present
tudy.
Human neutrophils are the most abundant leukocytes in
lood and constitute the ﬁrst line of innate host defense against
athogens and associated acute inﬂammations (Bockmann et al.,
001; Fadeel et al., 1998; Freitas et al., 2008). Neutrophils aremobi-
ized to the sites of invasion or inﬂammation, ingesting pathogens
nto phagosomes (Fadeel et al., 1998; Freitas et al., 2009a,b, 2008).
he phagosome fuses with neutrophilic cytoplasmatic granules
ontaining cytotoxic enzymes, namely lysosomal enzymes, as well
s NAPDH oxidase and myeloperoxidase, which are responsible for
he oxidative burst and consequent generation of ROS (Brasen et al.,
010; Fadeel et al., 1998; Freitas et al., 2009a,b, 2008). While these
vents are important for the elimination of pathogens, it is not clear
ow these cells cope with ION, and which consequences ION have
n their lifespan.
Neutrophils have a short lifespan that is regulated by the onset
f apoptosis. In fact, apoptosis in mature neutrophils is a consti-
utive process that results in a rapid turnover of the circulating
eutrophil population [(5×1010 neutrophils per day are released
rom bone marrow (Goncalves et al., 2010)] with a t1/2 of 5 to
h in vivo and 24 to 36h in vitro (Watson et al., 1998). This
rocess is essential for the normal resolution of inﬂammation in
issues, because it culminates in the recognition and clearance
f the apoptotic neutrophils by macrophages (Rowe et al., 2002).
hile it has been postulated that these cells undergo apoptosis
pontaneously (Goncalves et al., 2010; Rowe et al., 2002), exter-
al factors may inﬂuence this process, as we have previously
hown (Freitas et al., 2013a), and therefore the inﬂuence of the
ifferent nanoparticles in this process requires further investiga-
ion.
Necrosis is an unorganized process associated with extensive
amage, resulting in an intense inﬂammatory response. In neu-
rophils, this process may occur due to a lack of intracellular
denosine triphosphate (ATP), necessary to apoptosis. Due to the
nergy-consumptive oxidative burst and consequent depletion of
ntracellular ATP stores, these cells may be unable to maintain cel-
ular homeostasis and membrane integrity, occurring an inﬂux of
ater andextracellular ions. This inﬂuxwill trigger the intracellular
rganelles and thewhole cell swelling,with all the cellular contents
eing released into the extracellular ﬂuid and surrounding tissues
Kroemer et al., 2007; Turina et al., 2005).
Considering the lack of knowledge on the activation of neu-
rophils and modulation of their lifespan by ION, the aim of this
ork was to evaluate the effects of ION in magnetite form (poly-
crylic acid (PAA)-coated and non-coated) on human neutrophils,
amely their capacity to activate the oxidative burst and to modify
heir lifespan through necrosis and/or apoptosis.tters 225 (2014) 57–65
2. Materials and methods
2.1. Materials
Human venous blood was obtained from healthy human
volunteers from Hospital de Santo António (Porto, Portugal).
Histopaque 1077, histopaque 1119, Dulbecco’s phosphate buffer
saline, without calcium chloride and magnesium chloride (PBS)
[2.68mM KCl, 0.14M NaCl, 1.21mM KH2PO4, 8.10mM Na2HPO4],
RPMI 1640 medium, l-glutamine, penicillin, streptomycin, try-
pan blue solution 0.4%, phorbol 12-myristate 3-acetate (PMA),
dihydrorhodamine 123 (DHR), diphenyleneiodonium chloride
(DPI), N-acetyl-Ile-Glu-Thr-Asp-p-nitroanilide, N-acetyl-Asp-Glu-
Val-Asp-p-nitroanilide, Ac-Leu-Glu-His-Asp-p-nitroanilide, potas-
sium phosphate, phenlymethylsulfonyl ﬂuoride, leupeptin, pep-
statin, HEPES and ethylenediamine tetraacetic acid (EDTA) were
obtained from Sigma Chemical Co (St Louis, USA). -Nicotinamide
adenine dinucleotide reduced dipotassium salt (NADH), sodium
pyruvate, CHAPS, tritonTM X-100, dithiothreitol, ferrous chloride,
ferric chloride, NH4OH, KCl and polyacrylic acid PAA (average
Mw 1800) were obtained from Sigma-Aldrich (St Louis, USA).
Hemacolor® was obtained from Merck (Darmstadt, Germany). (±)-
Nutlin-3 was acquired from Cayman (Michigan, USA). Sucrose
was obtained from Mallinckrodt Chemical Works (St Louis, USA).
Annexin-V-FLUOS Staining Kit was obtained from Roche Diag-
nostics GmbH (Mannheim, Germany). Nuclear Extract Kit and
TransAMTM p53Transcription FactorAssayKitswere acquired from
Active Motif (La Hulpe, Belgium).
2.2. Methods
2.2.1. Synthesis of iron oxide nanoparticles
ION “non-coated” magnetite particles were prepared follow-
ing previous well-known procedures with some modiﬁcations
(Massart et al., 1995). In brief, the procedure is based on the chem-
ical co-precipitation of a mixture of Fe(II) and Fe(III) chloride salts
(molar ratio 2:1) using NH4OH in a degassed 1M KCl aqueous solu-
tion at 60 ◦C. The dark precipitate was washed several times with
deoxygenated water, and ﬁnally the particles were stored at pH 9.6
(well-above their isoelectric point: 6.5). For the PAA-coated parti-
cles, PAA (25% w/w with respect to the Fe(II) salt) was added to the
reaction medium.
2.2.2. Characterization of iron oxide nanoparticles
Non-coated and PAA-coated ION were characterized using
transmission electron microscopy (TEM) (Hitachi H-7000, Japan).
Determination of the hydrodynamic size and zeta potential of the
nanoparticles inwater suspensions, in function of pH and [NaCl], as
well as in the medium used for the studies on human neutrophils
[RPMI 1640 (pH=7.4) supplemented with 10% fetal bovine serum,
2mM l-glutamine, 100U/mL penicillin and 0.1mg/mL strepto-
mycin] were made using a nanoparticle analyzer SZ-100 (HORIBA
Scientiﬁc) (DPSS laser 532nm). Before the dilutions, IONwere soni-
cated for 5min in order to avoid the formation of aggregates before
the preparation of the samples.
2.2.3. Isolation of human neutrophils by the gradient density
centrifugation method
Following informed consent, venous blood was collected from
healthy human volunteers by antecubital venipuncture, into vac-
uum tubes with K3EDTA. The isolation of human neutrophils was
performed by the gradient density centrifugation method as pre-
II. Original Researchwith 10% fetal bovine serum, 2mM l-glutamine, 100U/mL peni-
cillin and 0.1mg/mL streptomycin was the incubation medium
used.
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.2.4. Measurement of neutrophils’ oxidative burst
The measurement of neutrophils’ oxidative burst was per-
ormed by ﬂuorescence, by monitoring the oxidation of DHR to
hodamine 123 by neutrophil-generated reactive species (Freitas
t al., 2009a,b). Neutrophils (3×106 mL−1) were incubated for
4h with PAA-coated and non-coated ION (4, 20 and 100g/mL)
nd DHR (10M) at 37 ◦C. At the end of this incubation period,
ells were centrifuged (400g, 5min at 20 ◦C) and the supernatant
as discarded. The pellets were resuspended in 300L RPMI
640 medium and the ﬂuorescence was measured in a microplate
eader (excitation = 485nm and emission = 520nm). PMA was used
s positive control. Simultaneously it was performed an exper-
ment where the neutrophils were incubated with ION (20 and
00g/mL), DPI (20M) and DHR (10M).
.2.5. Evaluation of cellular necrosis
.2.5.1. Trypan blue assay. Trypan blue assay was performed
ccording to (Freitas et al., 2010). Neutrophils (2×106 mL−1)
ere incubated with PAA-coated and non-coated ION (4, 20 and
00g/mL) for 24h, at 37 ◦C. At the end of the incubation period,
0L aliquots of neutrophil suspensions were added to an equal
olume of 0.4% trypan blue in a microtube and gently mixed. After
min on ice, the neutrophil number and viability (viable cells
xcluding trypan blue) were determined. This dye enters in the
ecrotic cells, staining them blue, while the living cells remain
iscoloured.
.2.5.2. Lactate dehydrogenase (LDH) leakage assay. LDH leakage
as performed according to (Freitas et al., 2010). This release is
irectly related to the cellular membrane disruption and, conse-
uently, cellular death. Neutrophils (2×106 mL−1) were incubated
ithPAA-coatedandnon-coated ION(4, 20and100g/mL) for24h
t 37 ◦C. At the end of the incubation period, cells were centrifuged
6500g, 2min at 4 ◦C) and the supernatant was collected. Simulta-
eously it was performed a control assay with sonicated cells in
rder to determine the total LDH. LDH activity was determined by
ollowing the rate of oxidation of NADH at 340nm.
.2.6. Evaluation of apoptosis
.2.6.1. Evaluation of apoptosis by morphology. Evaluation of apo-
tosis bymorphologywasperformedaccording to (Saldanha-Gama
t al., 2010). Neutrophils (1×106 mL−1) were incubated with PAA-
oated and non-coated ION (4, 20 and 100g/mL) for 16 and 24h
t 37 ◦C. At the end of these incubation periods, cells were cen-
rifuged in a microscopic slide (Cytospin, 300 rpm, 6min at room
emperature), stained with Hemacolor®, and counted under light
icroscopy to determine the proportion of cells showing charac-
eristic apoptotic morphology (round and dark nucleus that results
rom the chromatin condensation occurring in apoptosis, signaled
ith arrows). At least 400 cells were counted per slide.
.2.6.2. Evaluation of apoptosis by ﬂow cytometry. Apoptotic neu-
rophils were analysed by ﬂow cytometry after simultaneous
taining with annexin-V labeled with ﬂuorescein and propid-
um iodide, according to (Sladek et al., 2005). Annexin-V is a
a2+-phospholipid-bindingprotein thathas ahighafﬁnity for phos-
hatidylserine and propidium iodide is impermeant to live cells
nd apoptotic cells, but stains dead cells with red ﬂuorescence,
ightly binding to the nucleic acids in the cell. The commer-
ial Annexin-V-FLUOS Staining Kit (Roche Diagnostics GmbH,
annheim Germany) was used according to the manufacturer’s
nstructions. Neutrophils (1×106 mL−1)were incubatedwith PAA-
oated and non-coated ION (4, 20 and 100g/mL) for 16h, at
7 ◦C. At the end of the incubation period, cells were centrifuged
400g, 5min at 20 ◦C) and the supernatant was discarded. Pellets
ere resuspended in 1mL of PBS and centrifuged (200g, 5min attters 225 (2014) 57–65 59
20 ◦C). After centrifugation, pellets were resuspended in 100L of
annexin-V and were incubated for 15min in the dark. After incuba-
tion, samples were centrifuged (200g, 5min at 20 ◦C) and the pellet
was resuspended in 300L PBS and 3L propidium iodide.
Fluorescence signals for each samplewere collectedusing a Bec-
ton Dickinson FACSCaliburTM ﬂow cytometer (Becton Dickinson,
Inc., Mountain View, CA, USA) equipped with a 488nm argon-ion
laser, as described in Freitas et al. (2013b).
2.2.7. Evaluation of pro-apoptotic signalling
2.2.7.1. p53-DNA binding. Neutrophils (8×106 mL−1) were incu-
bated with PAA-coated and non-coated ION (4, 20 and 100g/mL)
for 24h at 37 ◦C. At the end of this incubation period, neutrophils’
desoxyribonucleic acid (DNA)wasextractedusingaNuclearExtract
Kit (Active Motif) according to manufacturer’s instructions, with
slight modiﬁcations. In order to obtain a more efﬁcient nuclear
extraction, sonication (4 cycles, 12 s) was performed to disrupt
neutrophils’ nuclear membrane before centrifugation (14,000g,
10min 4 ◦C). Cell lysates were diluted to 3.5g total protein with
lysis buffer and used for the p53 determination. For this purpose,
TransAMTM p53 Transcription Factor Assay Kit was used accord-
ing to manufacturer’s instructions, as described in Thompson et al.
(2004). (±)-Nutlin-3 was used as positive control.
2.2.7.2. Measurement of caspases 3, 8 and 9 activities. Neutrophils
(10×106 mL−1) were incubated with PAA-coated and non-coated
ION (4, 20 and 100g/mL) for 16 and 24h at 37 ◦C. At the end
of these incubation periods, cells were centrifuged (400g, 5min
at 20 ◦C) and the supernatant was discarded. Pellets were resus-
pended in 100L of lysis buffer (10mM potassium phosphate,
1mM EDTA, 0.5% Triton X-100, 2mM phenlymethylsulfonyl ﬂu-
oride, 3g/mL aprotinin, 10g/mL leupeptin, 10g/mL pepstatin,
and 10mM dithiothreitol). After incubation for 20min on ice, sam-
ples were centrifuged at 18,000g for 20min, at 20 ◦C. An aliquot
of each sample (50L) was diluted to a ﬁnal volume of 250L
in assay buffer consisting of 50mM HEPES, 10% sucrose, 0.1%
CHAPS, and10mMdithiothreitol supplementedwith100Mof the
colorimetric caspase-3, 8 or 9 substrates (N-acetyl-Asp-Glu-Val-
Asp-p-nitroanilide, N-acetyl-Ile-Glu-Thr-Asp-p-nitroanilide and
Ac-Leu-Glu-His-Asp-p-nitroanilide, respectively). Samples were
incubated for 120min at 37 ◦C and the absorbance was measured
at 405nm (Weinmann et al., 1999).
2.2.8. Statistical analysis
Statistics were calculated using GraphPad PrismTM (version 5.0;
GraphPad Software). The results are expressed as the mean± SEM
(from at least four individual experiments). Statistical comparison
between groupswas performed using the one-way analysis of vari-
ance, followed by Bonferroni’s post hoc test. The values of p lower
than 0.05 were considered as statistically signiﬁcant.
3. Results
3.1. Characterization of iron oxide nanoparticles
Both PAA-coated and non-coated ION particles have a simi-
lar size distribution, with a mean particle size of 9.9±2.3nm and
10.1±2.4nm (Mean± SD) for the non-coated and PAA-coated ION,
respectively (Figs. 1 and 2 of Appendices A and B). Although non-
coated (withoutpolymer) IONnanoparticlesmaybestable inwater,
they easily agglomerate by changing the pH (due to the change
of the surface charge) or increasing the ionic strength (due to the
II. Original Researchshielding of surface charge). In fact, non-coated particles are only
stable at basic pHs, and are already destabilized at pHs below
≈9 (surface charge≈<−25mV). However, PAA-coated particles are
perfectly stable at neutral and even at slightly acid pHs (above ≈6)
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II. Original Researchig. 1. Neutrophils’ oxidative burst in cells exposed to (A) PAA-coated ION (4–100
7 ◦C for 24h. *p<0.05 and ****p<0.0001 comparatively to control (without ION),
omparatively to 20g/mL non-coated ION. Data are expressed as percentage of ne
Fig. 3 of Appendices A and B). Concerning the stability is associ-
ted with the ionic strength, it was observed again that non-coated
articles are destabilized already at NaCl concentrations ≈0.1mM,
hile PAA-coated particles need ≈0.01M to be destabilized (Fig. 4
f Appendices A andB).When the IONwere dispersed in RPMI 1640
edium, the large hydrodynamic sizes observed and the fact that
eta potential was approximately 0mV indicates that both types
f nanoparticles tend to agglomerate when resuspended in this
edium, though inmuch higher intensity in the case of non-coated
ON (Fig. 5 of Appendices A and B).
.2. Effect of ION on neutrophils’ oxidative burst
Neutrophils’ oxidative burst was assessed using the probe DHR
10M) in neutrophils exposed to PAA-coated and non-coated ION
4–100g/mL) and ION with DPI (20M) at 37 ◦C for 24h (Fig. 1A
nd 1B). The neutrophils’ oxidative burst was observed in the pres-
nce of both ION. This effect followed a concentration-dependent
anner for PAA-coatednanoparticles, but in the case of non-coated
ON, it occurred in a concentration-independent manner, having
chieved the maximum activation at 20g/mL. The activation of
ig. 2. Neutrophils’ apoptosis assessed by microscopic morphology after exposure to PAA
*p<0.01 and ****p<0.0001 comparatively to control (without ION). Data are expressed
n≥4).L) and (B) non-coated ION (4–100g/mL) in the absence and presence of DPI, at
.01 comparatively to 100g/mL PAA-coated ION and p<0.001 and p<0.0001
hil activation. Values are given as mean± SEM (n≥4).
oxidative burst triggered by both ION was approximately 20 times
lower than positive control PMA (396±49%). However, it was con-
sidered statistically signiﬁcant, as it can be seen in Fig. 1A and
B. Activation was blocked in the presence of DPI (20M), which
means that the neutrophils’ oxidative burst observed in the pres-
ence of both nanoparticles is due to NADPH oxidase activation.
3.3. Effect of ION on neutrophils’ death by necrosis
No effect was found for any of the PAA-coated and non-coated
ION (4–100g/mL) both at the trypan blue and LDH leakage assays
(data not shown), which demonstrates that the ION studied do not
seem to disrupt the cellularmembrane at the present experimental
conditions.
3.4. Effect of ION on neutrophils’ death by apoptosis3.4.1. Apoptosis evaluated by morphology
As it can be observed in 2A andB and3B, the percentage of apop-
totic cells increased in the presence of PAA-coated ION relatively
to control (without ION), in a concentration-dependent manner.
-coated and non-coated ION (4–100g/mL) at 37 ◦C: (A) 16h and (B) 24h. *p<0.05,
as percentage of apoptosis relatively to control. Values are given as mean± SEM
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II. Original Researchig. 3. Neutrophils’ apoptosis assessed by microscopic morphology at 16h: with
ampliﬁcation 40×). Arrowheads indicate apoptotic neutrophils.
n the contrary, the percentage of apoptotic cells decreased in the
resence of non-coated ION (2A and B and 3C), which indicates
hat these nanoparticles exert the opposite effect of PAA-coated
ON, having the capacity of protecting neutrophils from apoptosis.
.4.2. Apoptosis evaluated by ﬂow cytometry
It was veriﬁed that the proportion of annexin-V(+)/PI(−) cells
ncreased in the presence of PAA-coated ION, in a concentration-
ependentmanner (4Aand5B). This demonstrates, once again, that
AA-coated ION cause acceleration of apoptotic death. On the con-
rary, the proportion of annexin-V(+)/PI(−) cells decreased in the
resence of non-coated ION, in a concentration-dependentmanner
4B and 5C). This result is in agreement with the previous results
ig. 4. Neutrophils’ apoptosis assessed by ﬂow cytometry after exposure to (A) PAA-co
p<0.05, **p<0.01 and ***p<0.001 comparatively to control. Data are expressed as perceN (A), with 100g/mL PAA-coated ION (B) and 100g/mL non-coated ION (C)
that demonstrate that this type of nanoparticles is able to protect
neutrophils from apoptosis.
3.5. Apoptotic signalling
3.5.1. p53-DNA binding
Regarding PAA-coated ION, a marked heterogeneity was
observed among subjects, evidencing two different groups of indi-
viduals’ neutrophils: one of the groups (non-responders) did not
present any increase in p53 activity in the presence of the nanopar-
ticles, when compared to the control; the other group (responders)
presented a signiﬁcant increase in p53 activity in the presence of
these nanoparticles, well evidenced for the concentrations of 20
ated ION (4–100g/mL) and (B) non-coated ION (4–100g/mL) at 37 ◦C for 16h.
ntage of annexin-V(+)/PI(−) cells. Values are given as mean± SEM (n≥4).
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Fig. 5. Flow cytometric analysis of annexin V binding assay. Neutrophils incubated at 37
curve) and non-coated (C—blue curve) ION. (For interpretation of the references to color
Fig. 6. p53 activation in neutrophils exposed to PAA-coated ION (4–100g/mL) at
37 ◦C for 24h. *p<0.05 comparatively to control (without ION). Data are expressed
as percentage of p53 activation relatively to control. Values are given asmean± SEM
(n≥4).
Fig. 7. Caspase3activity inneutrophils exposed toPAA-coatedandnon-coated ION(4–100
to control (without ION). Data are expressed as percentage of caspase 3 activation relativ
II. Original Research◦C for 16h without ION (A—black area) and with 100g/mL PAA-coated (B—green
in this ﬁgure legend, the reader is referred to the web version of this article.)
and100g/mL (Fig. 6). Non-coated IONdidnot inﬂuencep53 activ-
ity (data not shown).
3.5.2. Measurement of caspases 3, 8 and 9 activities
Concerning PAA-coated ION, it was observed that caspases 3,
8 and 9 activities were increased in the presence of ION, in a
concentration-dependent manner (7A and B, 8A and 9A and B).
For the non-coated ION, the opposite effect was observed for cas-
pases 3 and 9, given that these nanoparticles exhibited the ability
to inhibit caspases 3 and 9 activity, comparatively to control (with-
out ION) (7A and B and 9A and B). However, they did not alter the
caspase 8 activity comparatively to control (data not shown). These
results are in agreement with those obtained in the evaluation of
apoptosis.
g/mL)at37 ◦C: (A)16hand (B)24h. *p<0.05, **p<0.01, ***p<0.001comparatively
ely to control. Values are given as mean± SEM (n≥4).
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Fig. 8. Caspase 8 activity in neutrophils exposed to PAA-coated ION (4–100g/mL)
at 37 ◦C for 16 and 24h. *p<0.05 and **p<0.01 comparatively to control. Data are
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txpressed as percentage of caspase 8 activation relatively to control (without ION).
alues are given as mean± SEM (n≥4).
. Discussion
This work was undertaken to evaluate the putative capacity of
AA-coated and non-coated ION to activate the oxidative burst in
uman neutrophils and to modify their lifespan in vitro. It was
learly evidenced that both ION studied were able to trigger neu-
rophils’ oxidative burst and that PAA-coated ION increased, while
on-coated ION decreased, apoptotic signaling and apoptosis.
Neutrophil’s oxidative burst occurred in a concentration-
ependent manner following exposure to PAA-coated ION. For
on-coated ION, the highest neutrophil activationwas observed for
0g/mL, probably due to NADPH oxidase inhibition at the higher
oncentration tested (100g/mL). In both cases, the observed
xidative burst was reverted in the presence of a NADPH oxidase
nhibitor (DPI),which demonstrates the full involvement of NADPH
xidase activation in the observed effect. This enzyme reduces
olecular oxygen to superoxide radical
(
O−2 ·
)
in the presence of
ADPH. After O−2 · production, other ROS, namely hydrogen per-
xide (H2O2), hypochlorous acid (HOCl), hydroxyl radical (HO•)
nd singlet oxygen (1O2), and RNS, particularly nitric oxide (•NO)
nd peroxynitrite anion (ONOO−), are formed in cascade (Brasen
t al., 2010; Freitas et al., 2009a,b), which characterizes the neu-
rophils’ oxidative burst. Although the interaction of PAA-coated
ON with neutrophils is reported for the ﬁrst time in the present
tudy, ION with other types of coatings have been shown to
ig. 9. Caspase 9 activity in neutrophils exposed to PAA-coated and non-coated ION (4–1
o control (without ION). Data are expressed as percentage of caspase 9 activation relativtters 225 (2014) 57–65 63
promote ROS production in other cell types. Bae et al. (2011), using
2′,7′-dichloroﬂuorescein diacetate (DCFH-DA), demonstrated that
carboxydextran-coated ION increased intracellular levels of ROS in
mouse hepatocytes, and Lunov et al. (2010a,b) demonstrated that
carboxydextran-coated superparamagnetic ION induced a time-
dependent ROS production in human macrophages. Choi et al.
(2009) also showed that anionic clay layered IONcausedan increase
in ROS production in human lung cancer A549 cells. On the other
hand, Karlsson et al. (2008) observed, also using DCFH-DA, that
non-coated ION do not potentiate the ROS production in A549 type
II lung epithelial cells. Since the concentrations tested were similar
in these different studies, it is important to highlight that the ION
effects can bedistinct according to the type of coating, or the type of
cells tested. While neutrophils, monocytes and macrophages may
react to ION through the activation of NADPH oxidase, as shown in
the present study for neutrophils, other mechanisms may also be
involved in the production of ROS. Shubayev et al. (2009) hypoth-
esized that ION induce redox cycling and catalytic chemistry via
Fenton reaction. Our study did not ascertain the intervention of ION
in this reaction. Nevertheless, onceNADPHoxidase is activated, the
cascade of ROS and RNS production succeeds, and HO• is expected
to be generated through the Fenton reaction.
The formation of ROS and RNS, and ensuing oxidative stress
may intervene in apoptotic pathways, namely through the activa-
tion of the mitochondrial apoptotic pathway (Franco et al., 2009).
In fact, there are reports concerning the ability of ROS and RNS
to interfere directly in apoptosis through mitochondrial mem-
brane permeabilization and cytochrome c release, as well as in Jun
N-terminal protein kinase (JNK) activation (Circu and Aw, 2010;
Huang et al., 2008). Another pathway involving ROS and RNS is
through direct activation of p53 (Sharma et al., 2012). It is thought
that ROS and RNS-induced DNA damagemay trigger p53 activation
(Simbula et al., 2007). Phosphorylation in response to DNA dam-
age enhances the interaction of p300 and PCAF with p53, thereby
leading to p53 acetylation and consequent activation (Sakaguchi
et al., 1998). Therefore, these two pathways may be connected
to each other. In fact, the activation of p53 triggers the expres-
sion of Bax and Noxa, two pro-apoptotic proteins that induce an
increase in mitochondrial permeability, leading to the release of
cytochrome c, apoptosis inducing factor (AIF) and Diablo/Smac and
the consequent mitochondrial apoptotic pathway (Chen and Shi,
2002). Besides the above rationale, the expression of pro-apoptotic
proteins and/or thedecrease in anti-apoptotic proteinsmaybe acti-
vated by several other factors and/or stimuli. For example, Miyake
II. Original Researchchondrial apoptosis by decreasing anti-apoptotic proteins.
In the present study, p53 activation by PAA-coated ION was
demonstrated, for theﬁrst time, inpart of the subjects tested. In line
00g/mL) at 37 ◦C: (A) 16h and (B) 24h. **p<0.01 and ***p<0.001 comparatively
ely to control. Values are given as mean± SEM (n≥4).
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ith these results, Wu et al. (2012) and Wu and Sun (2011) have
eported before that non-coated ION induced p53 gene expres-
ion and increased phosphorylation levels of p53 in PC12 cells, and
hat this activation is associated with increased levels of Bax and
ecreased levels of Bcl-2. On the other hand, the opposite was also
eported by Huang et al. (2009), in which it was referred slight
ecreases in p53 expression in ferucarbotran-labeled human mes-
nchymal stem cells, and it was also reported that ION do not
hange the expression of p53 mRNA in K562/A02 cells (Chen et al.,
009). While this activation may represent a link, as described
bove, between ROS and an apoptotic pathway, the truth is that
53 did not demonstrate to be essential for neutrophil activation
n our study, given that apoptosis activation occurred for all donors
estedwith PAA-coated ION,while p53 activation occurred only for
ne group (named responders).
In this study, the proportion of apoptotic cells was increased
n the presence of PAA-coated ION, in a concentration-dependent
anner. However, the results obtained with these ION seem to be
ore evident for the morphologic assay, comparatively to the ﬂow
ytometry assay. This happens because, when cells are annexin V+,
his means that phosphatidylserine was translocated to the outer
ell membrane leaﬂet, an event that occurs during apoptotic pro-
ess (Lunov et al., 2010a,b). Thus, it is possible that some of the
ells have already initiated theprocess of apoptosis, even in control,
lthough they do not present the characteristic apoptoticmorphol-
gy when they are counted on the morphologic assay, presenting
lready the phosphatidylserine on the outer side of the membrane
eaﬂet. Therefore, annexin V+ control cells is approximately 80%
nd, consequently, the increase after treatment with PAA-coated
ON will not be so evident as it is in cytospin assay. Neverthe-
ess, it is evident that these ION have the ability to accelerate a
atural feature of neutrophils that correspond to a short lifespan
ediated by apoptosis. In contrast, in the presence of non-coated
ON, the proportion of apoptotic cells decreased in a concentration-
ependent manner. Likewise, Lunov et al. (2010a,b) reported that
xposure of macrophages to carboxydextran-coated superpara-
agnetic ION triggered translocation of phosphatidylserine to the
uter cell membrane leaﬂet, indicating increased apoptosis. Choi
t al. (2009) also reported that non-coated ION triggered the same
n human lung cancer A549 cells. On the other hand, it was previ-
usly reported a lack of effect of non-coated ION on mature mouse
endritic cells’ apoptosis (Mou et al., 2011). Once again, it is impor-
ant to highlight that the effect of ION is not necessarily the same in
ifferent types of cells, namely in what concerns to the production
f reactive species and ensuing apoptotic signaling.
For a better clariﬁcation of the apoptotic pathways involved in
he observed pro- and anti-apoptotic effects, caspases 3, 8 and 9
ctivities were assessed. It was observed that the activities of cas-
ases 3, 8 and 9 were increased in the presence of PAA-coated
ON, in a concentration-dependent manner. Given that caspase
is involved in the extrinsic apoptotic pathway and caspase 9
s involved in the mitochondrial apoptotic pathway (Chen and
hi, 2002; Franco et al., 2009; Letuve et al., 2002), these data
uggest that PAA-coated ION interfere with both apoptotic path-
ays, promoting the apoptosis acceleration by both pathways.
egarding caspase 3, as this is one of the effector caspases, inter-
ening in a late apoptosis stage, common to mitochondrial and
xtrinsic pathways, its increase just corroborates the activation
f signaling caspases. Caspase 3 activity increase was previously
hown to be triggered by carboxydextran-coated ION in a mouse
iver cell line (NCTC 1469) (Bae et al., 2011). Likewise, Lunov
t al. (2010a,b) reported that carboxydextran-coated superpara-
agnetic ION and ultrasmall superparamagnetic ION increased the
aspase 3 activity in human macrophages. Dilnawaz et al. (2012)
lso reported an increase in caspases 3 and 9 activation caused by
ransferring-conjugated curcumin-loaded superparamagnetic IONtters 225 (2014) 57–65
in the leukemic cell line K562. It was also found by Zhang et al.
(2011) that tetraheptylammonium-coated ION have the capacity
to increase the ability of daunorubucin to induce apoptosis in K562
cells through caspase 8 activation, which is in accordance to our
results. These results suggest that coating may be important for
the activation of apoptotic signaling, bymaintaining IONdispersed,
though the type of coating may not have an important role in the
ﬁnal effect, though this assumption needs further evaluation. For
non-coated ION, it was observed that these nanoparticles exhibit
the capacity to inhibit caspases 3 and 9 activation, explaining why
these nanoparticles induce a delay in the apoptotic process. These
results are in accordance with Khan et al. (2011), which showed
that non-coated ION reduced caspase 9 activity in HeLa cells. The
fact that non-coated ION inhibited caspases 3 and 9 but did not
interfere with caspase 8 demonstrates that these nanoparticles
only inhibited the mitochondrial apoptotic pathway, not interfer-
ing with the extrinsic apoptotic pathway. Although, at the present
stage, the mechanism(s) involved could not be determined, this is
an important ﬁnding to be considered upon exposure to ION in the
workplace and in the environment.
This study also shows that none of the studied ION studied seem
to alter neutrophils’ lifespan by necrosis. These results are in agree-
mentwith the studies ofKarlssonet al. (2008),whichdemonstrated
that non-coated ION did not inﬂuence cellular necrosis in cultured
A549 type II lung epithelial cells. Furthermore, Wang et al. (2009)
performed a study in order to assess the dextran-coated ION effect
on rat adipose-derived stem cells, reaching the same conclusions.
Hussain et al. (2005) used the LDH leakagemethodology and stated
that the non-coated ION do not produce cytotoxicity up to the con-
centration of 100g/mL in BRL 3A RAT liver cells. However, for
similar concentrations, Choi et al. (2009) reported that non-coated
ION cause an increase in LDH leakage in human lung cancer A549
cells, whichmeans that these nanoparticles can have different toxi-
cologicmechanisms, according to the cells they are in contactwith.
Concerning the limitations of the present study, the fact that
it was performed in vitro does not consider the interaction exist-
ing between different cells that occur in vivo. Therefore, the factors
produced by adjacent cells that occur in vivo and may inﬂuence
themodehowdifferent physiological processes occur, namely apo-
ptosis and neutrophil activation, are not taken into account in this
study. Another factor that cannot be studied in vitro is the bone
marrow and macrophage response to a smaller neutrophils’ life-
span, and therefore how a new equilibrium may be reached in vivo.
The concentrations used in our study do not seem to constitute
a limitation, since they are in accordance with the ones used in
therapeutic applications: formagnetic resonance imaging, the con-
centration usually used is around45mol Fe/kg,which is about the
concentration of 70g/mL (for 50kg human weight and 5000mL
human blood volume) (Apopa et al., 2009).
5. Conclusion
In this study it was evaluated the ability of PAA-coated and non-
coated ION to induce oxidative burst in human neutrophils and to
inﬂuence the respective death trends. The obtained results show
that both ION induce oxidative burst through NAPDH-oxidase acti-
vation. It was also shown that, while necrosis was not affected,
PAA-coated ION accelerate the apoptotic death of human neu-
trophils by themitochondrial and extrinsic pathways. p53 revealed
not to be essential to this effect. However, for some donors, PAA-
coated ION showed to be able to activate p53. Non-coated ION
II. Original Researchshowed to inhibit the mitochondrial pathway, not interfering with
the extrinsic pathway.
Though these effects still need to be conﬁrmed in vivo, the
observed effects may have important clinical implications in the
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Appendix A. Supplementary data 
The following are the supplementary data to this article: 
Figure 1 Supplementary: TEM image and size distribution for non-coated ION particles 
dispersion with a mean particle size (± standard deviation) of 9.9±2.3 nm. 
Figure 2 Supplementary: TEM image and size distribution for PAA-coated ION particles 
dispersion with a mean particle size (± standard deviation) of 10.1±2.4 nm. 
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Figure 3 Supplementary: pH dependence of the surface charge for the non-coated and 
PAA-coated ION particles dispersed in water. 
Figure 4 Supplementary: [NaCl] dependence of the surface charge for the non-coated 
and PAA-coated ION particles dispersed in water.  
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Figure 5 Supplementary: ION dispersed in RPMI 1640 medium: (A) PAA-coated ION 
and (B) non-coated ION.  
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production. The obtained results showed that PAA-coated 
and non-coated ION were able to induce all the tested 
cytokines and that activation of transforming growth factor 
beta (TgF-β)-activated kinase (TAK1), p38 mitogen-acti-
vated protein kinases (p38 MAPK) and c-Jun N-terminal 
kinases (JNK) were involved in this effect.
Keywords Iron oxide nanoparticles · Human blood cells · 
Inflammation · cytokines · Interleukins
Introduction
Owing to their unique physico-chemical properties, nano-
materials have been recognized as promising candidates 
for starting a new revolution in science and technology 
(Ahamed et al. 2013; comfort et al. 2013). Iron oxide nan-
oparticles (ION) are among the nanoparticles (NP) with 
higher potential in biomedical applications, namely for 
magnetic resonance imaging (Beckmann et al. 2009; Janic 
et al. 2008; lim et al. 2008; Serkova et al. 2010), tissue 
repair (Pareta et al. 2008; Taylor and Webster 2009), drug 
delivery (chen et al. 2012; Prijic et al. 2010), hyperthermia 
(giustini et al. 2011; Ito et al. 2006), transfection (gupta 
and gupta 2005; Prijic et al. 2010; Shi et al. 2010), tissue 
soldering (Schlachter et al. 2011), and as antimicrobial 
agents (Hu et al. 2011; Taylor and Webster 2009).
To prevent the precipitation of iron oxide cores, ION for 
medical imaging are always coated with a layer of protec-
tive and biocompatible colloid, usually a polymer that acts 
as a steric and/or electrostatic stabilizer (Roohi et al. 2012). 
The more frequently applied coatings are dextran (e.g., 
Endorem® and Feridex®) (Kedziorek et al. 2010; Kumar 
et al. 2012; Weinstein et al. 2010), carboxydextran (e.g., 
Resovist® and Supravist®) (corot et al. 2006; lunov et al. 
Abstract Iron oxide nanoparticles (ION) can have a wide 
scope of applications in biomedicine, namely in magnetic 
resonance imaging, tissue repair, drug delivery, hyperther-
mia, transfection, tissue soldering, and as antimicrobial 
agents. The safety of these nanoparticles, however, is not 
completely established, namely concerning their effect 
on immune system and inflammatory pathways. The aim 
of this study was to evaluate the in vitro effect of poly-
acrylic acid (PAA)-coated ION and non-coated ION on 
the production of six cytokines [interleukin 1 beta (Il-1β), 
tumor necrosis factor alpha (TNF-α), interleukin 6 (Il-6), 
interleukin 8 (Il-8), interferon gamma (IFN-γ) and inter-
leukin 10 (Il-10)] by human peripheral blood cells, and 
to determine the inflammatory pathways involved in this 
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2010; Weinstein et al. 2010) and silicone (e.g., lumiren® 
and AMI-121®) (Kumar et al. 2012), among others. 
Recently, the use of polyacrylic acid (PAA) has also been 
described in the literature for use in gene delivery (cao 
et al. 2013; Sun et al. 2012), as well as in liver and kidney 
imaging (Iversen et al. 2013). PAA is an aqueous soluble 
polymer with a high density of reactive functional groups 
that make it very attractive in biomedicine, mainly due to 
its capability to form flexible polymer chain–protein com-
plexes trough electrostatic, hydrogen bonding or hydropho-
bic interactions (Pineiro-Redondo et al. 2011).
In spite of the potential importance of ION in the bio-
medical field, there are still few studies performed so 
far evaluating the effect of these NP on the inflamma-
tory process. We have recently shown that PAA-coated 
and non-coated ION trigger neutrophils’ oxidative burst 
in a NADPH oxidase dependent manner, and that PAA-
coated ION increase while non-coated ION prevent apop-
totic signaling and apoptosis in these cells (couto et al. 
2014). More generally, previous studies have reported that 
ION may induce an increase in the number of inflamma-
tory cells (Kim et al. 2013; Shen et al. 2011a; Valois et al. 
2010; Zhu et al. 2008) and it has been described that ION 
are able to induce cytokine production in some cell types, 
namely γ-Fe2O3 NP, which was shown to increase tumor 
necrosis factor alpha (TNF-α) levels in RAW264.7 cells 
(Park et al. 2014), Fe3O4 NP, which increased interleukin 2 
(Il-2), interleukin 6 (Il-6) and interferon gamma (IFN-γ) 
levels in mice lymph node cell cultures (Ban et al. 2012) 
and Resovist® (carboxydextran-coated Fe3O4/Fe2O3 NP),
which increased TNF-α and interleukin 10 (Il-10) levels 
in the THP-1 cell line (laskar et al. 2012). There are also 
some studies regarding the effect of ION on inflammatory 
pathways, namely dimercaptosuccinic acid-coated Fe3O4 
NP, which activated JAK/STAT pathway in RAW264.7 
cells (liu et al. 2011), and Resovist® and Supravist® (car-
boxydextran-coated Fe3O4/Fe2O3 NP), which induced 
c-Jun N-terminal kinases (JNK) activation in human mac-
rophages (lunov et al. 2010). These studies have been per-
formed under tightly controlled experimental conditions,
using only one cell type and do not reflect the in vivo con-
ditions in which the intercellular communication networks
play an important role in inflammatory processes.
The human whole blood assay has been successfully 
used for the study of inflammatory processes involving the 
production of cytokines and the involved pathways (Hornef 
et al. 1995; Hussain et al. 2002; Jabs et al. 1996; Myrian-
thefs et al. 2003) and therefore seems to be a good model 
for screening the pro-inflammatory effects of xenobiotics, 
although, to the best of our knowledge, this model was 
never used before for NP. The aim of this study was to eval-
uate the effect of ION in magnetite form (PAA-coated and 
non-coated) on their capacity to induce cytokine production 
(interleukin 1 beta (Il-1β), TNF-α, Il-6, interleukin 8 
(Il-8), IFN-γ and Il-10) by ex vivo human blood cells and 
by which pathways (p38 MAPK, JNK and NF-kB).
Materials and methods
Materials
Human venous blood was collected from healthy human 
volunteers from Hospital de Santo António (Porto, Portu-
gal), following informed consent. RPMI 1640 medium, 
l-glutamine, penicillin, streptomycin, 4-[4-fluorophenyl]-
2-[4-methylsulfinylphenyl]-5-[4-pyridyl]1H-imidazole (SB
203580), anthra[1,9-cd]pyrazol-6(2H)-one 1,9-pyrazoloan-
throne (SP 600125), curcumin, pyrrolidine dithiocarbamate
(PDTc), 5Z-7-oxozeaenol and lipopolysaccharides from
Escherichia coli 026:B6 (lPS) were obtained from Sigma
chemical co (St louis, USA). Ferrous chloride, ferric
chloride, NH4OH, Kcl and PAA (average Mw 1,800) were 
obtained from Sigma-Aldrich (St louis, USA). Multi-Ana-
lyte ElISArray Human Kit was obtained from Qiagen® 
(Boston, USA). Non-coated and PAA-coated ION were 
obtained from Nanogap (Santiago de compostela, Spain), 
and their preparation and physico-chemical characteriza-
tion was performed as reported before (couto et al. 2014). 
Briefly, ION “non-coated” magnetite particles preparation 
was based on the chemical co-precipitation of a mixture 
of Fe(II) and Fe(III) chloride salts (molar ratio 2:1) using 
NH4OH in a degassed 1 M Kcl aqueous solution at 60 °c. 
The dark precipitate was washed several times with deoxy-
genated water, and finally, the particles were stored at pH 
9.6 (well above their isoelectric point: 6.5). For the PAA-
coated NP, PAA [25 % w/w with respect to the Fe(II) salt] 
was added to the reaction medium. PAA-coated and non-
coated ION were characterized using transmission electron 
microscopy (TEM) (Hitachi H-7000, Japan). Determination 
of the hydrodynamic size and zeta potential of the studied 
NP, in RPMI 1640 suspensions, was performed using a 
nanoparticle analyzer SZ-100 (HORIBA Scientific) (DPSS 
laser 532 nm). Both PAA-coated and non-coated ION 
have a similar size distribution, with a mean particle size 
of 9.9 ± 2.3 nm and 10.1 ± 2.4 nm (mean ± SD) for the
non-coated and PAA-coated ION, respectively. However, 
when the ION were dispersed in RPMI 1640 medium, large 
hydrodynamic sizes [3,941 ± 101 nm and 1,963 ± 148 nm
(mean ± SEM) for the non-coated and PAA-coated ION,
respectively], and low zeta potentials [−11.13 ± 2.83 and
−2.30 ± 2.4 mV (mean ± SEM) for the non-coated and
PAA-coated ION, respectively] were observed, which indi-
cates that both types of NP tend to agglomerate when resus-
pended in RPMI 1640 medium, though in much higher 
intensity in the case of non-coated ION. Before dilutions, 
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ION were sonicated for 5 min in order to avoid the forma-
tion of aggregates before the preparation of the samples.
Methods
Whole blood assay
The whole blood assay was performed according to (Myr-
ianthefs et al. 2003) in order to determine the amount of 
cytokines produced in response to ION. Heparinized blood 
collected from healthy human volunteers was diluted 10 
times in RPMI 1640 culture medium and incubated at 
37 °c in a 5 % cO2 atmosphere for 24 h with PAA-coated 
and non-coated ION (0.4, 1.5 and 4 µg/ml). These con-
centrations are within those usually attained in biomedical 
applications [up to 70 μg/ml (Apopa et al. 2009)]. After 
this incubation period, the content of each well was trans-
ferred to Eppendorf tubes, centrifuged (600g, 5 min, 20 °c) 
and the supernatants were collected and stored at −20 °c
until subsequent measurements. cytokine (Il-1β, TNF-α, 
Il-6, Il-8, IFN-γ and Il-10) levels in the supernatant were 
evaluated using an ElISA kit according to manufacturer’s 
instructions (Multi-Analyte ElISArray Human Kit, Qia-
gen®). Simultaneously, blood samples were incubated with 
PAA-coated and non-coated ION (4 µg/ml) and with each 
one of the following inhibitors: SB 203580 (p38 MAPK 
inhibitor) (5 μM) (Windheim et al. 2007), SP 600125 
(25 μM) (JNK inhibitor) (chowdhury et al. 2008), cur-
cumin [activator protein 1 (AP-1) inhibitor] (1 μM) (Han 
et al. 2002), PDTc (NF-kB inhibitor) (10 μM) (Zhang 
et al. 2011) and 5Z-7-oxozeaenol (TAK1 inhibitor) (1 μM) 
(Windheim et al. 2007). The inhibitors were incubated with 
the blood for 30 min before the addition of ION, for 24 h. 
lPS (2.5 μg/ml) (Hornef et al. 1995; Hussain et al. 2002) 
was used as positive control.
Statistical analysis
Statistics were calculated using graphPad Prism™ (version 
6.0; graphPad Software). The results are expressed as the 
mean ± SEM (from at least four individual experiments).
Statistical comparison between groups was performed 
using the one-way analysis of variance, followed by Bon-
ferroni’s post hoc test. p values lower than 0.05 were con-
sidered as statistically significant.
Results
cytokine production (Il-1β, TNF-α, Il-6, Il-8, IFN-γ and 
Il-10) was assessed by ElISA after incubation of PAA-
coated and non-coated ION (0.4, 1.5 and 4 μg/ml) with 
heparinized blood for 24 h at 37 °c. As can be observed in 
Figs. 1a, b, 2a, b, 3a, b, 4a, b, 5a, b, 6a, b, both ION were 
able to increase the production of the six studied cytokines, 
in the following decreasing order of extent, for PAA-coated 
ION Il-6 > Il-8 > TNF-α > IFN-γ > Il-1β > Il-10 and for 
the non-coated ION Il-8 > Il-6 > Il-1β > IFN-γ > TNF-
α > Il-10. The effect was seen, in most of the cases, in a 
concentration-dependent manner, being always statistically 
significant for the highest concentration tested (4 μg/ml). 
Additionally, lPS (2.5 μg/ml), used as positive control, 
showed a strenuous activation of all the cytokines tested 
(data not shown).
At this point, for a better integration of the obtained 
results, it is important to reflect on the possible pathways 
involved in cytokine production. Stimulation of inflam-
matory cells, such as neutrophils, macrophages, and T 
lymphocytes initiates a rapid cascade of protein phospho-
rylation, where MAPK kinases (MKK) are activated by 
MKK kinases (MAPKKK). One of the MAPKKK seems 
to correspond to transforming growth factor beta (TgF-
β)-activated kinase (TAK1). When TAK1 is activated, usu-
ally by TgF-β, Il-1, TNF-α, or by a pro-inflammatory 
stimulus, a generation of K63-linked polyubiquitin chains 
occurs, serving as scaffolds for the oligomerization of 
TAK1. This oligomerization is dependent upon the TAK1 
binding proteins, which possess polyubiquitin binding 
domains. TAK1 proteins that are brought together at pol-
yubiquitin chains are hypothesized to phosphorylate and 
activate one another. They are then competent for activation 
of MKK 3, 6 and other kinases, resulting in p38 MAPK 
and JNK activation (clark and Dean 2012; craig et al. 
2000; Noubade et al. 2007). MAPK are involved in many 
aspects of immune responses, including initiation of innate 
immunity, activation of adaptive immunity, and termination 
of immune responses through cell death and regulatory T 
cells (Pasquinelli et al. 2013). The p38 MAPK is a ubiqui-
tous, highly conserved protein kinase that plays an impor-
tant role in the inflammatory response (Bachstetter et al. 
2011; clark and Dean 2012; Noubade et al. 2007; Pas-
quinelli et al. 2013; Stambe et al. 2003). The JNK are also 
members of the MAPK family. The classical JNK pathway 
is equally activated following the exposure of cells to extra-
cellular stresses and a diversity of stimuli (guma and Fire-
stein 2012; Kim et al. 2006). TAK1, as well as kinases from 
inhibitor of kB (IkB) kinase family (IKK), can also activate 
NF-kB pathway. NF-kB is comprised of two subunits (p65 
and p50) that are retained in the cytoplasm in their inactive 
form by virtue of their interaction with the IkB and is one 
of the most important inducible transcription factors whose 
modulation triggers a cascade of signaling events (craig 
et al. 2000; gomes et al. 2008; Rhodus et al. 2005).
considering the above, we used several inhibitors 
to ascertain the pathways involved in the production of 
cytokines: p38 MAPK inhibitor (SB 203580), JNK inhibitor 
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(SP 600125), AP-1 inhibitor (curcumin), NF-kB inhibitor 
(PDTc) and TAK1 inhibitor (5Z-7-oxozeaenol). Inhibi-
tors, by themselves, did not change cytokine production in 
the whole blood (data not shown). It was verified that SB 
203580 and 5Z-7-oxozeaenol decreased or inhibited the 
production of all the ION-induced cytokines tested for both 
Fig. 1  Il-1β activation follow-
ing exposure to: a PAA-coated 
ION (0.4–4 µg/ml), b non-
coated ION (0.4–4 µg/ml),  
c PAA-coated ION (4 µg/ml) in 
the presence of inhibitors and  
d non-coated ION (4 µg/ml) 
in the presence of inhibitors, at 
37 °c, for 24 h. ****p < 0.0001 
and ***p < 0.001 when com-
pared to control (without ION) 
and ηηηηp < 0.0001, ηηηp < 0.001 
ηηp < 0.01 and ηp < 0.05 when 
compared to control (ION 
4 µg/ml). Values are given as 
mean ± SEM (n ≥ 4)
Fig. 2  TNF-α activation fol-
lowing exposure to: a PAA-
coated ION (0.4–4 µg/ml),  
b non-coated ION (0.4–4 µg/
ml), c PAA-coated ION (4 µg/
ml) in the presence of inhibi-
tors and d non-coated ION 
(4 µg/ml) in the presence of 
inhibitors, at 37 °c, for 24 h. 
*p < 0.05 when compared to
control (without ION) and
ηηp < 0.01 and ηp < 0.05 when
compared to control (ION
4 µg/ml). Values are given as
mean ± SEM (n ≥ 4)
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types of ION (Figs. 1c, d, 2c, d, 3c, d, 4c, d, 5c, d, 6c, d). 
This fact shows that PAA-coated ION and non-coated ION 
increase the production of cytokines through activation 
of p38 MAPK and TAK1. SP 600125 was equally able to 
decrease IFN-γ production for both ION (Fig. 5c, d) and 
also decreased non-coated ION-induced TNF-α and Il-8 
Fig. 3  Il-6 activation following 
exposure to: a PAA-coated ION 
(0.4–4 µg/ml), b non-coated 
ION (0.4–4 µg/ml), c PAA-
coated ION (4 µg/ml) in the 
presence of inhibitors and  
d non-coated ION (4 µg/ml) 
in the presence of inhibitors, at 
37 °c, for 24 h. ***p < 0.001 
and **p < 0.01 when compared 
to control (without ION) and 
ηηηηp < 0.0001, ηηηp < 0.001, 
ηηp < 0.01 and ηp < 0.05 when 
compared to control (ION 
4 µg/ml). Values are given as 
mean ± SEM (n ≥ 4)
Fig. 4  Il-8 activation fol-
lowing exposure to: a PAA-
coated ION (0.4–4 µg/ml), 
b non-coated ION (0.4–4 µg/
ml), c PAA-coated ION (4 µg/
ml) in the presence of inhibi-
tors and d non-coated ION 
(4 µg/ml) in the presence of 
inhibitors, at 37 °c, for 24 h. 
****p < 0.0001, ***p < 0.001 
and **p < 0.01 when compared 
to control (without ION) and 
ηηηηp < 0.0001, ηηηp < 0.001 
and ηηp < 0.01 when compared 
to control (ION 4 µg/ml). Val-
ues are given as mean ± SEM
(n ≥ 4)
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Fig. 5  IFN-γ activation follow-
ing exposure to: a PAA-coated 
ION (0.4–4 µg/ml), b non-
coated ION (0.4–4 µg/ml),  
c PAA-coated ION (4 µg/ml) 
in the presence of inhibitors and 
d non-coated ION (4 µg/ml) 
in the presence of inhibitors, at 
37 °c, for 24 h. ***p < 0.001 
and **p < 0.01 when compared 
to control (without ION) and 
ηηηηp < 0.0001, ηηp < 0.01 and 
ηp < 0.05 when compared to 
control (ION 4 µg/ml). Values 
are given as mean ± SEM
(n ≥ 4)
Fig. 6  Il-10 activation follow-
ing exposure to: a PAA-coated 
ION (0.4–4 µg/ml), b non-
coated ION (0.4–4 µg/ml),  
c PAA-coated ION (4 µg/ml) 
in the presence of inhibitors and 
d non-coated ION (4 µg/ml) 
in the presence of inhibitors, at 
37 °c, for 24 h. ****p < 0.0001 
and **p < 0.01 when compared 
to control (without ION). Values 
are given as mean ± SEM
(n ≥ 4)
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production (Figs. 2d, 4d), which means that JNK pathway 
is involved in the TNF-α and Il-8 production stimulated by 
non-coated ION, as well as IFN-γ production stimulated 
by PAA-coated and non-coated ION. However, in the pres-
ence of SP 600125, Il-1β and Il-6 production increased 
for both types of ION tested (Figs. 1c, d, 3c, d). Addition-
ally, in the presence of curcumin, Il-1β and Il-6 produc-
tion increased for both types of tested ION (Figs. 1c, d, 3c, 
d), TNF-α production increased for non-coated ION (Fig. 
2d) and IFN-γ production increased for PAA-coated ION 
(Fig. 5c). In the presence of PDTc, Il-1β and TNF-α pro-
duction increased for both types of ION (Figs. 1c, d, 2c, 
d) and IFN-γ production increased for PAA-coated ION
(Fig. 5c).
Discussion
This work was undertaken with the aim of evaluating the 
ability of PAA-coated and non-coated ION to induce the 
production of cytokines in the human whole blood cells in 
vitro and to identify the pathways involved in this effect. 
It was clearly evidenced that both types of ION are able to 
induce the production of all the tested cytokines (Il-1β, 
TNF-α, Il-6, Il-8, IFN-γ and Il-10), in most of the cases, 
in a concentration-dependent manner, although at different 
extents for each one. These cytokines are known to mediate 
inflammatory reactions, as indicated by cytokines produced 
and/or associated with Th1 cells, as IFN-γ, TNF-α, Il-1β 
and Il-8, and also by their involvement in B-cell activa-
tion and differentiation (Th2), as Il-6 and Il-10 (chizzo-
lini et al. 1997; Rhodus et al. 2007; yang et al. 1998). Of 
note, ION have been previously shown to induce the pro-
duction and release of cytokines by Th1 cells, while their 
influence on Th2 cells remains uncertain. For example, Zhu 
et al. described that, in ovalbumin-sensitized rats, magnetic 
ION have the ability to increase the percentages of Th1 and 
T-cytotoxic-cell type 1, decreasing at the same time the per-
centages of Th2 and T-cytotoxic-cell type 2, which suggest
that magnetic ION are able to skew the immune response
toward Th1 responses (Zhu et al. 2012) and it was also
reported that Fe3O4 NP increase Th1 immunity in much 
greater extent than they increase Th2 immunity (chen et al. 
2010; Shen et al. 2011b). In the present study, we observed 
that, concerning Th2 cytokines, although Il-10 is just 
slightly increased comparatively to control, Il-6 is greatly 
increased by ION, being the most activated cytokine for 
PAA-coated ION and the second most activated for non-
coated ION. Accordingly, it was previously described an 
increase in Il-10 production by c57Bl/6 J mice perito-
neal macrophages (Siglienti et al. 2006) and THP-1 cells 
(laskar et al. 2012) after exposure to Resovist®, as well 
as it was described an increase in TNF-α, Il-6 and Il-1β 
production in the presence of IFN-γ (yeh et al. 2010) by 
murine macrophages after exposure to Resovist®.
Regarding the pathways involved in the ION-induced 
cytokine production, we demonstrate here, for the first 
time, that SB 203580 and 5Z-7-oxozeaenol decreased or 
inhibited the production of all the ION-induced cytokines 
tested for both types of ION, which reveals that PAA-
coated and non-coated ION have the ability to activate p38 
MAPK and TAK1, increasing this way the production of 
cytokines. given that TAK1 is competent for activation of 
MKK 3, 6 and other kinases, its activation indirectly results 
in p38 MAPK and JNK activation (clark and Dean 2012; 
craig et al. 2000). Moreover, TAK1 has also the ability to 
activate the NF-kB pathway (craig et al. 2000), and there-
fore, this pathway is also indirectly activated. concerning 
p38 MAPK, this protein was shown to be activated by both 
types of ION. Once p38 MAPK is activated, it is translo-
cated to the nucleus, where it phosphorylates and activates 
nuclear transcription factors members of the AP-1 fam-
ily, such as activating transcription factor 2 (ATF-2) and 
c-Fos, resulting in the production and secretion of pro-
inflammatory cytokines, such as Il-1β and TNF-α (Bach-
stetter et al. 2011; clark and Dean 2012; Kim et al. 2006;
Noubade et al. 2007; Pasquinelli et al. 2013; Stambe et al.
2003). Therefore, it became evident the reason why both
ION were able to induce an increase in the levels of these
two cytokines. It is also known that Il-1β is a potent acti-
vator of Il-6 synthesis and p38 MAPK has been shown to
be a central signaling pathway that controls Il-6 mRNA
stability (Mavropoulos et al. 2013; Miyazawa et al. 1998;
Patil et al. 2004). TNF-α has also been shown to induce
Il-6 production (craig et al. 2000). Il-8, the most potent
known chemotactic agent for neutrophils (Bhattacharyya
et al. 2011; Dauletbaev et al. 2011) is also greatly up-regu-
lated upon exposure to Il-1β or TNF-α, the early response
cytokines (Dauletbaev et al. 2011; Kim et al. 2006). There-
fore, after p38 MAPK activation and consequent activation
of the ATF-2 and c-Fos, Il-1β and TNF-α will be produced
and, subsequently, these cytokines will induce the pro-
duction of other cytokines, namely Il-6 and Il-8. Il-10,
a cytokine considered to have an anti-inflammatory role,
showed to be also induced by Il-1 and TNF-α (Foey et al.
1998). Il-10 is reported to inhibit monocyte production of
Il-1 and TNF-α, which suggests that these three cytokines
form an autoregulatory feedback loop (Foey et al. 1998). In
our study, for both ION, the amount of Il-1β and TNF-α
produced was considerably superior to the amount of Il-10
produced, and for this reason, this feedback loop was not
evidenced.
The production and release of IFN-γ represents an 
early and critical event in the immune response to intracel-
lular pathogens that influences both innate and acquired 
immune responses (Mavropoulos et al. 2005). p38 MAPK 
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is required for the induction of IFN-γ gene and the mech-
anisms by which p38 MAPK may participate in the tran-
scriptional activation of IFN-γ are through ATF-2 activation 
or cAMP response element-binding protein (cREB) phos-
phorylation (Fukushima et al. 2005; Mavropoulos et al. 
2005; Pasquinelli et al. 2013; Rincon et al. 1998). There-
fore, as p38 MAPK was directly activated by both types of 
ION and indirectly activated due to TAK1 activation, this 
fact indicates that the increase in IFN-γ production is medi-
ated through this pathway, involving p38 MAPK-induced 
ATF-2 and cREB activation.
SP 600125 (JNK inhibitor) was able to decrease IFN-
γ production for both ION and also decreased non-coated 
ION-induced TNF-α and Il-8 production. These facts 
show the involvement of JNK in non-coated ION-induced 
TNF-α and Il-8 production, as well as PAA-coated and 
non-coated ION-induced IFN-γ production. In accordance, 
it was previously described that Fe3O4 NP activate JNK in 
a ROS-independent manner (Konczol et al. 2011) and that 
Resovist® and Supravist® induce JNK activation in human 
macrophages (lunov et al. 2010). In our study, ION seem 
to activate JNK pathway directly, since the inhibition of 
JNK results in the diminution of IFN-γ, Il-8 and TNF-α 
production, and indirectly, given that TAK1 activation not 
only results in the p38 MAPK activation, but also in JNK 
activation. After JNK activation, they subsequently phos-
phorylate a variety of substrates, namely c-Fos and ATF-
2, similarly to p38 MAPK, and additionally c-Jun, which 
will result in the transcription of the cytokine genes previ-
ously mentioned for p38 MAPK, such as TNF-α and IFN-γ 
(guma and Firestein 2012; Kim et al. 2006; Mavropoulos 
et al. 2013; Rhodus et al. 2005; Shen et al. 2005; Stambe 
et al. 2003; yang et al. 1998).
On the other hand, in the presence of SP 600125, the 
Il-1β and Il-6 production increased for both types of ION 
tested. In the presence of curcumin [activator protein 1 (AP-
1) inhibitor], the Il-1β and Il-6 production increased for
both types of ION tested, the TNF-α production increased
for non-coated ION and the IFN-γ production increased for
PAA-coated ION. In the presence of PDTc (NF-kB inhibi-
tor), the Il-1β and TNF-α production increased for both
types of ION and the IFN-γ production increased for PAA-
coated ION. Nevertheless, this does not mean that JNK,
NF-kB and AP-1 family are not involved in ION-induced
cytokine production. As previously mentioned, the fact that
JNK inhibition decreases the production of some cytokines
shows the involvement of this pathway in ION-induced
cytokine production. Moreover, p38 MAPK and JNK
Fig. 7  Inflammatory pathways 
triggered by the studied PAA-
coated and non-coated ION
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pathways activate some members of AP-1 family that led to 
the production of the above mentioned cytokines (Bachstet-
ter et al. 2011; clark and Dean 2012; Noubade et al. 2007; 
Pasquinelli et al. 2013; Stambe et al. 2003) and, addition-
ally, TAK1 also activates IKK, which phosphorylates IkB 
and consequently activates NF-kB, increasing the tran-
scription of TNF-α, Il-1, Il-6 and Il-8 (craig et al. 2000; 
gomes et al. 2008; Rhodus et al. 2005; Shen et al. 2005). 
However, as clark and Dean (2012) stated, in the presence 
of inhibitors of these pathways, a negative feedback mecha-
nism may occur, thereby enhancing or prolonging TAK1 
activation. consequently, this may be an explanation for 
the fact that the cytokine induction is increased in the pres-
ence of JNK, AP-1 family and NF-kB inhibitors, e.g., in the 
presence of a NF-kB inhibitor, the TAK1 will activate p38 
MAPK and/or JNK more effectively and, consequently, the 
production of some cytokines may be further increased. 
concerning the limitations of the present study, the fact that 
this study was performed in vitro does not allow evaluating 
the interaction and the effect that this increase in cytokines 
production may have in the different organs and cells of the 
organism. Therefore, an in vivo study is essential to further 
study these aspects.
Conclusion
The results obtained in the present study help to unveil the 
mechanisms involved in the effects of ION in the MAPK 
and NF-kB inflammatory pathways. As depicted in Fig. 7, 
both types of ION were shown to directly activate TAK1, 
p38 MAPK and JNK pathways. The activation of these 
pathways results in the production of IFN-γ, as well as in 
the production of Il-1β and TNF-α, that will stimulate the 
Il-6, Il-8 and Il-10 production. Additionally, the activa-
tion of TAK1 results equally in NF-kB activation, and 
consequently, the transcription and resultant production of 
Il-8, TNF-α, Il-1 and Il-6 will take place.
Though these effects still need to be confirmed in vivo, 
the mentioned effects are indicative that ION may induce 
inflammation and suggest that appropriate anti-inflamma-
tory prophylaxis may be sought when they are used in their 
diverse biomedical applications.
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Nowadays, the amount of iron oxide nanoparticles (ION) used in
the diverse biomedical applications is signiﬁcant. In fact, there are
several formulations available in the market including ION in the
formulation, namely Endorem1, Resovist1, Combidex1, among
others (Azoulay et al., 2008; Kedziorek et al., 2010; Kumar et al.,
2012; Lunov et al., 2010). However, despite the considerable use of
ION worldwide, their safety is still an important matter of debate.
Some studies point that ION may be cytotoxic, stimulating the
production of reactive oxygen and nitrogen species (ROS and RNS)
(Hoskins et al., 2012; Hsiao et al., 2008; Kenzaoui et al., 2012; Naqvi
et al., 2010) and triggering loss of viability in varied cell lines
(Cochran et al., 2013; Ge et al., 2013; Schwarz et al., 2012; Yu et al.,
2012). Using human neutrophils, we have also demonstrated that
polyacrylic acid (PAA)-coated and non-coated ION activate
oxidative burst, leading to the sustained production of ROS
(Couto et al., 2014). These last results emphasize the potential
involvement of cells from the human innate defense system in the
deleterious effects of ION.
One of the possible implications of sustained production of
high levels of ROS and RNS is oxidative stress-related
deoxyribonucleic acid (DNA) damage (AshaRani et al., 2009;
Schwartz and Rotter, 1998; Shackelford et al., 1999) and,
accordingly, some reports in the literature have already shown
that ION may induce DNA damage, namely Fe2O3 nanoparticles
(NP) in human lung ﬁbroblasts IMR 90 cells (Bhattacharya et al.,
2009, 2012) and oleate-coated Fe3O4 NP in human peripheral
lymphocytes (Magdolenova et al., 2013). In conditions of
oxidative stress and/or in the presence of xenobiotics that cause
DNA damage, cells have the ability to arrest cell cycle in G1 and
G2 to allow adequate functioning of DNA repair systems and
prevent the propagation of damage to the resulting daughter
cells (AshaRani et al., 2009; Malumbres and Barbacid, 2009;
Shackelford et al., 1999). Concerning ION, previous studies
reported that g-Fe2O3 NP and Fe3O4 NP increase the proportion
of cells in G1 phase of the cell cycle in RAW 264.7 cells (Park et al.,
2014b), and in cells from the mouse bronchoalveolar lavage ﬂuid
(Park et al., 2010). Fe3O4 NP also induce G2/M arrest in PC12 cells
(Wu et al., 2012) and decrease the number of cells in S phase in
mouse bronchoalveolar lavage ﬂuid (Park et al., 2010).
Given that PAA has been increasingly described as a promising
coating for ION used in several applications, namely in gene
delivery (Cao et al., 2013; Sun et al., 2012) and in liver and kidney
imaging (Iversen et al., 2013), and that PAA-coated and
non-coated ION seem to activate ROS production, it is of
paramount importance to assess its potential genotoxicity. In
the present study, we evaluated the effect of PAA-coated and
non-coated ION on human T lymphocytes, as these cells may be
involved in the immune response to the administration of ION
(Katsnelson et al., 2010; Park et al., 2010; Shen et al., 2011; Valois
et al., 2010; Zhu et al., 2008). Moreover, they have the important
role of stimulating macrophage and B-lymphocyte activities
mainly via production of regulatory cytokines (Newsholme, 2001)
and present a high rate of division, being therefore possible target
cells for the deleterious effects of pro-oxidant agents with
potential genotoxic effects (Lialiaris et al., 2008; Zhang et al.,
2008). Noteworthy, it is known that these cells are highly
susceptible to the genotoxicity of bleomycin (BLM), a well-known
iron-dependent clastogenic agent, by formation of a ternary
complex with Fe2+ and oxygen, which binds to DNA, inducing
double strand breaks that result in chromosome breaks, gaps,
dicentric chromosomes, rings and radial ﬁgures (Jaloszynski et al.,
1997; Mir et al., 1996; Paika and Krishan, 1973; Vernole et al.,
1998). Notably, BLM has also been shown to exert a synergistic
effect with other xenobiotics concerning genotoxic promotion(Lee et al., 2004; Poli et al., 2002), and it is therefore of additional
interest to study the clastogenic effects of BLM in the presence
of ION.
Considering the above rationale, the present work was
performed with the aim of studying the ability of PAA-coated
and non-coated ION to induce genotoxicity in human
T lymphocytes. For that purpose, their inﬂuence on cell cycle
progression and on the induction of chromosome aberrations
was evaluated. Their possible cumulative effect with the
iron-dependent genotoxic agent BLM was further studied.
2. Materials and methods
2.1. Materials
Venous blood was collected by antecubital venipuncture from
healthy human blood donors at Hospital de Santo António (Porto,
Portugal), following informed consent. Lyophilized BLM sulphate
15,000 UI was obtained from TEVA Pharmaceutical Industries Ltd.
(Israel). RPMI 1640 medium, Dulbecco’s phosphate buffer saline,
without calcium chloride and magnesium chloride (PBS) [2.68 mM
KCl, 0.14 M NaCl,1.21 mM KH2PO4, 8.10 mM Na2HPO4], L-glutamine,
fetal bovine serum, penicillin, streptomycin and histopaque 1077
were obtained from Sigma Chemical Co. (St Louis, USA). Ferrous
chloride, ferric chloride, NH4OH, KCl and PAA (average Mw 1800)
were obtained from Sigma–Aldrich (St Louis, USA). Phytohaemag-
glutinin and colcemid were obtained from Gibco (Invitrogen
Corporation, USA). Acetic acid, methanol, Türk’s solution and
Giemsa’s azur eosin methylene blue solution were obtained from
Merck (Darmstadt, Germany). Mouse anti-human CD3 monoclonal
antibodies conjugated with ﬂuorescein isothiocyanate (FITC)
and Coulter1 DNA PrepTM Reagents Kit were obtained from
Beckman Coulter (Hialeah, FL, USA). Polyclonal rabbit anti-mouse
immunoglobulins conjugated with FITC were obtained from
Dako A/S (Glostrup, Denmark).
ION non-coated and PAA-coated magnetite particles were
obtained from Nanogap (Santiago de Compostela, Spain), and
their preparation and physico-chemical characterization was
performed as reported before (Couto et al., 2014). Brieﬂy,
preparation of “non-coated” ION was based on the chemical
co-precipitation of a mixture of Fe(II) and Fe(III) chloride salts
(molar ratio 2:1) using NH4OH in a degassed 1 M KCl aqueous
solution at 60 C. The dark precipitate was washed several times
with deoxygenated water, and ﬁnally the particles were stored at
pH 9.6 (well above their isoelectric point: 6.5). For the PAA-coated
ION, PAA [25% w/w with respect to the Fe(II) salt] was added to
the reaction medium. PAA-coated and non-coated ION were
characterized using transmission electron microscopy (TEM)
(Hitachi H-7000, Japan). Determination of the hydrodynamic size
and zeta potential of the studied NP, in RPMI 1640 suspensions,
were made using a NP analyzer SZ-100 (HORIBA Scientiﬁc) (DPSS
laser 532 nm). Both PAA-coated and non-coated ION have a
similar size distribution, with a mean particle size of 9.9  2.3 nm
and 10.1  2.4 nm (mean  SD) for the non-coated and PAA-coated
ION, respectively. However, when the ION were dispersed in
RPMI 1640 medium supplemented with fetal bovine serum, large
hydrodynamic sizes [5166  481 nm and 174  65 nm (mean 
SEM) for the non-coated and PAA-coated ION, respectively], and
low zeta potentials [1.91 0.35 mV and 3.02  0.73 mV (mean
 SEM) for the non-coated and PAA-coated ION, respectively]
were observed, which indicates that both types of NP tend to
agglomerate when resuspended in RPMI 1640 medium, though in
much higher intensity in the case of non-coated ION. Before
dilutions, ION were sonicated for 5 min (P selecta ultrasonic bath,
50 Hz) to disrupt possible aggregates before the preparation of
the samples.160
D. Couto et al. / Toxicology Letters 234 (2015) 67–73 69
II. Original Research2.2. Methods
2.2.1. Cell cultures
The procedure was performed as described in (Sousa et al.,
2013): samples of 0.5 mL of whole blood were used for lymphocyte
cultures in RPMI 1640 medium supplemented with 20%
fetal bovine serum, 2 mM L-glutamine, 100 U/mL penicillin and
0.1 mg/mL streptomycin. The cultures were stimulated with
5 mg/mL phytohaemagglutinin and incubated at 37 C with a 5%
CO2 atmosphere, for 24 h. In sequence, PAA-coated and non-coated
ION (4, 20 and 100 mg/mL) were added to the lymphocyte cultures
and the incubation proceeded for more 48 h. These concentrations
are within those usually attained in biomedical applications [up to
70 mg/mL (Apopa et al., 2009)]. Simultaneously, it was performed
an experiment to evaluate the genotoxic effect of ION in the
presence of BLM. For this purpose, BLM (10 mg/mL) was added 1 h
after the addition of the ION to lymphocyte cultures.
2.2.2. Isolation of human peripheral blood mononuclear cells by the
gradient density centrifugation method
Following 72 h of culture, isolation of human peripheral blood
mononuclear cells (PBMCs) was performed by the gradient density
centrifugation method, as described in (Ngkelo et al., 2012) with
slight adaptations: the tubes with the cells exposed to PAA-coated
and non-coated ION (4, 20 and 100 mg/mL) were centrifuged at
890  g for 10 min at 20 C. Cell pellets were re-suspended in 3 mL
of the centrifuged supernatant and placed on the top of 3 mL
of Histopaque 1077 in a 14 mL polypropylene tube. After
centrifugation at 890  g for 30 min, at 20 C, the layer
corresponding to PBMCs was collected to a new polypropylene
tube and PBS was added to wash the cells. The PBMC suspension
was then centrifuged at 890  g for 10 min, at 20 C. Afterwards, the
supernatant was decanted and new PBS was added to the tube and
centrifuged at 890  g for 10 min at 20 C. This last step was
repeated one more time. Cells were then re-suspended in PBS
and counted using a neubauer chamber and an optic microscope
(40) in the presence of Türk’s solution (the acetic acid of this
solution hemolyzes the erythrocytes and the PBMCs are stained
by the dye contained). The cell concentration was adjusted to
1 106 PBMCs/mL and, subsequently, the cells were used for cell
cycle analysis by ﬂow cytometry.
2.2.3. CD3 staining and cell cycle analysis by ﬂow cytometry
Isolated PBMCs were sequentially labeled with anti-CD3
monoclonal mouse anti-human and anti-IgG polyclonal rabbit
anti-mouse conjugated with FITC antibodies in order to label
T lymphocytes. Cell staining for surface CD3 was performed using a
two step-washing method, as previously described in detail (Lima
et al., 2000). This method is based on the sequential use both ofFig.1. Cell cycle distribution (expressed in percentage) following exposure to (A) PAA-coa
as mean of the percentages of T lymphocytes in the phases G0/G1, S and G2/M (n  7)FITC-conjugated primary mouse anti-human CD3 monoclonal
antibodies and FITC-conjugated secondary polyclonal rabbit
anti-mouse immunoglobulins, a strategy that increases the FITC
signal of CD3 positive cells without an appreciable increase in
nonspeciﬁc staining. This procedure obviates difﬁculties imposed
by the decrease of expression of cell surface antigens when cells
are simultaneously stained for DNA, due to permeabilizing
procedures. As a ﬁrst step, cells were incubated with 10 mL of
FITC-conjugated mouse anti-human anti-CD3 for 15 min at room
temperature, protected from light, and washed twice in PBS. As a
second step, 20 mL of FITC-conjugated rabbit anti-mouse immu-
noglobulins (Dako A/S, Glostrup, Denmark) were added and cells
were incubated under the same conditions. Once this incubation
period was completed, cells were washed once in PBS and then
processed with the Coulter1 DNA-Prep Reagent Kit (Beckman
Coulter, Hialeah, FL), according to the manufacturer’s instructions.
Brieﬂy, 100 mL of DNA Prep LPR reagent (to lyse red cells and
permeabilize cell membranes) was added and vortexed for 8 s;
after that, 2 mL of DNA-Prep stain (propidium iodide solution with
RNAse) were added and vortexed for 10 s. Finally, the samples were
incubated at 4 C in the darkness for 15 min before acquisition.
2.2.3.1. Data acquisition and analysis. Data acquisition was carried
out in an EPICS-XL-MCL ﬂow cytometer (Beckman Coulter, Hialeah,
FL, USA) equipped with a 15-mW air-cooled 488-nm argon
laser, using the XL2 software program (Beckman Coulter,
Hialeah, FL). Instrument alignment and standardization were
performed daily and electronic compensation was used to
remove spectral overlap. Samples were injected at a ﬂow rate of
12  3 mL/min. A normal blood sample was processed in parallel
and the red ﬂuorescence high voltage was adjusted to place the
mean channel of the G0/G1 peak of normal blood lymphocytes
at the channel 200  10. Information was acquired and stored
as list mode data for each staining. For cell cycle analysis, cell
doublets were excluded and T lymphocytes were gated based
on their positivity for CD3. Then, cell cycle distribution was
analyzed using the Multicycle software (Phoenix Flow Systems,
San Diego, CA).
2.2.4. Cytogenetic analysis
Cytogenetic analysis was performed as described in (Sousa
et al., 2013): cells previously incubated with ION in the presence
and absence of BLM (10 mg/mL) were harvested after 1 h
incubation with colcemid (10 mg/mL), followed by hypotonic
treatment with 75 mM KCl and ﬁxation in a 1:3 solution of acetic
acid:methanol. Chromosome preparations were made by the air
drying method.
For each independent experiment, analysis of chromosome
aberrations was performed by one scorer on 50 Giemsa-stainedted and (B) non-coated ION (4, 20 and 100 mg/mL), at 37 C, for 48 h. Values are given
.
161
Fig. 2. Typical chromosomal aberrations observed in the present study (ampliﬁcation 100): metaphase without any chromosomal aberration (A); metaphase with a gap (B),
indicated by a black arrowhead; metaphase with dicentric chromosomes and acentric fragments (C), indicated by black and blue arrowheads, respectively; metaphase with a
ﬁgure, breaks and an acentric fragment (D), indicated by black, orange and blue arrowheads, respectively; metaphase with rings and a break (E), indicated by black and orange
arrowheads, respectively; pulverized metaphase (F). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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consecutive metaphases that appeared intact, with sufﬁcient well-
deﬁned chromosome morphology, were selected for study. Each
cell was scored for chromosome number and the number and types
of structural abnormalities. Achromatic areas less than a chromatid
in width were scored as gaps while those wider than a chromatid
were scored as breaks. Chromatid exchange conﬁgurations (like
triradial and tetraradial ﬁgures), dicentric and ring chromosomes
were scored as rearrangements. Gaps were excluded in the
calculation of the chromosome breakage frequencies and
rearrangements were scored as two breaks.
2.2.5. Statistical analysis
Results are expressed as the mean  SEM (from at least seven
individual experiments). Statistical comparison between groupswas performed using the one-way analysis of variance, followed by
Bonferroni’s post hoc test using GraphPad PrismTM (version 6.0;
GraphPad Software). P values lower than 0.05 were considered as
statistically signiﬁcant.
3. Results
3.1. CD3 immunoﬂuorescent staining and cell cycle distribution
For a good knowledge of the cell cycle, it is important to reﬂect
on its different phases. The period between mitoses is termed
interphase. DNA replication occurs at a discrete time during
interphase, termed DNA synthesis phase or S phase. The period
between mitosis and the subsequent S phase is known as Gap 1
(G1), while the period between S phase and the following mitosis is162
Fig. 3. Aberrant cells (expressed in percentage) in the presence of BLM (10 mg/mL)
and: PAA-coated ION (4, 20 and 100 mg/mL) and non-coated ION (4, 20 and
100 mg/mL), at 37 C, for 48 h. Values are given as mean  SEM (n = 12).
D. Couto et al. / Toxicology Letters 234 (2015) 67–73 71
II. Original ResearchGap 2 (G2). Cells in a metabolically active state but not progressing
to, or through DNA synthesis or cell division, are said to be
quiescent or resting (G0). In the typical dividing eukaryotic cell, G1
phase lasts approximately 12 h, S phase 6–8 h, G2 phase 3–6 h, and
mitosis about 30 min, although the exact length of each phaseFig. 4. Mean number of breaks per cell following exposure to BLM (10 mg/mL) and:
PAA-coated ION (4, 20 and 100 mg/mL) and non-coated ION (4, 20 and 100 mg/mL),
at 37 C, for 48 h. Values are given as mean  SEM (n = 12).varies with cell type and growth conditions (Shackelford et al.,
1999).
Cell cycle distribution of T lymphocytes exposed to PAA-coated
and non-coated ION (4, 20 and 100 mg/mL) for 48 h at 37 C
was assessed by ﬂow cytometry. It was veriﬁed that none of
the ION tested had interference in the progression of cell cycle
(Fig. 1A and B).
3.2. Cytogenetic effects
In human T lymphocyte cultures exposed to PAA-coated
and non-coated ION (4, 20 and 100 mg/mL), no induction of
genotoxicity was observed, as all the metaphases analyzed, in each
culture condition, presented 46 chromosomes without any
chromosomal aberration (Fig. 2A).
The possible cumulative effect of ION on BLM-induced
lymphocyte cultures was also evaluated. For that purpose, human
T lymphocytes were exposed to BLM at a pre-determined
concentration that induces chromosomal aberrations, such as
gaps (black arrowhead in Fig. 2B), breaks (orange arrowheads in
Fig. 2D and E), acentric fragments (blue arrowheads in Fig. 2C and
D), dicentric chromosomes (black arrowheads in Fig. 2C), rings
(black arrowheads in Fig. 2E), ﬁgures (black arrowhead in Fig. 2D)
and pulverized metaphases (Fig. 2F). In the BLM-induced cultures
exposed to PAA-coated and non-coated ION (4, 20 and 100 mg/mL),
although both ION showed some tendency to increase the
genotoxicity of BLM, it did not reach signiﬁcance, which allow
us to conclude that, under the present experimental conditions,
none of the studied ION potentiate the genotoxicity of BLM
(Figs. 3 and 4, Tables 1 and 2).
4. Discussion
This work was performed with the aim of evaluating the ability
of PAA-coated and non-coated ION to induce genotoxicity in
human T lymphocytes and to evaluate the possible cumulative
effect with the iron-dependent clastogenic agent BLM. It was
observed that, in isolated studies, the tested ION had no genotoxic
effects, neither affected the cell cycle, nor affected signiﬁcantly the
clastogenicity of BLM.
Previous studies indicate that ION have genotoxic potential, as
shown for Fe2O3 NP in human lung ﬁbroblasts IMR 90 cells
(Bhattacharya et al., 2009, 2012) and oleate-coated Fe3O4 NP in
human peripheral lymphocytes (Magdolenova et al., 2013).
However, in agreement with our study, there are also reports
showing absence of genotoxicity, namely Fe3O4 NP in
TK6 lymphoblastoid cells and human peripheral lymphocytes
(Magdolenova et al., 2013) and g-Fe2O3 NP, dextran-coated Fe3O4
NP and Fe3O4 NP in human B-lymphoblastoid MCL5 cells (Singh
et al., 2012). Many factors may be involved in these differences,
namely some particularities in the characteristics of ION, like size
and coating, and its interaction with the different cells. For
example, Magdolenova et al. (2013) found that oleate-coated Fe3O4
NP induced DNA damage in human peripheral lymphocytes and
TK6 lymphoblastoid cells but Fe3O4 NP did not exert the same
effect, which demonstrates, in this case, the inﬂuence of the
coating on genotoxicity.
The mechanism by which BLM, a known antibiotic used in
anticancer therapy, induces chromosome damage is through
simultaneous binding to oxygen and redox-active transition
metals, such as Fe2+. The ternary complex of BLM with Fe2+ and
oxygen binds to DNA, Fe2+ is oxidated to Fe3+ and a nucleophilic
attack at the DNA desoxyribose C40 position occurs, inducing this
way breaks, gaps, dicentric chromosomes, rings and ﬁgures (Mir
et al.,1996; Paika and Krishan,1973). Therefore, as both ION used in
this study are presented in the form of magnetite, where iron is163
Table 1
BLM (10 mg/mL) and PAA-coated ION-induced chromosome instability in lymphocyte cultures from 12 individuals.
% Aberrant cells Number of breaks per cell
Individuals BLM BLM + ION 4 mg/mL BLM + ION 20 mg/mL BLM + ION 100 mg/mL BLM BLM + ION 4 mg/mL BLM + ION 20 mg/mL BLM + ION 100 mg/mL
1 31 n.a. n.a. 32 0.57 n.a. n.a. 0.77
2 23 n.a. n.a. 53 0.36 n.a. n.a. 1.22
3 30 n.a. n.a. 44 0.74 n.a. n.a. 0.84
4 31 39 25 21 0.57 0.82 0.60 0.35
5 16 22 18 36 0.32 0.34 0.38 1.06
6 41 40 42 31 0.80 0.82 1.10 0.64
7 28 19 31 24 0.49 0.24 0.56 0.33
8 62 65 78 71 2.08 2.02 2.63 2.47
9 42 34 44 44 0.80 0.80 0.90 0.82
10 30 32 37 34 0.78 0.76 0.69 1.24
11 28 33 39 53 0.73 1.31 1.24 2.06
12 22 37 34 35 0.35 0.74 0.52 0.73
Mean  SEM 32  3 36  4 39  6 40  4 0.7  0.1 0.9  0.2 1.0  0.2 1.0  0.2
n.a. not analyzed.
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was hypothesized that Fe2+ ions from ION could interact with
BLM in the presence of oxygen, which would exacerbate its
genotoxicity. However, although both ION showed some tendency
to increase the genotoxicity of BLM, it did not reach signiﬁcance,
which allow us to conclude that, under the present experimental
conditions, none of the studied ION potentiate the genotoxicity
of BLM.
It is known that proper progression through the cell cycle is
monitored by checkpoints that sense possible defects during DNA
synthesis and chromosome segregation. Activation of these
checkpoints induces cell cycle arrest through modulation of
cyclin-dependent kinase (CDK) activity. Cell cycle arrest allows
cells to properly repair eventual defects, thus preventing their
transmission to the resulting daughter cells (Malumbres and
Barbacid, 2009). Therefore, in conditions of oxidative stress and/or
in the presence of agents that cause DNA damage, cells have the
ability to arrest proliferation in G1 and G2 until the damage is
repaired (AshaRani et al., 2009; Malumbres and Barbacid, 2009;
Shackelford et al.,1999). In this study, we observed that none of the
ION tested were able to interfere with the cell cycle. These data are
in agreement with the ones obtained by Liu et al. (2011), who
reported that dimercaptosuccinic acid-coated Fe3O4 NP have no
effect on the cell cycle of THP-1 and RAW 264.7 cells. However, the
opposite has also been described: Park et al. (2014b) reported that
g-Fe2O3 NP increased the proportion of RAW 264.7 cells in G1
phase. Additionally, dimercaptosuccinic acid-coated Fe3O4 NP
increased the number of cells in G2/M phase in HepG2 hepatocytes
(Liu et al., 2011). Consequently, the effect depends of the different
characteristics of ION and cell type. For example, Park et al. (2014a)Table 2
BLM (10 mg/mL) and non-coated ION-induced chromosome instability in lymphocyte c
% Aberrant cells
Individuals BLM BLM + ION 4 mg/mL BLM + ION 20 mg/mL BLM + ION 100 mg/
1 31 n.a. n.a. 51
2 23 n.a. n.a. 39
3 30 n.a. n.a. 45
4 31 54 29 24
5 16 16 20 30
6 41 49 27 42
7 28 23 41 24
8 62 80 73 65
9 42 44 36 30
10 30 21 24 28
11 28 43 45 31
12 22 33 37 39
Mean  SEM 32  3 41  7 37  5 37  4
n.a. not analyzed.stated that, in a MH-S cell line, Fe2O3 NP increased the number of
cells in the G1 phase, while Fe3O4 NP increased the number of cells
in the G2/M phase, which reveals that different types of ION may
inﬂuence cell cycle in a different manner.
5. Conclusion
From the results obtained in the present study, it can be
concluded that the tested PAA-coated and non-coated ION are
not direct genotoxic agents in human T lymphocytes, neither
potentiate the genotoxicity of an iron-dependent clastogenic
agent – BLM.
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Abstract 
Iron oxide nanoparticles (IONs) have physical and chemical properties that render 
them useful in the development of new biomedical applications. Still, so far, in vivo safety 
studies of IONs with coatings with biomedical interest are still scarce. The aim of this 
study was, therefore, to provide a better clarification of the acute biological effects of 
polyacrylic acid (PAA)-coated IONs, by determining their biodistribution in several organs 
(liver, spleen, kidneys, brain, heart, testes, and lungs) and their putative pro-inflammatory 
and toxic effects. The biodistribution of PAA-coated IONs in several organs of the CD-1 
mouse, the plasma cytokines, chemokine and aminotransferases levels, blood counts, 
oxidative stress parameters, adenosine triphosphate (ATP) and histologic features in liver, 
spleen and kidneys were evaluated 24 hours after an acute intravenous administration of 
PAA-coated IONs in magnetite form (8, 20 or 50 mg/kg). The obtained results showed that 
these IONs accumulate mainly in liver and spleen and, to a lesser extent, in the lungs. 
Although our data showed that PAA-coated IONs do not cause severe organ damage, an 
inflammatory process seems to be triggered in vivo, as evidenced by an increased 
neutrophils’ and large lymphocytes’ frequency in blood. Moreover, an accumulation of iron 
in liver and spleen macrophages was observed and hepatic lipid peroxidation was elicited, 
showing that these nanoparticles are able to induce oxidative stress. These effects need 
to be further investigated regarding the mechanisms involved and also the long term 
consequences of PAA-coated IONs. 
Keywords: Iron oxide nanoparticles; biodistribution; inflammation; lipid peroxidation; 
histology; in vivo studies; CD-1 mice. 
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TNF-α – Tumor necrosis factor α
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1. Background
The use of nanoparticles (NPs) is considered a promising strategy in the 
development of new biomedical applications, due to their distinctive physical and chemical 
properties [1]. Among the various types of NPs used for biomedical applications, iron 
oxide NPs (IONs) are one of the most common [2]. Several formulations of these NPs are 
used mainly for magnetic resonance imaging and diagnosis [1,3] and are presently being 
investigated in cancer treatment with the concurrent use of hyperthermia [4,5], and in 
inflammation imaging [1,3,6]. The human exposure to IONs is usually acute on resonance 
imaging, this procedure being often repeated throughout the patient’s life [7,8]. 
So far the IONs available in the market are always coated, since coating is 
regarded as an improvement of these NPs biocompatibility. The most common coatings 
are based on dextran and its derivatives [9], though other coatings are being tested at this 
point. Recently, polyacrylic acid (PAA), an aqueous soluble polymer, has been shown to 
be a promising coating agent in gene delivery [10,11].  
Despite the widespread use of IONs, safety issues are still a matter of debate. In 
fact, in vitro studies using different cellular models have reported that IONs with diverse 
coatings may cause increased production of reactive oxygen species (ROS), activation of 
inflammatory pathways, and cell death, among other adverse effects [12-14]. In our 
previous in vitro studies, we have demonstrated that PAA-coated IONs in magnetite form 
are able to trigger the production of ROS in human neutrophils, eliciting apoptosis in that 
cellular model [15]. We have also verified that the same PAA-coated IONs have the ability 
to induce cytokine production (interleukin - IL) IL-6, IL-8, IL-10, tumor necrosis factor α 
(TNF-α), interferon γ (IFN-γ) and IL-1β via transforming growth factor beta activated 
kinase (TAK1) and p38 mitogen-activated protein kinase (MAPK) activation in human 
blood cells [16]. Altogether, these results show that PAA-coated IONs have a pro-
inflammatory potential that needs further investigation. 
There are few in vivo studies performed so far with IONs to study their putative 
toxic effects. In mice, Fe3O4 NPs triggered hepatic and renal damage [17], whereas in 
humans the administration of IONs in magnetic resonance imaging caused some adverse 
effects, namely urticaria [7,18-20], diarrhea [18], allergic reactions [7], nausea [18,21], 
headache [18,19], back and chest pain [18,20], flush [20], dyspnea [20], vertigo [21], 
erythema [20], skin discoloration [22], pruritus [19,20] and vasodilatation [18]. Regarding 
PAA-coated IONs and to the best of our knowledge, there is only one in vivo study that 
evaluated in mice, the renofunctional and basic cardiovascular functions, 24 hours and 96 
hours after a 10 mg/kg intravenous (i.v.) injection of PAA-coated γ-Fe2O3 IONs [23]. The 
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results obtained in that study suggest that these IONs do not affect kidney function but 
decrease blood pressure temporarily [23]. 
The aim of this work was to provide a better clarification of the acute effects of 
PAA-coated IONs, by determining their biodistribution in several organs (liver, spleen, 
kidneys, brain, heart, testes, and lungs) and putative pro-inflammatory and toxic effects 
following an acute i.v. administration in CD-1 mice. Histological analysis of liver, spleen 
and kidneys was done and general oxidative stress and energetic evaluations on liver and 
kidneys were also performed.  
2. Materials and Methods
2.1. Materials 
Isoflurane (Isoflo®) was obtained from Abbott Animal Health (USA). Iron standard 
for AAS (Trace CERT®, 1000 mg/L) and concentrated HNO3 (TraceSELECT®, ≥69.0% 
w/w) were obtained from Fluka (France) and H2O2 solution (TraceSELECT® Ultra, ≥30% 
v/v) from Fluka (Italy). Ultrapure water (resistivity >18.2 MΩ.cm at 25ºC) was obtained 
from an arium®pro (Germany) water purification system. Sodium hydroxide, potassium 
bicarbonate and Histosec® pastilles (paraffin) were acquired from Merck (Germany). 
Ethanol was obtained from Panreac AppliChem (Darmstadt, Germany). BD™ Cytometric 
Bead Array (CBA) was acquired from BD Biosciences (USA). HClO4, butylated 
hydroxytoluene (BHT), bovine serum albumin, 5,5'-dithio-bis(2-nitrobenzoic acid) (DTNB), 
β-nicotinamide adenine dinucleotide phosphate (β-NADPH), glutathione reductase, L-
glutathione reduced (GSH), L-glutathione oxidized (GSSG) disodium salt, 2-vinylpyridine, 
2-thiobarbituric acid (TBA), potassium phosphate monobasic, malondialdehyde (MDA),
acetonitrile [high performance liquid chromatography (HPLC) grade], ammonium acetate
(HPLC grade), adenosine triphosphate (ATP), luciferin and luciferase were obtained from
Sigma Chemical Co (USA). RC DC Protein Assay kit was obtained from Bio-Rad®
(California, USA). ABX Pentra reagents were purchased from HORIBA (Japan).
Commercial 4% buffered formalin was purchased from Klinipath (Netherlands). Xylene
was obtained from BDH - Prolabo (VWR International, Ireland).
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2.2. Methods 
 
2.2.1. Synthesis and characterization of the PAA-coated IONs 
 
PAA-coated magnetite particles were obtained from Nanogap (Santiago de 
Compostela, Spain), and their preparation and physico-chemical characterization was 
performed as reported before [15]. Briefly, IONs “non-coated” magnetite particles 
preparation was based on the chemical co-precipitation of a mixture of Fe(II) and Fe(III) 
chloride salts (molar ratio 2:1) using NH4OH in a degassed 1 M KCl aqueous solution at 
60ºC. The dark precipitate was washed several times with deoxygenated water, and 
finally the particles were stored at pH 9.6 (well above their isoelectric point: 6.5). For the 
PAA-coated IONs, PAA [25% w/w with respect to the Fe(II) salt] was added to the reaction 
medium. PAA-coated IONs were characterized using transmission electron microscopy 
(Hitachi H-7000, Japan). Determination of the hydrodynamic size and zeta potential of 
NPs to be used, in 0.9% saline solution, were made using a nanoparticle analyzer SZ-100 
(HORIBA Scientific) (DPSS laser 532 nm). PAA-coated IONs have a mean particle size of 
10.1 ± 2.4 nm (mean ± SD). When the IONs were dispersed in physiological serum, a 
large hydrodynamic size 46.7 ± 12 nm was observed, and the zeta potential was -1.56 ± 
0.45 mV. 
 
2.2.2. Animals 
 
Male mice (8 weeks) of CD-1 strain from Charles River laboratories (Barcelona, 
Spain), weighing 30-40 g were used in this study. Upon arrival, the animals were 
randomly housed in cages (each cage with 4 animals) and were maintained under a 
controlled environment [temperature 22.0 ± 2.0ºC, 40% humidity, and 12 hours light/dark 
cycles at the Institute for Biomedical Sciences Abel Salazar-University of Porto (ICBAS-
UP) animal house facility]. The animals had ad libitum access to food and water and 
throughout the experimental period had permanent veterinary supervision. 
All procedures were carried out to provide appropriate animal care, minimizing 
their suffering. Housing and experimental treatment of the animals were in accordance 
with the guidelines defined by the European Council Directive (2010/63/EU) transposed 
into Portuguese law (Decreto-Lei n.º 113/2013, de 7 de Agosto). Moreover, the 
experiments were performed with the approval of the Ethical Committee of the Faculty of 
Pharmacy, University of Porto (opinion nº 19/07/2014). Animals were allowed to adjust to 
the environmental conditions for 10 days, before starting the experiments. 
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2.2.3. Administration of PAA-coated IONs 
 
Administration of PAA-coated IONs was performed through an i.v. injection in the 
tail vein by experienced veterinarians. All stock solutions of the NPs were prepared daily 
in sterile conditions and PAA-coated IONs were suspended in 0.9% saline solution. Four 
groups were created with 6 animals each: control; PAA-coated IONs 8 mg/kg; PAA-coated 
IONs 20 mg/kg; and PAA-coated IONs 50 mg/kg. The 0.9% saline solution was 
administered to control animals on the same schedule and at the same equivalent volume 
of PAA-coated IONs administration. Animal weight was assessed before and 24 hours 
after the i.v. administration and animals were sacrificed 24 hours after administration of 
PAA-coated IONs. 
The use of IONs for imaging procedures has been reported to be between 2-7 
mg/kg in humans [24,25]. Regarding the equivalence to the doses used in humans, the 
correlations were made according to the allometric scaling principles using the formula: 
human dose (mg/kg) = animal dose (mg/kg) x (animal weight/human weight)1/4 [26]. In a 
70 kg man, to whom 7 mg/kg was administered, the equivalent dose in mice (30 g) is ca. 
49 mg/kg. Therefore, we are demonstrating the relevance of the present study, since we 
are using human pharmacological relevant doses. 
 
2.2.4. Blood and organ collection 
 
Animals were anesthetized and euthanized with isoflurane 24 hours after the PAA-
coated IONs administration. Blood was immediately collected from the inferior vena cava. 
A drop of blood was used for smears, whereas the remaining blood was placed into EDTA 
Vacutainer® tubes. Subsequently, the blood was centrifuged at 920 g, 10 minutes, at 4ºC 
and plasma was collected and stored at -20ºC for posterior cytokine, total creatine kinase 
(CK), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels. 
Immediately after sacrifice, the liver, spleen, kidneys, brain, heart, testes, and lungs were 
collected and weighted. The tail of the mouse was also collected. 
For iron determination in mice organs, a small sample (approximately 200 mg) of 
tissue and the totality of the tail was collected. The possible contaminating blood of each 
organ was thoroughly washed away with ultrapure water and agitation. The organ 
samples were stored in decontaminated polypropylene tubes at 4ºC until analysis. 
A portion of liver, spleen and kidney in control and 50 mg/kg PAA-coated IONs-
treated animals was taken for histological processing and analysis, as described below. 
The remaining liver and kidney tissue samples were homogenized in ice cold 
phosphate-buffered solution 0.1 M KH2PO4 pH 7.4 in an Ultra-Turrax® homogenizer and 
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processed as previously described [27]. An aliquot of the homogenates was placed in cold 
HClO4 (5% final acid concentration), with 0.05% of antioxidant BHT and immediately 
frozen at -80ºC (for a maximum of one month) until MDA determination through HPLC. 
Another aliquot of the homogenates was treated with HClO4 (5% final acid concentration) 
and centrifuged at 16000 g for 10 minutes at 4ºC. The resulting supernatant was 
separated and frozen at -80ºC for total glutathione (GSHt), GSSG and ATP 
determinations. The remaining homogenate was stored at -20ºC for protein determination. 
2.2.5. Measurement of plasma biomarkers 
CK, AST and ALT were determined using enzymatic assays in the apparatus ABX 
Pentra 400 with ABX Pentra reagents (HORIBA, Kyoto, Japan), according to the 
manufacturer’s instructions.  
2.2.6. Plasma cytokines and chemokine determination 
Cytokines (IL-6, IL-10, IFN-γ, TNF-α, and IL-12p70) and chemokine monocyte 
chemoattractant protein-1 (MCP-1) were determined in plasma using a BD™ Cytometric 
Bead Array (BD Biosciences®), in accordance to manufacturer’s instructions. 
Fluorescence signals for each sample were collected using BD Accuri™ C6 flow 
cytometer (California, USA) equipped with a 488 nm and a 640 nm lasers. Data were 
analyzed using FCAP ArrayTM software Version 3.0 (USA). 
2.2.7. Differential leukocyte counts in peripheral blood smears 
Blood smears were made on glass slides and air-dried. At least two blood smears 
were prepared per animal. The slides were stained using the Diff-Quik procedure, and a 
manual differential count of 100 leucocytes was performed under oil-immersion lens. 
Leukocyte nomenclature and morphology has been described previously for mouse [28] 
and it was followed in this study. 
2.2.8. Iron determination in organs 
Sample treatment and iron determination was performed as previously described 
[29]. Samples were placed in a dry oven (Spain) at 110°C until constant weight (ca. 
24 hours). Dried samples were weighed and placed in the microwave oven digestion 
vessels, previously decontaminated with 10% (v/v) HNO3 and thoroughly rinsed with 
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ultrapure water. Samples were digested using 2 mL of concentrated HNO3 and 0.5 mL of 
H2O2 (except for tail, where 4 mL and 1 mL, respectively, were used). The sample 
digestion was performed in a mls 1200 mega microwave oven from Milestone (Italy) 
equipped with an HPR 1000/10 rotor using the following power (W)/time (minute) 
programme: 250/1, 0/2, 250/5, 400/5 and 600/5. After cooling, sample solutions were 
made up to 25 mL with ultrapure water (50 mL for tail samples) and stored in closed 
propylene tubes at 4°C until analysis. In each digestion batch (10 samples), a sample 
blank was also performed. 
Iron determination was performed using a PerkinElmer (Germany) model 3100 
atomic absorption spectrometer. An Intensitron™ (PerkinElmer) hollow cathode lamp was 
used as a light source (λ= 248.3 nm).  
Calibration standards were prepared by diluting the commercial iron standard with 
0.2% (v/v) HNO3 solution. Calibration curves were obtained with five calibration standards 
with concentrations ranging from 0 to 4 mg/L. Data were expressed as organ iron (μg 
iron/g of organ). 
 
2.2.9. Histological analysis 
 
To assess the effect of PAA-coated IONs administration on liver, spleen and 
kidneys histology, basic histopathological analysis of the exposed animals to the highest 
concentration (50 mg/kg) was performed. In this study, liver was cut into ≈ 4 mm thick 
slabs and then a systematic selection was carried out and sampled pieces were 
processed for light microscopy. The spleen was cut in the midsagittal plane in two halves. 
The kidneys were divided in two equal parts: the cranial and caudal parts. Each half of 
both organs was then randomly selected for histological analysis. The organs were fixed 
in commercial 4% buffered formalin. After fixation (24 hours), the tissues were dehydrated 
through a series of graded ethanol solutions (70-99.8%), cleared in xylene, and 
impregnated and embedded in paraffin. Each organ was entirely sectioned (Microtome - 
Leica RM 2125) into thin sections (5 µm thick). For improving section adhesion, the 
sampled sections were mounted in silane coated microscope slides [Nuova Aptaca, 
Canelli (AT), Italy]. From each organ, the first section to be sampled was randomly 
selected. Four successive slides, with an equal number of sequential sections each, were 
set aside for posterior analysis. From then on every 5th slides a group of 4 slides were 
chosen to histological analysis. This allowed for the analysis of the entire organ to check 
the existence of focal lesions. The sections were then stained according with the following 
scheme: 1 - Haematoxylin-eosin (H&E); 2 - Perl’s Prussian blue; 3 - H&E; 4 - Masson's 
trichrome [30]. The Perl’s reaction was the method used to identify iron.  
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2.2.10. Oxidative stress parameters 
 
2.2.10.1. Glutathione assay 
 
The GSHt and GSSG levels of tissue homogenates were determined by the 
DTNB-GSSG reductase recycling assay, as previously described [27]. For the 
quantification of GSSG, 10 μL of 2-vinylpyridine was added to the acidic supernatant and 
shaken for 1 hour in ice to block GSH. Then, the determination of GSSG was performed 
as described above for GSHt. The GSH was calculated using the following formula GSH = 
GSHt – 2 GSSG. 
GSH and GSSG standard solutions (0-15 μM and 0-8 μM, respectively) were 
prepared in 5% HClO4 and results were expressed as nmol/mg protein. 
 
2.2.10.2. Lipid peroxidation 
 
Lipid peroxidation was measured by HPLC quantification of MDA [27], with some 
modifications. Briefly, the acidic liver and kidney homogenates were centrifuged (16 000 
g, 5 minutes, at 4ºC) and 200 μL of the resulting supernatant were incubated with 200 μL 
of TBA (0.8 % in water) for 60 minutes at 80ºC in a water bath. After cooling, 20 μL of the 
samples were injected into the HPLC system (Jasco, LC-2000 Plus, USA), equipped 
with quaternary pumps (PU-2089 Plus), an autosampler (AS-2057 Plus) and a 
fluorescence detector (FP-2020 Plus). MDA was separated on a C18 Synergi Hydro 
column (4 μm, 250 × 4.6 mm, Phenomenex), with a mobile phase consisting of (A) 
ammonium acetate aqueous solution (10 mM, pH 6.8) and (B) acetonitrile in the 
proportion 80/20 (v/v) in an isocratic mode at a flow rate of 1.0 mL/minute and at room 
temperature. The fluorescence detector was set at λexcitation = 525 nm and λemission = 560 
nm. MDA was quantified by comparison to external standards of MDA using seven-point 
analytical curves (0−3 μM, r2>0.98), which was prepared at the same experimental 
conditions that all samples. The MDA content was expressed as picomol MDA/mg protein. 
 
2.2.11. ATP measurement 
 
ATP measurement in liver and kidney homogenates was performed by the 
luciferin/luciferase solution bioluminescence assay, as described before [31]: 150 μL of 
tissue homogenates were neutralized with 150 μL of 0.76 M KHCO3 and centrifuged 16 
000 g, 1 minute, at 4°C. The ATP levels were quantified after the reaction of 100 μL of 
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neutralized supernatant with luciferin/luciferase solution. ATP standards (0-10 μM) were 
prepared in 5% HClO4. ATP intracellular levels were expressed in nmol/mg protein. 
 
2.2.12. Protein determination 
 
Protein content was determined with RC DC Protein Assay kit, according to the 
manufacturer’s instructions. Bovine serum albumin prepared in NaOH 0.4 M (0-1.2 
mg/mL) was used as standard. 
 
2.2.13. Statistical analysis 
 
Results are expressed as the mean ± SEM. Statistical comparison was made 
between control and PAA-coated IONs treated groups using the one-way analysis of 
variance (ANOVA), followed by Bonferroni’s post hoc test using GraphPad PrismTM 
(version 6.0; GraphPad Software, USA). For body weight comparison within the same 
group of animals, between 0 and 24 hours after PAA-coated IONs administration, the 
paired t test was performed. P values lower than 0.05 were considered as statistically 
significant. Outliers were identified using the ROUT method (Q=1%). 
 
3. Results 
 
3.1. Plasma levels of CK increased, while AST or ALT were not altered after i.v. 
administration of PAA-coated IONs  
 
As presented in table 1, no significant differences were found in plasma levels of 
AST or ALT from control mice (administered with 0.9% saline solution) and PAA-coated 
IONs (8, 20 or 50 mg/kg) treated mice. Only the levels of plasma CK for 8.0 mg/kg PAA-
coated IONs group increased significantly when compared to control animals. The group 
of 20 mg/kg PAA-coated IONs also showed a tendency to increase, although without 
reaching statistical significance (table 1). 
  
3.2. PAA-coated IONs did not cause any activation of plasma cytokines and 
chemokine MCP-1 
 
Cytokines (IL-6, IL-10, IFN-γ, TNF-α, and IL-12p70) and chemokine MCP-1 were 
determined in plasma collected from control mice (administered with 0.9% saline solution) 
and PAA-coated IONs (8, 20 or 50 mg/kg) treated mice. It was observed that the PAA-
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coated IONs did not cause any significant change in the levels of the tested cytokines and 
chemokine MCP-1, with their production being always residual for the control and the 
mice administered with PAA-coated IONs (data not shown). 
 
3.3. The number of large lymphocytes and neutrophils augmented after 
administration of PAA-coated IONs 
 
Differential leukocyte counts performed in blood of control mice (administered with 
0.9% saline solution) and PAA-coated IONs (8, 20 or 50 mg/kg) treated mice revealed: (1) 
an increase in the neutrophils’ frequency after the two highest concentrations of PAA-
coated IONs; (2) the small lymphocytes’ frequency was lower in the 50 mg/kg group; (3) 
the large lymphocytes’ frequency increased, being almost the double for the concentration 
of 50 mg/kg, compared to the control group (table 2). No significant differences were 
observed for monocytes, eosinophils or basophils. 
 
3.4. Administration of PAA-coated IONs led to a significant iron accumulation in 
liver, spleen and lung 
 
Animals were weighed before and after 24 hours of PAA-coated IONs 
administration. After sacrifice, all collected organs were weighed. As it is seen on table 3, 
organ weights were not changed when compared to control animals. 
In order to evaluate the biodistribution of PAA-coated IONs, iron levels were 
quantified in the liver, spleen, kidneys, brain, heart, testes, lungs and tail of control mice 
and PAA-coated IONs (8, 20 or 50 mg/kg) treated mice (figure 1). In treated animals, 
PAA-coated IONs accumulated mainly in the liver and spleen in the two highest PAA-
coated IONs doses (20mg/kg and 50 mg/kg) and in the highest concentration in the lungs. 
One spleen value was undetectable with this method, therefore we replaced it for the 
value obtained with the formula: detection limit (DL)/√2, as previously described [32]. The 
calculated DL for iron in the spleen was 614 μg/g. Moreover, PAA-coated IONs showed a 
small tendency to accumulate in heart (figure 1), although without statistical significance. 
In contrast, these IONs did not show to accumulate in brain, kidneys nor testes (data not 
shown). In the tail, iron levels increased in a concentration-dependent manner, which 
suggests that some retention of PAA-coated IONs resulted from the i.v. administration. 
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3.5. Iron accumulates mostly in the periportal zone of the liver and in the red pulp 
of the spleen 
 
Control animals showed normal liver histology. Iron-loaded Kupffer cells were 
found in exposed animals (figures 2A, B, C and D), whereas these were absent in animals 
not exposed to PAA-coated IONs (figures 2E and F). Due to iron presence, the cytoplasm 
of Kupffer cells was granular and golden brown on H&E staining (figure 2C). Exposed 
animals showed hepatic iron deposition, most marked in periportal region but present in 
all acinus zones. The histological examination using Perls’ blue staining, confirmed this 
result (figures 2B and D). No hepatic collagen deposition, a marker of fibrosis and 
examined by histology Masson's trichrome staining, was detected. In some liver areas, 
mainly in periportal regions, clusters of early necrotic hepatocytes were observed. These 
early necrotic cells showed increased cytoplasmic eosinophilia (figure 3). All alterations 
detected were present in the whole organ. 
Control animals exhibited normal spleen morphology on microscopic examination. 
Under light microscope, no apparent splenic alterations were observed in treated animals 
(50mg/kg-treated mice) on both H&E and Masson's trichrome staining’s (figures 4A, B and 
C). No iron was detected by Perls’ blue staining in the white pulp of both control and 
treated animals (figure 4D). When compared with the control mice (figure 4E), an increase 
in iron concentration was observed in splenic red pulp macrophages of animals in which 
PAA-coated IONs was administered (figure 4F). The iron was equally distributed by whole 
organ. 
Histological examination of kidney sections from control and the 50 mg/kg group 
revealed a normal kidney organizational architecture. The usual renal morphological 
structures, such as corpuscles, proximal, distal, and collecting tubules were found in 
treated animals (figure 5). No morphologic alterations compatible, with any sort of kidney 
pathology, were observed (figure 5). No iron was detected in this organ in the two animal 
groups by the Perl’s’ blue staining. 
 
3.6. Oxidative stress parameters 
 
3.6.1. PAA-coated IONs did not cause any significant change in liver or kidney 
glutathione 
 
GSSG and GSHt levels were determined in the liver and kidney in all groups of 
animals. Additionally, GSH and GSH/GSSG ratio were also calculated. It was observed 
II. Original Research
179
that PAA-coated IONs did not alter GSSG, GSH and GSHt levels nor GSH/GSSH ratio in 
mouse liver and kidney, even for the highest concentration tested (50 mg/kg) (table 4). 
 
3.6.2. PAA-coated IONs caused hepatic lipid peroxidation at the highest tested 
concentration 
 
MDA levels were measured in liver and kidney of control mice (administered with 
0.9% saline solution) and mice previously administered with PAA-coated IONs (8, 20 or 
50 mg/kg). It was clearly observed that PAA-coated IONs increased hepatic lipid 
peroxidation at the highest tested concentration (50 mg/kg) when compared to control 
values. In turn, PAA-coated IONs did not exert any significant effect in mouse kidney 
regarding lipid peroxidation (figure 6). 
 
3.7. PAA-coated IONs did not affect hepatic or renal ATP levels 
 
ATP measurement was assessed in liver and kidney of all groups tested. PAA-
coated IONs showed some tendency to diminish ATP levels in mouse liver at the highest 
concentration tested (50 mg/kg), without reaching significance (table 4). In the kidney, 
PAA-coated IONs did not alter ATP levels when compared to control animals (table 4). 
 
4. Discussion 
 
This work was undertaken to assess the biodistribution of PAA-coated IONs in 
several organs of CD-1 mice (liver, spleen, kidneys, brain, heart, testes, and lungs) and 
putative pro-inflammatory and toxic effects following an acute i.v. administration of these 
NPs. For this purpose, a time-point of 24 hours was selected. As major findings, it was 
observed that: 1) PAA-coated IONs showed to accumulate in the liver, spleen and lungs; 
2) the PAA-coated IONs treated animals showed significant iron accumulation in 
macrophages mostly in the periportal zone of the hepatic acinus and in the splenic red 
pulp; 3) no significant cytokine activation occurred, although PAA-coated IONs caused 
significant changes both in the blood levels of neutrophils and in activated lymphocytes; 4) 
PAA-coated IONs caused hepatic lipid peroxidation that was accompanied by early 
necrosis; 5) liver and kidney levels of glutathione and ATP were not affected by PAA-
coated IONs. 
AST and ALT are parenchymal intracellular enzymes released into systemic 
circulation when there is hepatocellular and cardiac injury, usually involving necrosis [33]. 
No significant differences were found in plasma levels of AST or ALT from both control 
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and PAA-coated IONs treated mice, thus suggesting that these NPs did not cause any 
substantial liver or heart necrotic damage. However, the histological examination of the 
highest IONs concentration tested (50 mg/kg) showed foci of early necrotic cells. Whether 
this small number of cells did not largely contribute to a significant change of 
aminotransferase plasma levels or if the cells have not yet released their content are two 
valid hypotheses. On the other hand, the plasma CK levels for 8.0 mg/kg PAA-coated 
IONs increased significantly when compared to control values. CK constitutes a marker of 
muscle damage [34]. The 20 mg/kg and 50 mg/kg PAA-coated IONs treated groups also 
showed a tendency to higher CK levels, however without reaching statistical significance. 
In fact, it has been described that changes in the values of serum CK after muscular 
damage follow a pattern where there is a rapid release of CK subsequently an injury and 
also a fast plasma clearance, making plasma values return to basal normal values in mice 
in less than 24 hours [34]. Therefore, it is possible that, for the highest concentrations, 
plasma CK values had already decreased to normal range or were decreasing to normal 
values at 24 hours after PAA-coated IONs administration. However, the mechanisms 
behind the CK alteration caused by PAA-coated IONs are yet to be elucidated. 
Given that some IONs are described to act on defense cells and inflammatory 
pathways [15,16,35], these aspects were evaluated on the present study. An increase in 
the number of neutrophils as well as in the large lymphocytes occurred for the highest 
dose of PAA-coated IONs tested (50 mg/kg). Since neutrophils constitute the first line of 
innate host defense against pathogens and associated acute inflammations [36] and that 
small lymphocytes, when activated, transform into large lymphocytes [37], the increase 
number of these cells may be indicative of an inflammatory process elicited by PAA-
coated IONs. During the inflammatory cascade, several mediators may be produced and 
cytokines may exert pivotal roles in those processes. Since lymphocytes, as well as 
neutrophils, are widely described as being cytokine producers [38,39], the putative effect 
of PAA-coated IONs in several plasma cytokine levels, such as IL-6, IL-10, IFN-γ, TNF-α 
and IL-12p70 and chemokine MCP-1 was evaluated. Despite IONs-induced increase of 
large lymphocytes’ and neutrophils in the highest dose tested, there was no effect on the 
levels of plasma cytokines/chemokine. We have recently shown, in vitro, that PAA-coated 
IONs (4 μg/mL) were able to extensively activate the production of several cytokines in 
human blood after a 24 hours incubation period [16]. In vivo cytokines suffer a rapid 
turnover and elimination, therefore the half-life of most cytokines is usually minutes in 
vivo, while in vitro, as there is a lack of renal and hepatic clearance, the half-life of 
cytokines is substantially longer [40]. We also hypothesize that, although rapid cytokine 
turnover can occur in vivo, the pharmacokinetic features of NPs implies the need for a 
longer extent of plasma exposure when compared to the in vitro studies. Cytokine signal 
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activation perhaps is in need of more time and therefore lymphocytes activation had not 
yet reflected in cytokine levels increase. In fact, Chen and colleagues reported that 72 
hours after non-coated Fe3O4 NPs acute administration to ICR mice (0-51.4 mg/kg), the 
levels of IFN-γ, IL-2 and IL-10 increased [41]. Although one could advocate for coating 
differences regarding the previously mentioned study, in our previous in vitro study, we 
demonstrated that the extensive activation of the cytokines was independent of the 
existence of coating in our IONs [16]. Therefore, the exposure time seemed to be of the 
essence for a putative cytokine production in vivo. To verify the accuracy of our 
methodologies in vivo, lipopolysaccharide was administered in different doses [5 and 15 
mg/kg intraperitoneal (i.p.)] and exposition times (2 or 4 hours) in CD-1 mice. The blood 
collected was used as a positive control, as lipopolysaccharide showed to cause increase 
in cytokines and the chemokine (unpublished results). 
The biodistribution in several organs was also studied herein. IONs mainly 
accumulated in liver, spleen and lungs. Iron is largely stored in ferritin, particularly in the 
cells of the liver, spleen and bone marrow, the former organs being involved in the iron 
recycling of aged red cells through macrophages phagocytosis [42]. The PAA-coated 
IONs were taken up by macrophages in the liver (Kupffer cells) and spleen, confirming 
that these IONs have specific uptake by the monocyte–macrophage system [9]. Histology 
of liver slices (Perl’s staining) confirms the presence of Prussian blue positive stained cells 
mainly in contact with main hepatic portal branches. IONs were also removed from the 
circulation by macrophages found in the red pulp of the spleen. A similar pattern of 
accumulation was also observed in a previous work, where Fe3O4 NPs coated with 
amphiphilic polymers containing carboxylic acid (total of 20 mg/kg in two i.v. injections 24 
hours apart) mainly accumulated in the liver and spleen, followed by lungs and kidneys of 
Kunming mice [43]. Almost all organs contain iron in vivo, but the most highly ferruginous 
organs are the liver and spleen, while the lungs also contain considerable amounts of iron. 
In ICR mice given 600 mg/kg Fe3O4 magnetic NPs by intragastric administration, the iron 
lung levels peaked at 6 hours and then decreased steadily after Fe3O4 magnetic NPs 
administration [44]. Actually, we have observed that, for the highest dose tested (50 
mg/kg) of PAA-coated IONs, an iron accumulation in the lungs occurred. Since the lungs 
have a very rich resident macrophages population that is reported to be able to phagocyte 
particles from the circulating blood [45], we believe that these macrophages were able to 
ingest the circulating PAA-coated IONs, as it happens for the liver and spleen.  
No significant differences were observed in iron content in the kidneys of either 
controls or PAA-coated IONs treated animals. In fact, in the work of Wang and colleagues 
[44], the iron content in the kidneys of Fe3O4 magnetic NPs treated mice remained slightly 
above the background level during the entire observation period (up to 10 days after 
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administration), indicating that renal excretion of iron is modest. Also in our study, we 
have shown that PAA-coated IONs do not significantly cross the blood brain barrier, while 
others have observed that albumin-coated γ-Fe2O3 NPs (ca. 25 mg/kg, administrated i.p.) 
were able to cross blood brain barrier in Swiss mice, reaching a maximum iron 
concentration at the end of 48 hours [46]. In another study performed by Wang and 
colleagues [44], Fe3O4 magnetic NPs also crossed the blood barrier, although the 
underlying mechanisms were not determined. The different coatings seem determinant for 
the IONs distribution in these animal models. 
Metal-containing NPs raise toxicity concerns because they can be quickly cleared 
from the blood by the reticuloendothelial system and can remain in organs, such as the 
liver and spleen, for prolonged periods of time [44,47]. Moreover, when a foreign body is 
internalized by phagocytes, an inflammatory process is triggered and production of 
inflammatory mediators and ROS may occur [48]. We have demonstrated in vitro that 
these PAA-coated IONs induce ROS production [15]. It is also known that oxidative stress 
is involved in hepatic and renal damage elicited by IONs in vivo [17]. In fact, MDA levels 
were increased in the mouse liver for the highest tested dose (50 mg/kg) when compared 
with control animals. To the best of our knowledge, this is the first time that PAA-coated 
IONs are reported to trigger MDA production in vivo. We hypothesize that this ROS 
generation occurred due to PAA-coated IONs internalization by liver phagocytes, which 
results in their activation with subsequent production of reactive species. The results 
obtained by Ma et al [17] also showed that Fe3O4 NPs were capable of increasing MDA 
production in mice liver (20 mg/kg i.p., once daily, for a week). Whether the observed lipid 
peroxidation in the present work can lead to the necrotic foci observed at the highest 
tested concentration is to be investigated. However, those necrotic foci were not sufficient 
to cause a considerable ALT and/or AST plasma increase or hepatic ATP changes in 
comparison to control animals.  
No significant differences were observed regarding hepatic GSH or GSSG levels. 
Ma and co-workers observed a significant decrease in GSH in Kunming mouse liver and 
kidney after daily 40 mg/kg i.p. administrations of Fe3O4 NPs for a week [17]. The 
cumulative higher dose certainly affected the cytosolic redox of these animals. Herein, no 
lipid peroxidation or GSH status alteration occurred in the kidney possibly because these 
PAA-coated IONs had no significant renal accumulation. 
The obtained results in this pre-clinical study with PAA-coated IONs showed that 
these IONs accumulate mainly in liver and spleen and, to a lesser extent, in the lungs. 
Although our data showed that PAA-coated IONs do not cause severe organ damage, an 
inflammatory process seems to be triggered in vivo, as evidenced by an increased 
neutrophils’ and large lymphocytes’ frequency in blood. Moreover, an accumulation of 
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PAA-coated IONs in liver phagocytes was observed and hepatic lipid peroxidation was 
elicited showing that these NPs are able to induce oxidative stress. These effects need to 
be further investigated regarding the mechanisms involved and also the long term 
consequences of PAA-coated IONs exposure. 
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Figure legends 
Figure 1. Iron biodistribution (liver, spleen, tail, lungs and heart) in CD-1 mice 
administered with PAA-coated IONs (0, 8, 20 or 50 mg/kg, i.v.) 24 hours before. 
***p<0.001, **p<0.01 and *p<0.05 when compared to control (mice administered with 
0.9% saline solution). Data are expressed as organ iron (μg iron/g of organ). Values are 
given as mean ± SEM (n = 6). 
Figure 2. Light micrographs of paraffin sections from mouse liver stained with 
haematoxylin-eosin (A, C and E) and Perl’s Prussian blue (B, D and F). No iron was 
detected in control animals with both stainings (E and F). In animals exposed to PAA-
coated IONs (A, B, C and D), iron-loaded Kupffer cells (thin arrows) in sinusoids (thick 
arrows - endotheliocytes) were observed. Under lower magnification, it is possible to 
detect the abundance of the iron in the liver of treated animals both with haematoxylin-
eosin (A) and with Perl’s Prussian blue (B). Boxed area in A is shown at higher 
magnification on image below (C), where it is possible to observe that, with this staining, 
the Kupffer cell cytoplasm has a granular and golden brown appearance. Binucleate 
hepatocytes (bH) are common in the mice. 
Figure 3. Light micrographs of paraffin sections from liver of mice exposed to PAA-coated 
IONs stained with haematoxylin-eosin. Under lower magnification (A) clusters of the early 
necrotic hepatocytes (eNH) were identified by an increase of eosinophilia. Boxed area is 
shown at higher magnification on the right (B). At this magnification, it is possible to 
observe a local distribution pattern of eosinophilic hepatocytes and also the presence of 
iron-loaded Kupffer cells (thin arrows). 
Figure 4. Mice spleen. With Masson's trichrome staining (A, B and C), both control and 
PAA-coated IONs mice spleens showed a normal morphology (A), with a smaller 
proportion of red pulp (R). In mice, the splenic red pulp (B) is a major site of myeloid, 
erythroid hyperplasia and megakaryocytic hyperplasia (Meg - megakaryocyte). As shown 
in C, the white pulp (W) is a lymphoid area consisting of sheaths of lymphoid cells 
composed primarily of T cells (T) around the central arteriole (A). No iron was detected in 
white pulp with the Perls’ blue staining, both in control and treated animals (50 mg/kg) (D). 
When compared with the control (E), the splenic red pulp had a great amount of iron-
laden macrophages in treated animals (50 mg/kg) (F). 
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Figure 5. Kidney of mice exposed to PAA-coated IONs stained with Masson’s trichrome. 
No histopathologic alterations were found in mice kidney after the treatment. 
Abbreviations are: PT – Proximal tubule; DT – Distal tubule; AT – Afferent arteriole; RSC - 
Renin-secreting cell; VP – Vascular polar; C – Renal corpuscle; BS – Bowman’s space; 
BC - Bowman’s capsule; P - Podocytes. 
Figure 6. MDA evaluation in liver and kidney of CD-1 mice administered with PAA-coated 
IONs (0, 8, 20 or 50 mg/kg) 24 hours before. ***p<0.001 when compared to control (mice 
administered with 0.9% saline solution). Data are expressed as pmol MDA/mg protein. 
Values are given as mean ± SEM (n ≥ 5). 
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Table 1. Plasma levels of AST, ALT and total CK in CD-1 mice exposed to PAA-coated 
IONs (0, 8, 20 or 50 mg/kg). 
 
 
Groups 
0 mg/kg 8 mg/kg 20 mg/kg 50 mg/kg 
AST (U/L) 66.8 ± 17.3  50.7 ± 8.1 45.8 ± 8.5 38.8 ± 3.5 
ALT (U/L) 32.4 ± 5.4 33.0 ± 3.5 22.8 ± 1.9 25.3 ± 2.2 
CK (U/L) 58.5 ± 6.3 124.3 ± 22.6* 88.0 ± 6.9 81.7 ± 13.2 
Values are presented as mean ± SEM, n = 4 to 6 per group. *p<0.05 when compared to control 
(mice administered with 0.9% saline solution). 
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Table 2. Leukocyte differential counts for mice injected with PAA-coated IONs (0, 8, 20 or 
50 mg/kg). 
Leukocytes (%) 
Groups 
0 mg/kg 8 mg/kg 20 mg/kg 50 mg/kg 
Neutrophils 12.0 ± 0.6 15.8 ± 0.8 18.7 ± 0.8** 21.2 ± 2.0****
Small Lymphocytes 75.5 ± 0.7 68.2 ± 2.4 68.8 ± 2.6 60.0 ± 2.5***
Large Lymphocytes 8.5 ± 1.5 11.2 ± 2.6 10.2 ± 2.5 16.8 ± 1.4*
Monocytes 3.0 ± 1.0 4.3 ± 0.4 2.2 ± 0.7 2.0 ± 0.9 
Eosinophils 0.3 ± 0.2 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
Basophils 0.7 ± 0.3 0.5 ± 0.3 0.2 ± 0.2 0.0 ± 0.0 
Values are presented as mean ± SEM, n = 6 per group. ****p<0.0001, ***p<0.001, **p<0.01 and 
*p<0.05 when compared to control (mice administered with 0.9% saline solution).
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Table 3. Body and organs weight of CD-1 mice administered with PAA-coated IONs (0, 8, 
20 or 50 mg/kg). 
Parameters 
Groups 
0 mg/kg 8 mg/kg 20 mg/kg 50 mg/kg 
0 hours 
Body weight (g) 34.50 ± 0.62 32.83 ± 0.40 33.33 ± 0.99 33.50 ± 1.18 
24 hours 
Body weight (g) 34.33 ± 0.61 32.75 ± 0.79 32.83 ± 1.11 33.00 ± 1.03 
Liver weight/total weight ratio (%) 6.55 ± 0.29 6.65 ± 0.15 6.30 ± 0.15 6.46 ± 0.31 
Spleen weight/total weight ratio (%) 0.38 ± 0.01 0.39 ± 0.02 0.39 ± 0.02 0.41 ± 0.04 
Lungs weight/total weight ratio (%) 0.52 ± 0.02 0.51 ± 0.01 0.51 ± 0.02 0.51 ± 0.04 
Kidneys weight/total weight ratio (%) 1.60 ± 0.92 1.77 ± 0.06 1.63 ± 0.08 1.81 ± 0.05 
Brain weight/total weight ratio (%) 1.28 ± 0.06 1.27 ± 0.03 1.36 ± 0.05 1.47 ± 0.07 
Heart weight/total weight ratio (%) 0.39 ± 0.01 0.38 ± 0.02 0.41 ± 0.01 0.40 ± 0.01 
Testes weight/total weight ratio (%) 0.52 ± 0.01 0.59 ± 0.04 0.58 ± 0.03 0.62 ± 0.05 
Values are presented as mean ± SEM, n = 6 per group. 
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Table 4. GSHt, GSSG, GSH, ATP levels and GSH/GSSG ratio of CD-1 mice exposed to 
PAA-coated IONs (0, 8, 20 or 50 mg/kg). 
Parameters Groups 
Liver Kidneys 
0 mg/kg 8 mg/kg 20 mg/kg 50 mg/kg 0 mg/kg 8 mg/kg 20 mg/kg 50 mg/kg 
GSHt (nmol/mg protein) 44.06 ± 4.60 46.18 ± 4.73 46.92 ± 3.90 48.19 ± 3.81 7.18 ± 1.98 7.30 ± 1.99 7.55 ± 1.73 7.78 ± 1.51 
GSSG (nmol/mg 
protein) 
1.16 ± 0.09 1.20 ± 0.08 1.34 ± 0.10 1.32 ± 0.14 0.12 ± 0.04 0.11 ± 0.02 0.11 ± 0.02 0.12 ± 0.02 
GSH (nmol/mg protein) 41.74 ± 4.42 43.79 ± 4.60 44.24 ± 3.78 45.54 ± 3.58 6.93 ± 1.92 7.08 ± 1.95 7.33 ± 1.69 7.54 ± 1.47 
GSH/GSSG ratio 35.54 ± 1.37 36.49 ± 2.57 33.32 ± 2.56 35.04 ± 2.03 54.11 ± 9.41 56.47 ± 8.70 65.26 ± 5.19 62.86 ± 8.05 
ATP (nmol/mg protein) 7.92 ± 1.12 6.90 ± 1.02 7.22 ± 1.01 5.38 ± 0.70 1.43 ± 0.39 1.42 ± 0.38 1.22 ± 0.19 1.64 ± 0.18 
Values are presented as mean ± SEM, n = 6 per group. 
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INTEGRATED DISCUSSION AND 
CONCLUSIONS 
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III.1. INTEGRATED DISCUSSION
Iron oxide nanoparticles (IONs) are endowed with unique physicochemical 
properties that enable its use in several biomedical applications. However, like any other 
drug or compound intended for human use, the safety of IONs needs to be clearly 
established, and all potential biological/adverse effects well studied. The studies 
assessing the effect of IONs on the cells of immune system, namely neutrophils, 
lymphocytes, monocytes, are still scarce and some of them have given contradictory 
results. Moreover, the biological effects of IONs with some coatings that are described as 
promising for some biomedical applications, namely polyacrylic acid (PAA), require further 
pre-clinical examination.  Therefore, we felt the need to deepen the knowledge existing so 
far in this area. 
We started our studies evaluating the interaction of PAA-coated and non-coated 
magnetite IONs in human neutrophils, given that these cells are the most abundant 
leukocytes in blood and constitute the first line of innate host defense against pathogens 
and associated acute inflammations [1]. In this first study, the ability of these IONs to 
induce oxidative burst was studied, given that neutrophils, when activated, produce 
reactive oxygen species (ROS) and reactive nitrogen species (RNS), mainly through the 
activation of the enzyme nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
[1]. It was verified that PAA-coated and non-coated IONs were able to trigger oxidative 
burst in human neutrophils. IONs-induced oxidative burst was inhibited by 
diphenyleneiodonium chloride (DPI), a NADPH oxidase inhibitor, demonstrating that 
IONs-induced oxidative burst occurs via NADPH activation. IONs are believed to induce 
redox cycling and catalytic chemistry via the Fenton reaction [2]. Our study, however, 
demonstrates that IONs also have the ability to activate NADPH oxidase. Although the 
hypothesis that IONs could be able to activate NADPH oxidase has been raised 
previously [3], this was, to the best of our knowledge, the first study showing the 
involvement of NADPH oxidase in the production of ROS induced by IONs. 
As it is known that ROS may interfere with cell death pathways, namely by 
triggering mitochondrial dysfunction and consequent cytochrome c release [4] or by 
downregulating antiapoptotic proteins related to extrinsic and intrinsic apoptotic pathways 
[5,6], the effect of these IONs on neutrophils’ cell death pathways was also evaluated. 
Although we observed that both IONs studied (PAA coated and non-coated IONs) do not 
induce necrosis, we observed that they are able to interfere with the natural apoptotic 
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course of neutrophils. However, PAA-coated and non-coated magnetite IONs revealed to 
trigger opposite responses regarding this process: while PAA-coated IONs demonstrated 
to increase apoptosis, non-coated IONs showed to inhibit and/or delay the apoptotic 
process. Two of the apoptotic pathways are the mitochondrial-mediated or intrinsic and 
the receptor-mediated or extrinsic. In mitochondrial-mediated or intrinsic apoptosis, a loss 
in membrane potential occurs and the consequent release of soluble factors into the 
cytosol, such as cytochrome c and apoptosis inducing factor (AIF), as well as 
Smac/Diablo takes place [7]. Cytochrome c forms a complex with a cytosolic protein 
named apoptosis protease-activating factor 1 (Apaf 1) to activate caspase 9 [7]. Receptor-
mediated or extrinsic pathway is triggered by the activation of death receptors such as 
those activated by Fas ligand, tumor necrosis factor (TNF)-related apoptosis-inducing 
ligand or TNF. The activation of these receptors results in the formation of the death-
inducing signaling complex composed by the Fas-associated death domain (FADD) and 
procaspase 8 and caspase 8 is activated [8]. In both pathways, the initiator caspases 
(caspase 8 in extrinsic and caspase 9 in intrinsic pathway) activate downstream effector 
caspases, mainly caspase 3, by proteolytic induction of its inactive zymogen form. Effector 
caspases cleave cytoplasmic and nuclear components, and promote deoxyribonucleic 
acid (DNA) degradation and cell dismantling, which converges in the demise of the cell 
[8]. In order to find out on which apoptotic pathway(s) IONs are interfering, caspases 3, 8 
and 9 activities were measured. PAA-coated IONs increased all these caspases activities, 
while non-coated IONs decreased only caspases 3 and 9. These data led us to conclude 
that PAA-coated IONs are able to induce apoptosis via intrinsic and extrinsic pathways, 
while non-coated IONs exert their inhibitory effect only via intrinsic pathway. Given that 
p53 is reported to be activated by DNA damage resulting from ROS and RNS production 
[9], and may trigger apoptosis, typically via mitochondrial pathway but also via receptor-
mediated pathway [10], we hypothesized that apoptosis could be also triggered in 
response to p53 activation due to ROS and RNS production. Our results showed, for the 
first time, that PAA-coated IONs were able to activate p53 in neutrophils in part of the 
individuals tested. Therefore, under the experimental conditions of this study, p53 
activation does not seem to be essential to trigger apoptosis, given that apoptotic process 
was increased for all donors tested with PAA-coated IONs, while p53 activation occurred 
only for one part of the donors. 
The interactions between the cell and IONs are determined by the 
physicochemical properties of the nanoparticles (NPs) surface, namely surface charge, 
hydrodynamic radius, agglomeration status, among others [11,12]. Consequently, PAA 
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coating will determine new interactions with the neutrophils, altering this way their 
properties and changing their effects. Visually, using optic microscopy, it was possible to 
observe that PAA reduce the aggregation phenomenon, highly visible in non-coated IONs 
and less visible in PAA-coated IONs. Therefore, it is possible that the aggregation state of 
the non-coated IONs may have perturbed the apoptotic process, while the PAA-coated 
IONs, well dispersed in the cytoplasm, could be able to activate cellular machinery, 
promoting a cellular response. 
The aim of our second work was to evaluate the effect of our IONs on cytokine 
production in human blood cells given that, after arrival of the neutrophils to the 
inflammation site, other inflammatory cells belonging to blood, namely lymphocytes, are 
activated, which results in an exacerbated cytokine production [13]. The results obtained 
showed us that both IONs studied were able to induce the release of the cytokines tested 
[IL-1β, TNF-α, IL-6, IL-8, interferon gamma (IFN-γ) and IL-10] by human blood cells, in the 
following decreasing order of extent, for PAA-coated IONs IL-6 > IL-8 > TNF-α > IFN-γ > 
IL-1β > IL-10 and for the non-coated IONs IL-8 > IL-6 > IL-1β > IFN-γ > TNF-α > IL-10. 
These cytokines are known to mediate inflammatory reactions, as indicated by cytokines 
produced and/or associated with Th1 cells, such as IFN-γ, TNF-α, IL-1β and IL-8, and 
also by their involvement in B cell activation and differentiation (Th2), such as IL-6 and IL-
10 [14,15]. Some previous studies have already reported that IONs are able to induce 
cytokine production in different cells [16,17]. However, these studies did not establish a 
correlation between the cytokines produced and the inflammatory pathways that may be 
behind their activation. Therefore, we used inhibitors of the most relevant pathways [c-
Jun-N-terminal kinase (JNK), p38 mitogen-activated protein kinase (MAPK), nuclear factor 
kB (NF-kB), activator protein 1 (AP-1) and transforming growth factor beta activated 
kinase (TAK1)], in order to find out which of those were able to inhibit cytokine induction 
triggered by IONs. By doing that, we were able to verify that TAK1 and p38 MAPK 
inhibitors were able to inhibit the production of all the cytokines tested, which led us to 
conclude that IONs studied activate TAK1 and p38 MAPK, inducing this way cytokine 
production. Moreover, JNK inhibitor also provoked a decrease of IFN-γ, IL-8 and TNF-α 
production, which demonstrates that JNK pathway induction by IONs is also directly 
involved in the production of these cytokines. AP-1 and NK-kB inhibitors, however, did not 
inhibit cytokine production, having in some cases even increased cytokine production. 
However, this does not mean that AP-1 and NF-kB are not involved in IONs-induced 
cytokine production. As it was previously referred, in the presence of inhibitors of these 
pathways, a negative feedback mechanism may occur, thereby enhancing or prolonging 
III. Integrated Discussion and Conclusions
204
TAK1 activation [18]. Moreover, as it is known, TAK1 is competent for activation of 
mitogen activated protein kinase kinase (MKK) 3, 6 and other kinases, and its activation 
indirectly results in p38 MAPK and JNK activation [18] and p38 MAPK and JNK activate 
some members of AP-1 family that lead to the production of the above mentioned 
cytokines [19,20]. Therefore, one may postulate that AP-1 is probably indirectly involved in 
the IONs-induced cytokine production. Likewise, TAK1 has also the ability to activate the 
NF-kB pathway [21], and therefore this pathway is also indirectly activated by IONs. It is 
important to mention that, given that both IONs studied (PAA-coated and non-coated 
IONs) showed to be able to activate cytokine production at a similar extent, although with 
some small variations in the production of each cytokine individually, PAA coating did not 
show to be able to alter the interaction of non-coated IONs with the immune system cells 
of the blood, and their ability to activate inflammatory pathways. In our first work, although 
we had concluded that these IONs had opposite effects concerning apoptosis, they had 
similar effects concerning ROS production by human neutrophils. In fact, inflammatory 
processes and ROS production in neutrophils are correlated. When neutrophils infiltrate 
sites of injury by responding to chemical cues elicited by proinflammatory cytokines and 
chemokines produced by monocytes, neutrophils, lymphocytes and other cells of the 
immune system, they produce ROS and RNS that can directly induce DNA base oxidation 
and deamination and can indirectly lead to base alkylation via lipid peroxidation [22,23]. 
Therefore, the aim of our third work was to evaluate the genotoxicity of PAA-
coated and non-coated IONs in human T lymphocytes, given that these cells have the 
important role of stimulating macrophage and B-lymphocyte activities mainly via 
production of regulatory cytokines [24] and present a high rate of division [25]. The results 
obtained showed that both IONs studied are not genotoxic to human T lymphocytes, not 
triggering the occurrence of chromosomal aberrations. Although there are studies 
reported in the literature that are in accordance with our study [26,27], some studies have 
already reported that IONs provoke genotoxicity in several cells [28,29]. The fact that 
different cells and/or cellular lines were used in these above mentioned cases, may have 
contributed to the differences in the results. It is known, as it was previously mentioned, 
that cell cycle arrest allows cells to properly repair eventual defects, thus preventing their 
transmission to the resulting daughter cells [30]. Indeed, in the presence of DNA damage, 
cells have the ability to arrest proliferation in G1 and G2 until the damage is repaired [30]. 
Consequently, we also evaluated the effect of IONs on the cell cycle. The results obtained 
show that PAA-coated and non-coated IONs did not have any effect on cell cycle, which 
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leads us to conclude that the absence of genotoxicity in human T lymphocytes is not 
related to cell cycle arrest and repair of eventual defects. 
It is known that bleomycin (BLM), a known antibiotic used in anticancer therapy, 
with clastogenic properties, exerts a synergistic effect with other xenobiotics concerning 
genotoxic promotion [31]. Given that BLM induces chromosome damage through 
simultaneous binding to oxygen and redox-active transition metals, such as Fe2+, as 
previously mentioned [32], and as both IONs used in this study are presented in the form 
of magnetite, where iron is present as a mixture of Fe3+ and Fe2+ ions [33], we considered 
that it would be important to evaluate the ability of IONs to interact with this clastogenic 
agent, exacerbating its genotoxicity. Our results demonstrated that, although both IONs 
showed some tendency to increase the genotoxicity of BLM, this increase was not 
statistically significant, which allow us to conclude that none of the studied IONs potentiate 
the genotoxicity of BLM under the experimental conditions in which the study was 
performed.  
Given that our PAA-coated and non-coated IONs had demonstrated relevant 
toxicological and inflammatory data in vitro, we felt it was important to verify if these 
relevant results could be reproducible in vivo. For this purpose, PAA-coated IONs were 
administered intravenously to male CD-1 mice with 8 weeks and their biodistribution and 
effects on organs were evaluated 24 hours after. The reason why only PAA-coated IONs 
were chosen for in vivo studies was that, when IONs are used for biomedical purposes, 
they are always coated in order to prevent aggregation [34]. Moreover, we had already 
verified in our three previous works that non-coated IONs have a great tendency to 
aggregate and this aggregation could potentially lead to embolism after intravenous 
administration [35]. 
In order to ascertain if PAA-coated IONs were able to cause liver, heart or muscle 
damage, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and creatine 
kinase (CK) were determinated in blood. The results revealed that PAA-coated IONs did 
not trigger ALT or AST alterations while, for CK, there were an increase for the lowest 
concentration tested. As it was previously mentioned, AST and ALT are parenchymal 
intracellular enzymes released into systemic circulation when there is hepatocellular and 
cardiac injury, usually involving necrosis [36]. Therefore, this result may lead us to 
conclude that the IONs studied did not cause hepatic and cardiac injury. However, when 
hepatic histological studies were performed, it was revealed that foci of early necrotic cells 
were found. The explanation found for this fact was that these cells probably had not time 
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to release their content and, consequently, the enzymes ALT and AST, until the moment 
the sacrifice occurred. Concerning CK, as this enzyme is a marker of muscle damage 
[37], its increase revealed that some muscular damage may have occurred. The reason 
why this increase occurred only for the lowest concentration, not having been observed an 
increase in a concentration-dependent manner, remains to be elucidated. 
Given that in our first work we had verified that PAA-coated IONs were able to 
trigger ROS production by human neutrophils and in our second work we had verified that 
these IONs were able to trigger cytokine production through inflammatory pathways 
activation, we considered that evaluating the pro-inflammatory potential of the same IONs 
in vivo was of utmost importance. Therefore, differential leukocytes counts, as well as 
cytokine production, in the whole blood, were evaluated. The cytokines here evaluated, 
accordingly to the cytokines evaluated in our second work, are equally cytokines that 
mediate inflammatory reactions, IFN-γ, TNF-α and IL-12p70 being involved in Th1 
responses and IL-6, IL-10 and monocyte chemoattractant protein-1 (MCP-1) in Th2 
responses [14,38]. The results obtained showed that, comparatively to control mice, PAA-
coated IONs-treated animals presented an increase in neutrophils and large lymphocytes. 
Given that, as previously referred, neutrophils constitute the first line of innate host 
defense against pathogens and associated acute inflammations [1] and that small 
lymphocytes, when activated, transform into large lymphocytes [39], this increase put in 
evidence the existence of an inflammatory process. However, contrarily to what had 
happened in vitro, there was not an increase in cytokine production in vivo. This does not 
mean that cytokine production in the presence of IONs did not occur. In fact, it is 
described that, once the cytokines are produced, they are rapidly cleared: the half-life of 
most cytokines is usually minutes in vivo, while in vitro, as there is lack of the renal and 
hepatic clearance mechanisms, the half-life of cytokines is substantially greater [40]. 
Therefore, at the end of 24 hours, it is possible that, in vivo, the cytokines produced by 
PAA-coated IONs had been already metabolized and eliminated and, for this reason, they 
were not detected as it had occurred in vitro. However, we also raised the hypothesis that 
the exposure time necessary to trigger cytokine production in vivo may be superior to the 
time observed in vitro and, therefore, cytokine production may have not occurred until the 
24 hours of study, occurring at a later time point. Further studies at several exposure 
times would be necessary in order to prove these hypotheses. 
Besides evaluation of the PAA-coated IONs capacity to induce necrotic damage 
and inflammatory processes, the biodistribution of the studied IONs indicated that they 
accumulated essentially in liver, spleen and, to a lesser extent, in lung. In fact, these 
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results were expected since, as it was previously referred, liver is the major site of iron 
storage, the site of synthesis for major proteins of iron metabolism and a regulator of iron 
traffic into the body [41]. It is, also, together with spleen, the major organ responsible for 
the recycling of iron [42]. This last fact may explain why PAA-coated IONs have also 
accumulated in the spleen. Regarding lung, we hypothesize that this accumulation 
occurred due to the capacity of lung macrophages to ingest particles from the circulating 
blood [43]. As macrophages are cells involved in inflammatory process, with functions in 
antigen presentation, phagocytosis and immunomodulation through production of 
cytokines and growth factors [22], the accumulation of these IONs in lung revealed a 
relationship with a possible pro-inflammatory process. Moreover, in our histological 
studies in liver, an accumulation of iron was observed in Kupffer cells of PAA-coated 
IONs-treated animals as well as a cytoplasmic eosinophilia in early necrotic cells, which, 
again, put in evidence the occurrence of an inflammatory process. Additionally, 
histological studies in spleen revealed an increase in iron concentration in splenic red pulp 
of PAA-coated IONs-treated animals. Given that red pulp is a blood filter that removes 
foreign material and contains also macrophages actively phagocytic [44], the 
accumulation of the IONs studied in the spleen played favourably with the hypothesis that 
PAA-coated IONs accumulate in organs rich in phagocytic cells. 
In fact, and as it was previously mentioned, when a foreign body is internalized by 
phagocytes, an inflammatory process is triggered with inflammatory mediators and ROS 
production [45]. Moreover, and as we had previously demonstrated in vitro in our first work 
that these IONs induce ROS production in human neutrophils, oxidative stress 
parameters, such as malondialdehyde (MDA), reduced glutathione (GSH) and oxidized 
glutathione (GSSG) levels were evaluated in liver and kidney, due to the role of these 
organs in metabolization and excretion, respectively. In liver, an increase in MDA levels 
was observed in PAA-coated IONs-treated mice, which suggested the occurrence of ROS 
formation in this organ and consequent macromolecules attack by these ROS, namely 
lipids containing carbon-carbon double bonds, leading to formation of lipid 
hydroperoxides, which form MDA, among others, as secondary products [46]. However, 
the observed ROS production was not enough to produce alterations in GSH and GSSG. 
In kidney, neither MDA nor GSH and GSSG levels were altered in PAA-coated 
IONs-treated mice. Moreover, in histological and biodistribution studies performed in 
kidney, we observed that the studied IONs do not accumulate in this organ and, for this 
reason, they do not exert any adverse effect. 
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As it is known that oxidative damage may impair adenosine triphosphate (ATP) 
production [47], we decided that it was important to evaluate ATP production. ATP levels 
were not significantly affected by PAA-coated IONs, although a decrease tendency in the 
liver was found. Therefore, in vivo, although an inflammatory process has been put in 
evidence, with consequent internalization of the studied IONs by phagocytes of the liver, 
spleen and lung, the oxidative damage seems to have been limited, not having caused 
severe damage to cell organelles, such as mitochondria. 
We finish this dissertation mindful of having contributed to a better understanding 
of the biological effects triggered by IONs but also certain that much more studies are 
required for a greater awareness of their consequences when they are used for 
biomedical purposes. 
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III.2. CONCLUSIONS 
 
 From the results obtained in this dissertation, it may be concluded that:  
 In vitro, PAA-coated and non-coated IONs: 
 
o induced oxidative burst in human neutrophils through NADPH oxidase 
activation; 
o PAA-coated IONs induced intrinsic and extrinsic apoptotic pathways, while 
non-coated IONs inhibited and/or delayed intrinsic apoptotic pathway in human 
neutrophils; 
o activated directly TAK1, JNK and p38 MAPK pathways, inducing thereby the 
production of the cytokines IL-1β, TNF-α, IL-6, IL-8, IFN-γ and IL-10 in human 
whole blood; 
o did not induce an increase in chromosomal aberrations nor in the cell cycle of 
human T lymphocytes, not being therefore genotoxic; 
o did not increase the genotoxic behavior of BLM. 
 
 In vivo, the acute administration of PAA-coated IONs: 
 
o accumulated in phagocytic cells in the periportal zone of the liver and in splenic 
red pulp as well as in the lung; 
o induced an increase in neutrophils’ and large lymphocytes’ frequency and a 
slight increase in CK levels in mouse blood; 
o did not induce alterations in AST, ALT and in the cytokines IL-6, IL-10, IFN-γ, 
TNF-α and IL-12p70 and chemokine MCP-1 levels in mouse blood; 
o induced an increase in MDA levels in mouse liver but not in mouse kidney; 
o do not induce alterations in GSSG, GSH and ATP levels nor in the GSH/GSSG 
ratio in mouse liver and kidney. 
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 As a final conclusion, the IONs studied revealed the ability to influence cell 
death processes and activate inflammatory pathways in vitro and in vivo, showing 
also a certain ability to cause liver toxicity in vivo. The results obtained in this 
study suggest that caution should be taken when these IONs are used for 
biomedical purposes and should constitute a starting point to further in vitro and in 
vivo studies, in order to determine more precisely the toxicological potential of 
these IONs and avoid nefarious consequences to the human health. 
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